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Abstract 
 
Chronic wounds are a rapidly growing clinical problem across the world, expensive to 
healthcare systems and severely injurious to the quality of life of those affected. Such 
wounds have been shown to contain bacteria within biofilms which can be difficult to 
identify and treat, and are implicated in the lack of healing.  The aim of this study was to 
improve our understanding of the characterisation of these bacterial communities within 
chronic wounds.  This was achieved through the collection of 18 unique chronic wound 
samples of various phenotypes and 9 acute wound samples.  The two bacterial species, 
Staphylococcus .aureus and Pseudomonas. aeruginosa, most commonly isolated from 
chronic wounds and known to be prolific biofilm formers and formidable human pathogens 
were the focus of this study.  Both PCR and culture demonstrated the presence of one or 
both species in all chronic wound samples and the presence of S. aureus in some acute 
samples. Novel monoclonal antibodies were developed to TNase (of S.aureus) and LPS (of P. 
aeruginosa) and their ability to detect the bacteria in vitro in a simulated chronic wound 
environment was evaluated.  The action of these monoclonal antibodies were calibrated 
and evaluated through the use of fluorescent microscopy, and direct and competition ELISA.  
Following this biofilms of S.aureus and P. aeruginosa both single species and mixed were 
evaluated utilising Peptide Nucleic Acid Flourescent In Situ Hybridisation, and the Confocal 
Laser Scanning Microscope to demonstrate the architecture of the biofilms produced and 
the locations of the bacteria within the biofilm.  Microbiologically using both culture and 
PCR, the widespread presence of S. aureus and P. aeruginosa throughout human chronic 
wound samples was demonstrated.  The ELISA and fluorescent microscopy illustrated the 
feasibility of MABs as a rapid and accurate detection system for identifying bacteria within 
chronic wounds.  The PNA FISH accurately identified individual species in mixed biofilms 
through multiplex staining.  It also visually demonstrated the tissue invasion of S. aureus, 
adhesive properties of P. aeruginosa and the synergy of these virulence factors in mixed 
biofilms.  This study has met its aims in that it has provided further evidence of techniques 
which could be successfully applied to rapidly identify bacteria within a chronic wound 
environment, and to characterise the structure and composition of bacterial biofilms 
formed within these wounds.  It provides a basis for the development of future clinically 
relevant rapid bacterial detection systems, and for the academic study of bacteria within the 
biofilm phenotype. 
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Chapter 1:  Introduction to thesis 
 
Chronic wounds are a large and growing problem worldwide, In the UK alone they cost the 
NHS (National Health Service) 3-5% of the UK total health spend (Posnett and Franks 2008).  
The annual cost is as high as £3.1 bn in the UK (United Kingdom) (Posnett and Franks, 2008), 
and up to US$25bn in the United States (Sen et al., 2009).  As the population of the world 
becomes progressively more elderly and the prevalence of diabetes and obesity rises this 
figure is likely to increase significantly.   
 
Chronic wounds are a burden on society and the individual economically; however for the 
individual with chronic wounds they are far more significant than that.  A chronic wound 
impacts on quality of life extensively, and data suggests that such wounds have a significant 
effect on quality of life throughout the developed world (Price and Harding 2004, Ribu et al., 
2007).  Patients living with chronic wounds experience pain and discomfort with half 
requiring analgesia (Price 2005) and many on regular opiate analgesia.  They can also 
experience odour and exudate leading to social discomfiture anxiety, social embarrassment 
and social withdrawal, all severely affecting quality of life (Mudge 2008). Many of these 
negative experiences associated with chronic wounds can be linked to the complications of 
bacterial infection.  
 
There are many differing causes for the development of chronicity within wounds however 
it is well recognised that the bacterial populations found within chronic wounds are 
significantly different to those found on normal skin (Martin et al., 2009). Infection of 
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wounds both clinically and sub clinically is a significant factor in the delaying of adequate 
and timely wound healing.  Unlike many other factors in the causation of chronic wounds 
this factor can be modified through appropriate and timely therapeutic interventions   
 
Bacteria do not exist planktonically throughout the majority of their lifestyle but in the 
biofilm phenotype (Stoodley et al., 2002).  This natural state of bacterial existence is of great 
benefit to the bacteria enabling enhanced protection against immune defence mechanisms 
and antibiotics.  Bacteria infecting chronic wounds exist largely in the biofilm phenotype. 
If it were possible to rapidly and accurately assess the bacteria present within a chronic 
wound, their phenotypic state, which species were present and absolute counts of bacteria 
of various species, we would then be able to assess which combinations were harmful, 
which neutral and even which possibly beneficial. With this information, tailor-made rapid 
and effective treatment targeted only at those who need it would be possible, negating the 
need for costly overprescribing and needless side effects from antibiotics and conversely 
reducing the significant population risk of the development of antibiotic resistance. 
 
Currently the most commonly used method of obtaining this information in the clinical 
setting is the use of wound swabs and classical microbiology to obtain both species and 
bacterial counts and antibiotic sensitivities.  These methods face obvious limitations, in that 
they provide no information on the bacterial phenotype, no accurate count of bacterial 
numbers and the possibility of missing microcolonies of culturable bacteria without even 
mentioning the unculturable bacteria that are not picked up (Davies et al., 2002).  These 
swabs frequently lead to overtreatment of wounds that are merely colonised rather than 
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infected and are slow to heal, leading to empirical and often inappropriate prescribing of 
antibiotics, with the attendant risks of that. 
 
To date scientifically various methods have been employed in the laboratory setting to try 
and elucidate the bacterial communities present within chronic wounds, including the use of 
PCR (Polymerase Chain Reaction), targeted antibodies and the use of FISH (Fluorescent In 
situ Hybridisation) and ELISA (Enzyme Linked Immunosorbent Assay).  These all have various 
shortcomings, and none have translated to clinical practice in the field of wound healing in 
contrast to other areas of medicine. 
 
The current state of knowledge of bacterial colonies present in chronic wounds is poor 
(Dowd et al., 2008), both in terms of total species present and arrangement within the 
biofilm phenotype.  If a solution is to be found to this problem a method of rapidly, reliably 
and accurately detailing bacterial communities within chronic wounds, both in terms of 
species present and phenotype, is necessary to then correlate against wound healing, and 
provide a basis for individually tailored treatment. 
 
Therefore there is a need for further work on the characterisation of bacterial communities 
within chronic wounds to find an accurate method for rapid and accurate detection of 
bacterial species presence and of their relationship to the biofilm state. 
 
To address this problem the literature was thoroughly reviewed which led to the collection 
of chronic wound fluid, debrided wound tissue and discarded dressings from patients with 
infected chronic wounds in order to subject this material to rigorous microbiological testing.  
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The collected material was utilised in experiments to develop rapid and accurate 
identification of microbial species within the samples.  In order to make the case for these 
methods it was decided to focus on the identification of two bacterial species commonly 
present within chronic wounds and known to have both significant virulence factors and be 
prolific biofilm formers: Pseudomonas aeruginosa and Staphylococcus aureus 
 
The thesis is structured into six chapters, an introduction, followed by a comprehensive 
review of the current literature.  Three experimental chapters each divided into 
introduction, materials and methods, results and discussion sections, followed by a final 
chapter consisting of a general discussion and synthesis of the entire thesis findings. 
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Chapter Two: Background and Literature Review  
 
Introduction 
In order to gain an appreciation of the current literature in this field the following topics 
were reviewed to help build a picture of the current state of knowledge of bacterial 
communities within chronic wounds, and in particular biofilm formation and the 
consequences of this for wound healing. 
 
This review has focused on the normal stages of healing and the reasons for the 
development of a chronic wound with particular reference to infection.  Following this the 
evidence for the presence of biofilms within chronic wounds is presented, with the 
associated implications of this for investigation and treatment of biofilms within wounds. 
Finally this review focuses on the methods currently utilised to characterise bacterial 
communities within chronic wounds.   The causes of chronic wounds have not been 
investigated in detail nor has the treatment of chronic wounds been exhaustively reviewed 
as this remains outside the scope of this thesis. 
 
Introduction to chronic wounds  
A chronic wound is defined by the Wound Healing Society as a wound, which does not heal 
in an orderly set of stages and in a predictable amount of time.   Wounds that do not heal 
within three months are considered chronic (Mustoe, 2005). The term ‘chronic wound’ is 
often used as an umbrella to encompass a broad spectrum of aetiologies.  The three 
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principal forms of chronic wounds are leg ulcers, diabetic ulcers and pressure ulcers but 
many other wound types can, and do, become chronic (Mustoe, 2004). 
 
Impact of chronic wounds 
The burden of chronic wounds falls disproportionately upon those who are immobilised, 
diabetic and/or geriatric.  Chronic skin wounds affect 3% of individuals over 60 years of age 
and 3.55 per 1000 in the general population in the UK (Vowden et al., 2009).  In the aging 
population this becomes a bigger problem year on year (Posnett and Franks, 2008).  More 
than 90% of chronic wounds fall into the three main categories: diabetic ulcers, venous leg 
ulcers and pressure ulcers (Price, 2005; Mustoe et al., 2006).  Chronic wounds are a major 
and growing world health problem, the cost of managing chronic wounds in the UK has 
been estimated at 2.3-3.1bn pounds a year in the UK alone and constitutes 3-5% of the UK 
total health spend (Posnett and Franks, 2008).  These costs are exacerbated by very slow 
healing rates, with as many as 67% diabetic foot ulcers remaining unhealed at 20 weeks 
(Kantor and Margolis, 2000) and only 42.6% healed at 24 weeks in a recent UK study 
(Jeffcoate et al., 2009).  Many of these wounds become infected and patients report living 
with cycles of active infected ulceration (Price et al., 2007).   
 
Chronic human infections including chronic wound infections constitute 60-80% of all 
human infection diseases (Costerton, 1995).  The financial cost of management of chronic 
wounds is growing exponentially.  Aside from the cost of day-to-day management of chronic 
wounds, such wounds can lead to the amputations of toes, feet and limbs.  Over 80000 
amputations are performed on patients with diabetes in the US per year the majority of 
these associated with diabetic ulceration and subsequent non-healing and infection (Centre 
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for Disease Control, 1997). In the UK it is predicted that the forecasted rise in type 2 
diabetes will lead to 25000 new cases of foot ulceration per year (Posnett and Franks, 2008). 
 
Chronic wounds are a cause of significant morbidity, economic costs, and have a significant 
negative effect on quality of life throughout the developed world (Price, 2004, Ribu et al., 
2007) and beyond.  The development of a chronic wound has severe consequences for the 
patient and carers; affected individuals are usually elderly, immunocompromised, or have 
serious concomitant systemic illnesses.  The affect on this already vulnerable population can 
be dramatic.  Physically there is pain and discomfort (with 50% requiring analgesia) (Price, 
2005), odour and restricted mobility.  Psychologically, there is a fear of social discomfort, 
worry about current health state and further deterioration, social embarrassment and 
withdrawal, all of which can severely adversely affect a patients quality of life (Mudge et al., 
2008). 
 
Wound healing 
Normal wound healing is a dynamic complex biological process that is not completely 
understood.  The process involves a complex cascade of cytokines and growth factors, cell 
proliferation, differentiation, migration, and neoangiogenesis.  Generally the wound healing 
process is sub-divided into three distinct phases for the purposes of description but it is 
important to remember that these phases are not purely sequential but have substantial 
overlap.  A summary of these processes is presented in Fig 2.1: each phase will be discussed 
in turn. 
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Fig. 2.1 A schematic illustrating the mechanisms involved in the normal wound healing 
process.  [ABC of Wound Healing (Grey and Harding 2006: permission to reprint –Professor 
K. Harding.) 
 
The Inflammatory phase of wound healing 
The inflammatory phase of wound healing begins at the time of injury and can last up to 10 
days in normal wound healing (Grey and Harding, 2006); its primary purpose appears to be 
to cleanse the wound of bacteria and tissue debris.  Following tissue damage there is an 
aggregation of platelets into the damaged area, which forms a ‘plug’.  Any damage to the 
endothelial lining of blood vessels triggers the coagulation and plasminogen cascades 
causing the formation of fibrin, which together with the platelets forms a clot.  The 
purposes of clotting are two-fold; firstly, the clot is haemostatic therefore preventing 
further haemorrhage and secondly, the clot provides a provisional matrix for the initial 
stages of tissue repair.   
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A combination of the degranulation of platelets within the clot and the endothelial damage 
at the time of injury results in the release of cytokines such as PDGF (platelet-derived 
growth factor) and TGFα (transforming growth factor alpha)(Barrientos et al., 2008),  which 
will then attract leucocytes into the area of tissue damage.  Bacteria will also colonise any 
open wound usually sourced from the patient’s own normal skin flora, and these bacteria 
will also promote the infiltration of white blood cells into the wound (Edwards and Harding, 
2004). 
 
The innate immune system is thus stimulated and (PMNLs) polymorphonuclear lymphocytes  
flood into the area of tissue damage to phagocytose bacteria and debris.  The PMNLs 
produce hydrolytic enzymes and oxygen derived free radicals to kill phagocytosed bacteria 
through inducing damage to protein lipids and DNA (deoxyribonucleic acid). 
   
The activity of PMNLs reduces a few days post initial injury and then macrophages infiltrate 
the site to phagocytose debris.  Monocytes and lymphocytes also infiltrate the wound at this 
point.  The macrophages release cytokines and growth factors, which facilitate the 
recruitment of fibroblasts, keratinocytes and endothelial cells into the wound for tissue 
repair.  To compliment this, enzymes produced by macrophages also degrade the 
provisional wound matrix (set up by the initial clot) through proteolytic enzymes and down-
regulate acute inflammatory signalling, thus orchestrating the next phase of wound healing, 
the proliferative phase. 
 
 
10 
 
 
The proliferative phase of wound healing 
The proliferation phase starts at around 3 days post tissue damage and can last up to 25 
days, and is characterised by the replacement of the provisional fibrin/fibronectin matrix 
with newly formed granulation tissue (Enoch and Price 2004).  Fibroblasts are key to this 
formation, they migrate into the wound (stimulated by cytokines produced by platelets, 
macrophages and other injured fibroblasts (Slavin, 1996) and proliferate thereby beginning 
the construction of the new extracellular matrix.  Fibroblasts produce fibronectin, a matrix 
protein which facilitates the migration of cells through the matrix.  Subsequently, fibroblasts 
go on to produce collagen and proteoglycans providing a denser matrix.  Angiogenesis and 
neovascularisation occur in this period and the granular appearance of granulation tissue is 
secondary to the formation of new capillaries. 
   
Angiogenesis is affected by the migration of endothelial cells from the wound edge and 
proliferating from the damaged edges of blood vessels.  The angiogenic process is mediated 
by growth factors, matrix proteins and hypoxic conditions (Enoch and Price 2004).  
Following the formation of healthy granulation tissue re-epithelialisation can occur. 
 
Re-epithelialisation and remodelling phase of wound healing 
Although commonly held to be the third stage of normal wound healing, re-epithelialisation 
begins within hours of injury and is, in fact, concurrent with the previously described 
phases.  Basal cells rapidly divide and migrate from wound edges due to a loss of contact 
inhibition, until stopped by contact with other epithelial cells (Singer and Clark 1999).  
Following initial coverage a new basement membrane is formed, further epithelial cell 
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growth and differentiation then establishes the stratified epithelial architecture of normal 
skin.  As well as contact inhibition, growth factors produced by fibroblasts, macrophages 
and keratinocytes themselves will all promote keratinocyte proliferation and migration.  
Some keratinocytes even undergo a marked morphological transformation through which 
they can phagocytose debris and migrate across the wound bed (Thomas and Harding, 
2002).  Wound healing does not end with re-epithelialisation as remodelling of the scar can 
continue for 12 to 18 months (Singer and Clark 1999). 
 
Not all wounds obligingly follow the pattern described above; this is particularly evident in 
the healing of chronic wounds and many wounds will appear arrested in one phase or 
progress more slowly than expected.  The exact causes of failure of normal wound healing 
are not known.  In routine wound healing, repair is affected by macrophages, keratinocytes, 
endothelial cells and fibroblasts, which are coordinated via a complex cascade of cytokines 
and growth factors in cell-to-cell and cell-to-matrix interactions.  In chronic wounds this 
response is impaired; there is prolonged inflammation, a defective wound matrix and failure 
of re-epithelialisation.   
 
The question that needs to be addressed is therefore why does a wound become chronic?  
This is a difficult question to answer.  It has been suggested that whatever the cause, non-
healing hinges on 3 mechanisms, cellular and systemic changes of aging, repeated 
ischaemia-reperfusion injury, and bacterial colonisation with resulting inflammatory host 
responses. (Mustoe et al., 2006) 
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Chronic wounds are difficult to study, as they are highly variable in patients and difficult to 
match for the purposes of randomised controlled trials.  Furthermore adequate laboratory 
models are difficult to construct.  Chronic wounds do not occur in animals, and are 
impossible to accurately reproduce in vitro.  To date, there are no recognised chronic wound 
models to facilitate further study of the factors affecting healing. 
 
Factors affecting delayed wound healing 
There is currently no single unifying theory which can explain why some wounds fail to 
progress to full healing and develop chronicity.  It is likely that the causes of chronic wounds 
are multifactorial (see Table 2.1).  Both systemic factors, such as metabolic disease states 
and inflammatory conditions, and local factors, such as bacterial colonisation and 
inappropriate microcirculation, inflammation and pressure states are all likely to play a role.  
There is a tendency for research to focus on the wound without considering the patient as a 
whole; many systemic and local factors have been shown to be associated with delayed 
wound healing.  When treating patients with chronic wounds it is essential to correct as 
many of these factors as possible.  Some, such as poor nutrition and vascular supply, may be 
treated medically or surgically, many however are impossible to correct.  Examples of 
factors we are unable to correct include inoperable vascular disease, chronic disease states 
and advanced age and immobility. In these cases care must be taken to optimise these 
conditions as far as possible.   
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Table 2.1 Factors increasing the risk of developing chronic wounds 
Adapted from (BMJ 2006) and (Grey and Harding, 2004) (reprinted with permission of 
Professor Harding)  
 
Interestingly all factors that cause an increased risk of the development of chronic wounds 
are well recognised to decrease the strength of host defence mechanisms to bacterial 
invasion.  Bacterial presence in any wound is inevitable as the wound provides a warm, 
moist, nutrient rich environment for bacterial growth and bacteria are ubiquitous in our 
environment.  Thus all wounds provide an environment for interaction between host and 
Local factors  Systemic factors  
 Inadequate blood supply  
 Increased skin tension  
 Poor surgical apposition  
 Wound dehiscence  
 Poor venous drainage  
 Presence of foreign body and foreign 
body reactions  
 Continued presence of microorganisms  
 Infection  
 Excess local mobility, e.g., over a joint  
 Advancing age and 
general immobility  
 Obesity  
 Smoking  
 Malnutrition  
 Deficiency of vitamins 
and trace elements  
 Systemic malignancy 
and terminal illness  
 Shock of any cause  
 Chemotherapy and 
radiotherapy  
 Immunosuppressant 
medications, corticosteroids, 
anticoagulants  
 Inherited neutrophil 
disorders such as leucocyte 
adhesion deficiency  
 Impaired macrophage 
activity (malacoplakia)            
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bacteria.  It is reasonable therefore to suggest that interplay between host defence factors 
and bacterial virulence factors will occur in every wound. 
 
A competent host could still develop a chronic wound if the burden and virulence of 
bacterial presence was high enough and similarly an incompetent host could heal normally 
in the presence of few bacteria with little or no virulence factors.  However wounds in hosts 
with impaired defences are more likely to develop chronicity than those in the 
immunocompetent (Landis, 2008).  The development of a chronic wound is not an ‘all or 
nothing’ event and it is very likely that the interplay between host and bacterial factors 
described here also explains delayed healing rates. 
 
Prevalence of bacteria in wounds 
Staphylococci, Streptococci, Enterococci and Gram-negative bacilli are the most commonly 
isolated bacteria from CVLUs (chronic venous leg ulcers) (Davies et al., 2007).  However, it 
has become increasingly apparent that hard to culture bacteria may also play an important 
role in the bacterial microflora of chronic wounds.  The most prevalent problem with 
identification of appropriate species in the literature has been the incomplete isolation of 
anaerobes, which is both complex and time consuming via culture (Davies et al., 2001).  
However, painstaking anaerobic culture has yielded a high frequency of strictly anaerobic 
bacteria including Peptostreptococcus and Bacteroides species, amongst others.    
Irrespective of our ability to culture microorganisms, the DNA of bacteria which have been 
in the wound should be present in all samples and molecular techniques exploiting the 
variations within the bacterial 16s ribosomal DNA sequences are being increasingly utilised.   
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The 16S rDNA gene sequencing tool provides a means of tracing and identifying bacteria 
from various sources by assessment of their phylogenetic relationships (Dowd et al., 2008).   
It is a powerful and accurate method that is applicable to small sample sizes and for 
identifying bacteria that are difficult or impossible to culture.  Molecular studies of chronic 
wounds using PCR and DGGE (Denaturing Gradient Gel Electrophoresis) and exploiting the 
RNA (Ribonucleic acid) 16S variability of bacteria to identify them has also shown that 
previously uncultured bacteria are present in wounds.  It has been estimated that less than 
5% of bacterial species are culturable by traditional methods (Amann et al., 2001: Moter and 
Göbel, 2000).  Thus chronic wounds can and do harbour extremely diverse bacterial species, 
both aerobic and anaerobic and a variety of species not previously recorded. 
 
Significance of bacteria in wounds 
A recent study by Davies et al. (2000: cited in Davies et al., 2007) showed that both bacterial 
diversity in a wound and bacterial density were independent predictors of increased healing 
time.  Predominant organisms found were S. aureus (34.8%) and P. aeruginosa (71.2%) for 
all wounds.  This confirmed the findings of a study by Stephens et al., (2003) showing that a 
diverse wound microflora can contribute both directly and indirectly to the ‘non-healing’ 
phenotype of chronic wounds. 
 
Commonly isolated chronic wound bacteria 
 
The impact of microorganisms on chronic wounds has been studied and reviewed using 
many different approaches to detect microorganisms and elicit their effects on wound 
healing, often highlighting particular species (Schraibman 1990), or groups of organisms 
(Wall et al., 2002).  The microflora of chronic wounds is usually polymicrobial and recent 
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studies using molecular techniques have emphasized the complex ecology of these wounds 
(Davies et al., 2003, Davies et al., 2004). Utilisation of conventional techniques has 
demonstrated a mean number of bacterial species per wound from 1.6-4.4 (Howell-Jones et 
al., 2005.)  Staphylococcus aureus and coagulase-negative staphylococci have been the 
predominant organisms isolated from both prospective, purpose-collected samples, and 
retrospective analysis of clinical investigations. In contrast molecular analysis reveals an 
average of 10 species per chronic wound, approximately four times more than 
demonstrated with culture (Martin 2009). A 2007 study (Davies et al.,) showed that the 
predominant organisms in chronic wounds from both surface swabs and tissue biopsies 
were Staphylococcus spp. and P. aeruginosa, present in 71.2% of patients.  In bacterial 
profiling studies (Gjodsbol et al., 2006) found that chronic venous leg ulcers harboured S. 
aureus in 93.5% and P. aeruginosa in 52.2% of cases, making these species ideal for 
characterisation of bacterial communities in chronic wounds.  These are far from the only 
species present in chronic wounds. Other commonly isolated aerobic bacteria are 
Staphylococcus epidermidis, Escherichia coli Enterobacter cloacae, Klebsiella species, 
Streptococcus species, Enterococcus species, and Proteus species, (Howell-Jones et al., 
2005).   This is by no means an exhaustive list, but is illustrative of the range of aerobic 
bacteria that exist in chronic wounds. Harder to culture anaerobic bacteria are also present 
(Bowler & Davies 1999) found anaerobes in 73% of non infected leg ulcers and 82% of 
infected leg ulcers. Commonly isolated anaerobic bacteria frequently identified from chronic 
wounds were Peptostreptococcus species and pigmented and non-pigmented 
Prevotella/Porphyromonas species, Finegoldia magna (previously classified as 
Peptostreptococcus magnus), Peptoniphilus, asaccharolyticus , Bacteroides Species and 
anaerobic cocci (Howell-Jones et al., 2005).    
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Special mention should be made of beta haemolytic streptococci, which although rarely 
isolated are considered so deleterious to wound healing that the Chronic Wound Care 
Guidelines of The Wound Healing Society in 2006 (Robson and Barbul 2006)  stated that a 
chronic wound should be treated for infection if there were “greater than 106 CFU/g of 
tissue of bacteria, or any beta heamolytic streptococci” echoing the views of Wiström et al., 
in 1999.  This bacteria is associated with a host of virulence factors and severe tissue 
destruction, and are particularly concerning in acute setting in which it is implicated in 
necrotizing fasciitis.  Vallalta Morales  2006  et al., state that beta haemolytic streptococci  
bacteraemia are more common in the “elderly and those with chronic diseases”  both of 
which are common in the chronic wound patient group.  The incidence is often quoted at 
less than 1% of chronic wounds however one study showed a rate of as high as 18.8% of 
chronic leg ulcers (Schraibman 1990) However it has been stated that “while the β-
haemolytic streptococci are associated with tissue destruction, their relevance to chronic (as 
opposed to acute) wound healing, particularly of non infected wounds, remains unclear”. 
(Davies et al., 2007 Pg 17). 
 
 
Bacterial colonisation vs. wound infection 
Intact skin provides a physical barrier against bacterial infection.  When a wound occurs, for 
whatever reason, microorganisms from the surrounding skin and the wider environment will 
take advantage of access to a warm moist environment.  No wound is sterile and species 
invading the wound may then establish themselves and colonise the wound.  There is some 
debate as to whether this should be considered an adverse event.  Many wounds with 
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bacteria present will heal normally and many acute wound models deliberately infected 
have healed at a normal rate or with slight delay (Kanno et al., 2010).  However, it is 
generally accepted that microbial colonisation can progress to a stage that inhibits normal 
wound healing and causes wound deterioration. 
 
Bacteria within chronic wounds will attract leucocytes and therefore a high protease oxidase 
environment results which is thought to explain that deterioration.  A randomised evaluator 
blind study on venous ulcers showed a modest, but statistically significant difference in 
healing when wounds are treated with silver sulfadiazine, which could be attributed to an 
increased rate of healing when the bacterial count decreases (Bishop et al., 1992).  The best 
model to explain this is the bacterial load pyramid described by Edwards and Harding (2004) 
in Figure 2.2 
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Fig 2.2 Harding/Edwards pyramid model of infection within chronic wounds (Edwards and 
Harding 2004). 
 
The model neatly illustrates the continuum of bacterial actions within a wound from initial 
contamination to septicaemia.  Where on the pyramid a given wound can be placed 
depends on a complex interplay of factors, including microbial (e.g., species virulence 
factors phenotype) and host factors (e.g., tissue, perfusion, immunocompetency, glycaemic 
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control, necrotic tissue and eschar).  The development of infection in chronic wounds is 
considered to reflect host susceptibility (Edwards and Harding, 2004). 
 
Mechanism of bacteria promoting wound chronicity 
It is important to remember that most colonised chronic wounds will heal eventually and 
they do so in the colonised state (Leaper, 1994).  It has been suggested that chronicity in 
wounds begins with a persistent tissue level of bacteria producing endotoxins resulting in a 
prolonged elevation of proinflammatory cytokines (Kirketerp-Moller, et al., 2008, Edwards 
and Harding, 2004).  This in turn causes an increase in matrix metalloproteases along with a 
decreased level of growth factors which shift the balance of the wound from a healing to a 
more chronic phenotype.  Inflammation is a normal and necessary part of normal wound 
healing, and it has been shown that sub-infective levels of bacteria which cause appropriate 
levels of inflammation, increase neutrophil and monocyte infiltrates and actually enhance 
the collagen formation, granulation tissue and wound healing (see table 2.2), (Edwards and 
Harding, 2004).  However some studies have suggested the presence of certain bacteria 
within a wound seem to prevent the normal healing process from taking place (Madsen et 
al., 1996). 
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Phase of Wound 
Healing Response 
Mediators Effect of Wound 
Colonization 
Effect of Wound 
Infection 
Inflammation Complement cascade 
proteins activate platelets 
causing release of 
inflammatory mediators, 
growth factors and 
fibronectin. Cellular 
response particularly 
neutrophils and 
macrophages 
Enhanced White cell 
accumulation chemotactic 
and bactericidal activity  
Increased consumption of 
complement proteins, resulting in 
decreased chemotaxis.  Plus 
depletion of platlets.  White cell 
function impaired in the presence 
of infection including by short chain 
fatty acid products by anerobic 
bacteria.  Increased production of 
cytotoxic enxymes and free oxygen 
radicals increase tissue damage. 
Localised thrombosis and release of 
vasoconstrictive metabolites 
increase tissue hypoxia and 
promote bacterial proliferation and 
tissue destruction 
Granulation tissue 
formation and 
angiogenesis 
Macrophages as stimulus 
to angiogenesis and 
granulation tissue 
formation 
Increased granulation tissue 
formation and angiogenesis 
Further increased turnover partly 
due to production of bacterial 
enzymes, resulting in oedematous, 
haemorrhagic friable granulation 
bed and excessive scar formation.  
Endotoxins in wounds stimulate 
production of interleukins and TNF 
which induce production of MMPs 
imbalance of MMPs decrease 
growth factor production  
Epithelialisation   Decreased if bacterial load is over 105 as bacterial metabolites inhibit 
migration of epithelium and digest 
dermal proteins and 
polysaccharides. Also increased 
production of neutrophil proteases 
damage vulnerable epithelium. 
Collagen 
Production 
 Increased tensile strength of 
wound 
Reduced numbers and proliferation 
of fibroblasts with disorganised 
collagen production. Both increased 
production and Breakdown of 
collagen with overall effect of 
decreased wound strength. 
Endotoxins decrease collagen 
deposition and cross linking and 
associated with Surgical 
debridement. 
Wound Contraction   Significantly delayed 
 
Table 2.2  Edwards and Harding 2004- “effects of bacterial colonisation on wound healing” 
Reproduced with permission. 
 
Diagnosis of wound infection 
Wound infection is known to impair wound healing in both acute and chronic wounds.  Thus 
diagnosis of wound infection is extremely important.  No wound is sterile and bacterial 
colonisation will occur in all chronic wounds.  Bacterial colonisation can vary in terms of 
species present and load and is not a constant event.  The impact of colonisation on a 
wound can be evaluated as being from beneficial through to neutral or harmful (Cogen, 
2008).  Colonisation in itself is widely considered to be a normal phase of wound healing.  
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However, the progression to ‘critical colonisation’ (Edwards and Harding, 2004) and the 
differences between these two states is controversial.  Critical colonisation refers to a 
transitional state between colonisation and invasive wound infection (Edwards and Harding, 
2004).  It can be defined as the inability of a wound to maintain a balance between 
increasing bioburden and an effective immune system denoted by a delay in healing but not 
deterioration of the wound or other overt signs of infection (White et al., 2006). Clinically, 
an unhealthy looking wound bed without signs of invasive infection may be seen.  Absolute 
bacterial CFUs (colony forming units) are difficult to quantify despite several authors 
postulating ≤ 105CFU/g tissue (Heggers, 1998), which is not unreasonable, as bacterial loads 
above this level have been linked to the rejection of split skin grafts.  However, this 
interpretation does not take into account the difficulty of obtaining accurate CFU numbers 
of non-randomly distributed bacteria present in a wound from one sample, or the presence 
of viable but non culturable bacteria, and the virulence and synergistic factors of different 
species (Percival et al., 2010) 
 
Diagnosis of wound infection is best elucidated on the basis of clinical signs by experienced 
clinicians.  Further microbiological investigations are useful, not for the diagnosis of wound 
infection, but for species identification and antibiotic susceptibilities. A notable wound care 
committee stated in 1999 (Diabetes Care, August 1999) that current microbiological 
investigations of wound infection were of limited use for diagnosing most infections.  It is 
important to remember that some wounds may fail to heal in the absence of infective signs 
and these may be critically colonised as previously described.   
 
23 
 
Patients with chronic wounds are regularly treated with antibiotics on the basis of wound 
swab results or empirically following visualisation of the wound.  A systematic review of the 
literature has shown little evidence for the benefit of antibiotics on wound healing (O’Meara 
et al., 2008).  However, expert clinicians believe that the judicious use of antibiotics in 
infected wounds is a vital part of the wound healer’s armoury.  Undoubtedly many courses 
of antibiotics are prescribed inappropriately on the basis of a microbiology wound swab 
report or following an assessment of a wound as infected, when it is only colonised.  Excess 
antibiotic prescribing encourages the development of resistant and multi-resistant strains of 
bacteria, with serious implications on a population level for human health (Knox and 
Holmes, 2002). 
 
Management of wound infection 
Wound management is currently empirical and based on principles of reducing bacterial 
load and preventing infection (Fonder et al., 2008).  Currently wound infection remains a 
clinical diagnosis and is therefore subjective, risking over diagnosis and inappropriate 
treatment.  Current treatment strategies depend on the extent of wound infection (Landis, 
2008).  Patients with critical colonisation and localised infection are often treated with 
dressings containing topical iodine or ionised silver, with topical antiseptics such as Betaine 
Polyhexanide, or with potassium permanganate soaks all of which are felt to act locally to 
reduce bacterial load (Landis, 2008, Fleck, 2006, White et al., 2006).  Systemic or spreading 
infection should be treated with systemic antibiotics either orally or intravenously.   
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Biofilms  
For much of the twentieth century it was generally accepted that microorganisms existed 
naturally in a ‘free growing’ or so-called planktonic form.  These planktonic organisms were 
culturable and easily studied in both medicine and the wider scientific world.  Scientific 
study centred on cultures of single species bacteria grown in a variety of liquid or solid 
specific media in aerobic or anaerobic conditions. 
 
However, in recent years it has become increasingly clear that most bacteria exist in the 
’biofilm phenotype‘ for the majority of their lifecycle, spending relatively small amounts of 
time in the free or planktonic state (Stoodley et al., 2002).  Over the last few decades 
awareness of the relevance of biofilms to human disease has been recognised, leading to 
increased research into bacteria in the biofilm phenotype. 
 
Bacteria from biofilms were first described by Antonie van Leeuwenhoek (1632-1723).  Van 
Leeuwenhoek’s 1683 report to The Royal Society on the examination of “animalcules” in the 
plaque scraped from his teeth was the first description of live bacteria recorded.   
However, the general theory of biofilm predominance was not postulated until 1978 
(Costerton et al., 1978).  This theory states that the majority of bacteria grow in matrix 
enclosed biofilms adherent to surfaces, in a nutrient sufficient aquatic ecosystem and that 
these sessile bacterial cells differ profoundly from their planktonic counterparts.   
The importance of biofilms was slow to be recognised by the medical community.  The 
concept was first developed and recognised by industry, especially in industrial water 
systems and then in dentistry, a field that had the advantage of dental plaque to study 
(Costerton et al., 1995).  Over the last two decades and with advances in microscopy, it has 
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become clear that rather than just bacterial ‘slime’ these biofilms are organised and 
attached in complex ways.  Biofilms have been increasingly recognised for their significant 
role in human disease, predominantly in dentistry but increasingly by the medical 
community. The National institute of Health in the USA estimates that over 80% of all 
human infections are biofilm related (NIH 1997).  Given the ubiquity of biofilms it seems 
that extrapolations from planktonic cultures can no longer be considered reliable in 
determining outcome in clinical infection and its management. 
 
The classic definition of a biofilm is a ‘community of microorganisms often adhered to a 
surface and encased in an EPS (exopolysaccharide) or glycocalyx matrix’ (Saye, 2007, 
O’Toole et al., 2000). 
 
Biofilms in chronic wounds 
The incorporation of biofilms into the existing models of chronic wounds allows 
interpretation of the biochemistry and cellular biology of the chronic wound environment in 
a different and more logical way.  Chronically elevated pro inflammatory cytokines and 
matrix metalloproteases, and increased elastase could all be explained by the possible 
effects of biofilms on the host’s immune system (Wolcott et al., 2008).  They are also 
thought to influence host fibroblast activity, impair keratinocytes and prevent endothelial 
cells initiating angiogenesis. 
 
There is evidence that microorganisms within a wound contribute to the non-healing or 
chronic phenotype and will often form biofilms on the surface (Sutherland, 2001).  Biofilms 
have been identified macroscopically as slime layers in almost every different chronic 
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wound phenotype from venous leg ulcers, diabetic ulcers and pressure ulcers, and these 
have subsequently been confirmed to be biofilms at a microscopic level.  The ubiquity of 
biofilms within the chronic wound environment has led to speculation that they may be a 
causative factor in wounds developing chronicity.  Studies of serial wound debridement of 
chronic wounds have suggested that it may be correlated to improved wound healing rates 
and more frequent closure (Wollcott et al., 2010).  This effect is thought to be secondary to 
the removal of biofilm.  It has been suggested that the presence of biofilm phenotype 
infections can be considered a primary impediment to chronic wound healing (Kanno et al., 
2010). 
 
Excess bio-burden on a wound bed is thought to be one of the most important barriers to 
wound healing (Dowd et al., 2008).  This ‘bio burden’ comprises bacteria, devitalised tissue, 
proteinaceous exudate and white blood cells.  Given that these surface-associated bacteria 
will form into biofilms they could be considered the most important element of a wounds 
bio-burden.  
 
The complexity of biofilms 
Initially biofilms were considered to represent a simple ‘slab’ of matrix material with 
randomly embedded cells.  However the advent of CLSM (confocal laser scanning 
microscopy) has allowed further study of biofilm structure (Malic et al., 2009).  Biofilms are 
not formed by a particular species or set of bacteria but are communities of one or more 
bacteria living in a structured and ordered environment of microcolonies, water channels 
and waste channels, with differing microenvironments held together by an extracellular 
scaffold of polysaccharides protein and DNA associated with the surface.  The nature of a 
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biofilm allows these bacteria to cooperate and thrive in a manner reminiscent of a 
multicellular organism.  Biofilms provide a multitude of microenvironments and indeed 
some dental biofilms have been shown to harbour over 500 different bacterial taxa 
(Whittaker et al., 1996).  The level of sophistication apparent within biofilms requires a 
system of intracellular communication and cellular specialization not thought to exist in 
bacteria prior to recent biofilm studies. 
 
Bacteria and Biofilms    
It is important to emphasise that bacterial species have grown in the biofilm phenotype for 
millions of years, and that this must therefore be a very successful strategy for bacterial 
survival, propagation and new colonisation.  This distinct and ubiquitous phenotype of 
bacterial growth has only been studied for the last few decades and investigation of its 
structures, physiology and effects are at an early stage.  Within biofilms, development 
occurs resulting in structures and patterns and metabolic activities, which are not 
randomised or localised but integrated throughout the biofilm (Stoodley et al., 2002).   
Biofilms are important in understanding how bacteria interact with their environment. They 
show how bacteria are capable of radically altering their physiology and expressed genes to 
adapt to, exploit, and thrive in challenging environments.  Indeed biofilms are likely to have 
evolved due to their ability to allow a protected microenvironment for growth within a 
hostile macroenvironment. 
 
Characteristics of Biofilms 
A biofilm can be defined as “a structured community of bacterial cells living in a self-
produced polymeric matrix and adherent to an inert or living surface” (Costerton, 1999 
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p1318). No two biofilms are the same; they are a product of the interaction between 
bacterial species, a suitable surface, and the external environment.  A biofilm’s strength is in 
its heterogeneity, different protein expression, multiple cooperating species, differing 
metabolic rates and microenvironments affording different levels of protection, nutrient 
and oxygen availability throughout the biofilm.  Those bacteria nearest to the surface are 
most metabolically active, closest in phenotype to planktonic cells and are most vulnerable 
to attack by host defences and antibiotics.  All biofilms are surrounded by an EPS matrix or 
glycocalyx, which acts as both a physical barrier to penetration by biological and 
pharmacological antimicrobials and facilitates the adherence of bacterial cells to each other, 
surfaces and foreign bodies (Stoodley et al., 2002).   
 
Biofilm formation 
The development of biofilms is unique in biology and is a remarkable and complex process 
involving the coming together of independent small prokaryotic cells to form a functional 
and sophisticated multicellular community. 
 
It is now generally recognised that bacteria will form biofilms preferentially in whatever eco 
system they inhabit and that planktonic bacteria are the exception rather than the rule.  
Many aspects of biofilm formation seem counterintuitive.  Biofilms will form preferentially 
in high shear environments, and indeed can form in shear forces of greater than 5000 
Reynolds (Peyton et al., 1993), a force which greatly exceeds the shear found in heart valves.  
Indeed biofilms seem to favour turbulent flow.  Research from industry has shown that 
smooth surfaces are colonised as easily as rough surfaces (Costerton, 1995). 
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Reversible attachment 
The first stage of biofilm formation involves conveyance of bacterial species to the 
appropriate surface.  This may be a passive action, e.g. convection in liquids or an active one 
such as flagella induced motility, and there is some speculation as to whether a high flow 
environment aids this process (Sauer et al., 2002). 
 
Biofilm formation begins with bacterial adhesion to a surface.  When planktonic bacteria 
attach to a surface they begin to secrete EPS.  Studies have shown adherence within 3 hours 
(Harrison-Balestra et al., 2003).  Adhesion of bacteria to smooth surfaces is explained by the 
classical DVLO (Derjaguin-Landau-Verwey-overbeek) theory of colloid stability, describing 
the interaction of attractive van der Waal’s forces and repulsive interactions resulting from 
the electrical double layer of the cell (Hermansson, 1999).  The first adhesion phase is 
governed by physical or chemical interactions between surface and cell.  However, although 
DVLO theory explains the experimentally low levels of bacterial attachment to negatively 
charged surfaces, it does not explain the variety of attachment behaviours seen with other 
types of surfaces and electrolyte solutions.  Despite it not being an all encompassing theory 
of bacterial attachment it can be argued that it describes one of many components of the 
adhesion process (Katsikogianni and Missirilis, 2004). 
   
Initial attachment is reversible with the bacteria surrounded by only small amounts of EPS 
and these often motile bacteria can still leave the surface and resume their planktonic 
lifestyle.  During this period of reversible attachment bacteria can exhibit several species-
specific behaviours such as rolling, creeping, aggregate formation and windrow formation 
(Costerton et al., 1995).  It is thought that when planktonic bacteria sense appropriate 
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environmental conditions and a surface to attach to, they may move from the reversible 
attachment phase to become irreversibly bound through various adhesions (Sauer et al., 
2002).   
 
Irreversible attachment 
Irreversible adhesion is not a random event.  Numerous transcription regulators coordinate 
the phenotypic changes that result in attachment and as many as 800 proteins within a 
single species alter their expression (Sauer et al., 2002).   Bacterial phenotypes then alter 
rapidly.  P. aeruginosa can alter its metabolism within 10 hours to express a biofilm 
phenotype (Harrison-Balestra et al., 2003).  Once attached, biofilm cell accumulation can 
occur by 3 mechanisms, first by simple division of the attached bacteria, secondly by 
recruitment of cells from the bulk fluid and thirdly by redistribution of attached cells via 
surface motility (particularly relevant for mobile species such as P. aeruginosa) (Sauer et al., 
2002). 
 
Biofilm maturation 
Following attachment biofilms undergo a period of maturation transforming themselves 
from a collection of bacterial cells surrounded by EPS to a complex organised multicellular 
structure.  Channels and pores are formed for nutrient delivery and waste removal and 
bacteria are redistributed away from the substratum and into microcolonies.  Cell to cell 
communication is thought to occur through various chemicals (quorum sensing agents) 
(Kong et al., 2006) whose release is dependent on cell densities and is thought to organise 
this structural reconfiguration.  Once attached to a suitable surface, like any animal the 
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biofilm needs nutrients to grow and reproduce.  In a suitable environment progression to 
mature biofilm can be very rapid.   
The biofilm structure is largely determined by the ‘slime-like’ matrix of EPS which provide 
the structural support for the growing biofilm and consists of polysaccharides, proteins and 
nucleic acids.  The developed EPS matrix consists of very long and thin molecular chains that 
can associate in a number of different ways (Sutherland, 2001). 
 
The time taken to form a mature biofilm is controversial and estimates range from 10 hours 
to several months.  In reality, the time taken to form the biofilm depends on nutrient 
availability, inoculation load of bacteria, species of bacteria, motility of bacteria, and of 
course the definition of a mature biofilm.  Therefore time of biofilm development is likely to 
exhibit extensive variation and can take up to 10 days to reach structural maturity (Stoodley 
et al., 2002). 
 
The exchange of nutrients facilitated by the architecture of biofilms enables the biofilm 
community to develop considerable thickness and complexity whilst maintaining individual 
cells in microenvironments that are optimal for them in terms of location within the biofilm 
and their nutrient requirements.  Cells in differing regions of a biofilm have been shown to 
exhibit differential gene expressions (Stoodley et al., 2002), demonstrating biofilm 
organisation and cell to cell communication. 
 
Biofilm dispersal 
Mature biofilms often release planktonic bacteria and groups of bacteria into the local 
environment.  These cells are not merely planktonic bacteria that could not be incorporated 
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into the biofilm, but deliberately ejected bacterial cells produced by the biofilm (Stoodley et 
al., 2002).  The obvious purpose of this is to ensure propagation of the biofilm in new 
environments.  This is a particularly troublesome phenomenon in vascular diseases such as 
endocarditis, where these groups of bacterial cells form septic emboli, with often severe 
clinical consequences for the patient. 
 
Physiology of biofilms 
The physiology of bacteria within biofilms is profoundly different to that of bacteria in the 
planktonic state.  It has been shown for Pseudomonas putida that irreversible attachment to 
a surface leads to a surface regulated switch from flagella based motility to type IV twitching 
based motility (Sauer and Camper, 2001).  There is also evidence of the production of 
adhesins binding the cells together and causing the architecture of microcolonies 
throughout the biofilm.  Mature biofilms have a very different protein profile to planktonic 
colonies; in a recent study of P. aeruginosa as much as 50% of the detectable proteome 
(over 800 proteins) was shown to have a six fold or greater difference in expression,  of 
these more than 300 were undetectable in planktonic bacteria (Sauer and Camper, 2001).  
These proteins are known to be involved in metabolism, phospholipid and 
lipopolysaccharide (LPS) synthesis, membrane transport, secretion, adaptation and 
protective mechanisms.  
 
In mature biofilms, cells will detach and revert to a planktonic form. This is not simple 
physical forces acting on the biofilm but a physiological process thought to be regulated 
either by cell density or a lack of nutrients available for the biofilm. (See figure 2.3)  
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Fig 2.3“Life cycle of a biofilm”, (Biofilm hypertextbook, Montana State University Center for 
Biofilm Engineering) 1: individual cells populate the surface. 2: EPS is produced and 
attachment becomes irreversible. 3 & 4: biofilm architecture develops and matures. 5: 
single cells are released from the biofilm. 
 
Structure of biofilms 
Biofilms can often be thick enough to be visible without the use of a microscope.  Biofilms 
can consist of millions of bacterial cells, often multispecies and organised to allow a stable 
structure of physiologically cooperating organisms.  Particular species or bacteria are found 
consistently in certain locations within towers, mushrooms or microcolony biofilm 
structures  (Costerton et al., 1997).  Some areas of the matrix are devoid of cells, whereas 
others will be heavily populated often with regular cell spacing.  The orderliness of the 
structure points towards sophisticated cell-to-cell communication systems. 
 
Biofilms can develop structurally into many different forms, from a flat appearance to one 
of towers and mushroom shaped microcolonies.  The biofilm structure is a result of a myriad 
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of interacting factors including bacterial factors such as twitching, motility growth rate, 
quorum sensing, EPS production and non bacterial factors such as shear forces, flow 
direction and available nutrients. 
 
Effect of flow on biofilm structure 
Under conditions of low laminar flow most biofilms will form towers and mushroom shaped 
microcolonies with no evidence of any directionality.  Under higher unidirectional flows the 
biofilms unsurprisingly become elongated and filamentous or mat like in the downstream 
direction (Stoodley et al., 2002). 
 
Effect of shear forces on biofilm structure  
Fluid shear also influences the structure of biofilms.  Biofilms grown at higher shear have 
been shown to be smoother and denser than those grown at lower shear (Lui and Tay, 
2002).  It is as yet unclear whether this effect is due to altered gene expression in response 
to the environment or simple natural selection of bacteria producing EPS with the strongly 
adhered remaining attached and the more weakly attached being removed.   
 
Cell to cell signalling within biofilms 
Biofilms are not random aggregates of microorganisms but highly structured and organised 
communities.  To develop and maintain this level of differentiation requires an effective 
system of cell-to-cell communication.  Cell-to-cell communication is also essential to 
orchestrate the expression of virulence factors, the delicate coordination of which are 
required to successfully invade the host and for survival of the organism within the host 
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(Kong et al., 2006).  Amongst bacteria, the regulatory systems involved are collectively 
referred to as QS (Quorum Sensing) systems.   
 
QS systems have gained the attention of the scientific community due to the possibility of 
manipulating these communication processes as a novel method of disease control.  The 
signalling mediators of QS are small molecules called autoinducers (QS molecules) 
(Costerton et al., 1999).  At a low bacterial cell concentration autoinducers are in low 
concentrations but at higher densities, a threshold concentration is reached and a 
transcriptional regulator is activated regulating the expressions of various genes and 
therefore proteins. 
   
It would be reasonable to postulate that different autoinducers are responsible for cell to 
cell signalling in different phases of biofilm formation, from reversible attachment through 
to dispersal.  Table 2.3 provides a list of autoinducers of interest in staphylococcal biofilm 
formation. 
Function in biofilm 
phase 
Factor QS system 
Attachment AtIEa 
PSMs 
Agr 
Agr 
Cell-cell adhesion PIA luxS 
Detachment PSMs Agr 
 
Table 2.3 Autoinducers of interest in Staphylococcal biofilm formation  
(Kong et al., April 2006) 
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The concept of QS as a means of bacterial communication has emerged as being essential to 
the formation of biofilms with several studies showing impaired biofilm formation when QS 
genes are knocked-out.  It has been shown that discreet QS molecules promote the 
formation of biofilms and also their dissolution to release planktonic bacteria again (Kong et 
al., 2006).   
 
Studies on P. aeruginosa biofilms have shown that the LasR-Lals system controls expression 
of a battery of extracellular virulence factors and those mutants with a knocked out version 
of this gene form only thin undifferentiated microcolonies which disperse with weak 
detergents.  When the missing signal is restored P. aeruginosa biofilms revert back into 
healthy biofilms, thereby indicating the requirement of this QS signal in development of the 
Pseudomonas biofilm (Davies et al., 1998).  Such studies indicate that QS molecules must 
have an effect on genes expressed in distant cells of the same species and are therefore in 
effect a bacterial hormone system. 
 
Virulence of biofilms 
Biofilms are not just of academic interest as they can have extreme significance in a clinical 
environment.  For all of human history we have been beset with acute epidemic infectious 
diseases involving the planktonic phenotype bacterial cells of specialised pathogenic 
bacteria, only recently contained by vaccination schemes and antibiotics.  However, more 
than half of infectious diseases affecting individuals involve commensal or common 
environmental bacterial species.  These can cause devastating and life threatening chronic 
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infections such as those involving implantable devices, chronic wounds and osteomyelitis 
which can be secondary to the biofilm phenotype. 
   
Hospital associated infections or nosocomial infections are estimated to kill approximately 
99,000 people per year in the USA (United States of America) and around 50,000 per year in 
Europe (Bryers, 2008).  Of these infections, 60-70% are associated with an implantable 
medical device i.e. a biofilm infection (Amman et al., 2001).  Medical device infections have 
a directly attributable cost of $5bn per annum in the U.S.A alone (Wenzel, 2007). The UK has 
no published figures on the cost of medical device infections to the NHS but it is likely to be 
substantial.  These figures do not even consider the cost of biofilm disease on body surfaces, 
especially chronic wounds.  Biofilm infections share clinical characteristics, they develop 
preferentially on inert surfaces such as medical devices, dead tissue or bone but can also 
grow on living tissues e.g. endocarditis (Costerton et al., 1999).  Due to the nature of 
biofilms, planktonic cells are released deliberately and periodically, which can give rise to 
infective emboli or close and distant acute infections.  
 
Since biofilms tend to be slow growing, symptoms generally develop at a comparable rate.  
Unlike planktonic cells, microorganisms within a biofilm are protected from host defence 
molecules such as antibodies, which may cause immune complex damage to the 
surrounding tissues (Jackson and Cochrane, 1988).  This damage can allow further nutrient 
availability and actually increase the opportunity for biofilm growth.  Similarly, antibiotic 
therapy in these cases can arrest symptoms caused by any microorganisms that leave the 
biofilm and become planktonic, but have a limited or no effect on the biofilm itself.  A 
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patient with biofilm based infection will therefore often have repeating cycles of antibiotic 
therapy followed by a perceived resolution and then recurrence.   
Eradication often requires the surgical removal of the biofilm and the affected surface.  
Although not always the most dramatic of infectious processes, biofilm infections are 
notoriously difficult to resolve, for reasons outlined above.  Biofilm infection commonly 
manifests in insidious chronic and recurrent infections.  These biofilm infections pose a 
number of clinical challenges involving rapidly evolving antibiotic resistance, unculturable 
organisms, chronic inflammation and the ability to shed new biofilm formers in the shape of 
planktonic bacteria and biofilm microcolonies. 
 
Beneficial biofilms 
Are all biofilms ‘bad’ biofilms?  Biofilms are formed by both commensal and pathogenic 
bacteria and can be considered the predominant phenotype of bacteria in nature.  Biofilms 
form when bacteria and surfaces abound.  The gut contains many biofilms, there are 
biofilms on our teeth and biofilms have also been described in vaginal mucous.  These are all 
biofilms coexisting with humans in a healthy state and could be considered at best neutral 
and in many respects highly desirable.  These biofilms appear to have a passive protective 
role in preventing harmful bacteria colonising this environment and in the case of gut 
bacteria an active role in breaking down nutrients for absorption by the body. 
 
Microbes found on the skin are generally categorised as opportunistic pathogens or 
potential pathogens.  However some have advanced the theory that certain members of the 
ubiquitous skin microflora could be mutually beneficial to the human host without impaired 
immunity and with intact skin (Cogen et al., 2008).  In this regard, a symbiotic mutually 
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dependent relationship with the host similar to bacteria within the gastrointestinal tract has 
been postulated.   
 
Many bacterial species produce a variety of by-products that can protect the host. 
Pseudomonas fluorescence produces pseudomonic acid (commercially used as the antibiotic 
mupirocin) potent against staphylococci and streptococci, and also inhibits the transition of 
fungi from yeast to virulent filamentous forms (Cogen et al., 2008).  Certain strains of S. 
aureus can produce a proteinaceous bacteriocin (staphylococcin 462), which inhibits the 
growth of other strains of S. aureus (Cogen et al., 2008). 
 
Host immunity against biofilm infections 
The human immune system is well adapted and able to deal with bacteria in a planktonic 
state shorn of the protection of a biofilm.  However, when encountering a biofilm-based 
infection the immune system has to deal with a host of different behaviours, phenotypes, 
and defence mechanisms.  Most research into human immunity has been based on 
planktonic models and does not consider the biofilm with its protective layer of EPS, water 
and waste channels and deep lying persister cells behaving more like a multicellular 
organism than a mere aggregation of planktonic cells (Costerton et al., 1999). 
 
Antibiotics and biofilms 
Researchers working on industrial biofilms found they had higher resistance to 
bacteriophages, amoeba and chemically diverse biocides (Costerton et al., 1993). With 
respect to medicine, biofilms have been shown to withstand host immune responses and 
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exhibit greatly reduced susceptibility to antibiotics (Cos et al., 2010).  There are many 
mechanisms through which this may be achieved and these are outlined below. 
 
Barrier to antibiotic penetration 
The resistance of biofilms to antibiotics has been shown to be between 10-1000-fold higher 
compared with the planktonic form (Anderl et al 2000).  There are many theories postulated 
for the mechanism of biofilm resistance to antibiotics and one of the most popular is the 
barrier theory.   
It has been suggested that the extracellular polysaccharide matrix surrounding the biofilms 
acts as a ‘defensive barrier’, restricting accessibility of antibiotics to the microbial cells.  
Experiments have shown that although this is the case for some antibiotics, for many there 
is merely a reduction in diffusion of antibiotics through a biofilm (Singh et al., 2010).  This 
alone does not account for the reduced bactericidal effect.  Many antibiotics are able to 
penetrate the biofilm but still do not kill as many bacterial cells as expected (Anderl et al., 
2000).  It is likely, and predicted by mathematical models that if the antibiotic can be 
deactivated quicker than it diffuses, a formidable barrier is then created to further antibiotic 
attack of the biofilm (Stewart, 1996).  Various enzymes have been shown to be present in 
biofilms, from catalase to β-lactamases all of which contribute to the resistance of the 
biofilm (Stewart, 1996). The model of faster deactivation than penetration also holds true 
for the defences of biofilms versus reactive oxidants like hydrogen peroxide.  It is thought 
poor penetration by oxidative species accounts for the failure of phagocytic cells to destroy 
biofilm bacteria.  In 2003 (Mah et al) reported that by knocking out the gene ndvB that 
synthesised periplasmic glucans they increased sensitivity to tobramycin from 100-fold 
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reduction to 100000-fold reduction in viability.  This indicated that the periplasmic glucans 
interact with the tobramycin physically sequestering it in the biofilm and preventing its 
reaching sites of bactericidal action (Mah et al., 2003). 
 
Effect of biofilm growth rate on antibiotic susceptibility  
A reduced growth rate may also be a factor in the protection of biofilm cells from 
antimicrobial agents, with transition to a slow growth phase generally recognised as a factor 
that enhances resistance to antibiotics.  It is also important to consider that every microbial 
cell within the biofilm has its own local microenvironment, with different growth rates and 
differing gradients of oxygen, nutrients and waste products present.   
 
The high level of heterogeneity of the biofilm may be vital in negating the effects of many 
antibiotics.  It has also been postulated that QS may play a protective role in antibiotic 
resistance, but this is not yet clear.  There appear to be a multitude of interacting conditions 
within a biofilm combining to form an effective defence against host immunity and 
antibiotics. 
 
Role of persister cells in resistance of biofilms to antimicrobials 
Persister cells are the portion of a bacterial biofilm that remains viable immediately after 
exposure to antimicrobials.  These persister cells do not necessarily have an enhanced or 
inherent resistance to the administered antimicrobial and are of the normal phenotype of 
the other biofilm cells.  It is hypothesised these cells survive via a mechanism of temporarily 
disabling their system for programmed cell death which is triggered under certain 
circumstances such as starvation, which may be replicated in the lower reaches of a biofilm.  
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Persister cells are capable of reproducing and later repopulating the biofilm.  Such persister 
cells are a unique feature of biofilms and not evident in planktonic populations (Marsh 
2003). 
 
Biofilms in other parts of the body  
Biofilms are ubiquitous in nature.  Humans provide a wide range of accommodating surfaces 
for microbial attachment and subsequent biofilm development.  Dental plaque is perhaps 
the most studied and described biofilm (Costerton et al., 1999).  Candidal biofilms on oral 
and vaginal mucosa and central venous lines have also been reported in the literature 
(Douglas, 2003).  
 
Introduced foreign bodies, such as endotracheal tubes and urinary catheters (Donlan, 2011) 
have been shown to provide an environment conducive to biofilm development.  
Implantable foreign bodies such as pacemakers, prosthetic joints, silicone implants and 
meshes all provide inviting surfaces for biofilm formation, resulting in significant morbidity 
and often ultimately necessitate surgical removal.    
 
Biofilms are frequently seen in chronic wounds (see Fig.2.4 assumed biofilm) and are 
regularly recognised clinically; the warm moist environment exposed to bacteria from the 
air and surrounding skin is an inviting environment for biofilm formation. 
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Fig 2.4 Macroscopic image of an assumed biofilm in a chronic wound (biofilm is the shiny 
green portion of the wound) reproduced courtesy of Prof. D. Leaper (Department of Wound 
Healing, Cardiff University)  
 
In the case of chronic wounds, it has been suggested that the biofilms source of nutrition is 
not from locally necrotic tissue but from nutrient rich plasma, neutrophils, inflammatory 
proteins and iron from lysed red blood cells delivered by the body’s circulatory system 
(Wolcott, et al., 2008).  It has been suggested that in the case of chronic wounds the biofilm 
exploits chronic inflammation and capillary transudates to secure a persistent source of 
nutrition (Wolcott, et al., 2008).    
 
It is believed that the biofilm may associate closely with blood vessels to modulate the host 
inflammatory response (Rumbugh, 2007) as in a diabetic foot ulcer with an inadequate 
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blood supply and therefore decreased host inflammatory response, increased tissue 
necrosis is observed. In such instances the biofilm is manipulating its local environment in 
terms of inflammatory responses by modulating its own behaviour and virulence through 
QS (Sandal et al., 2007).   
 
P. aeruginosa biofilms 
Pseudomonas species are common and prolific biofilm formers and can play extensive roles 
in biofilm infections (Bjarnsholt et al., 2009).  As such P. aeruginosa biofilms are highly 
studied, both as single and mixed species biofilms. 
 
When treated with antibiotics 6 out of 7 diverse microbial biofilms shifted to P. aeruginosa 
only biofilms.  However isolates of these P. aeruginosa were susceptible to the antibiotics 
when cultured in planktonic form, showing the great protective value of the biofilm 
phenotype for bacteria (Flanagan et al., 2007). 
 
Mutant non-biofilm forming strains of P. aeruginosa have been identified.  One class has 
flagella and motility mutations resulting in poor initial surface adherence and the other has 
defective type 4 pili making them unable to form microcolonies.  It is thought that the 
‘twitching’ produced by these pili is a form of surface-associated motility and is essential to 
the formation of micro colonies (O’Toole and Kolter 1998). 
 
The biofilm structure appears to be largely determined by EPS, which consists of 
polysaccharides, proteins and nucleic acids.  These EPS molecules support and shape the 
biofilm.  It has been shown that mucoid strains of P. aeruginosa produce more structurally 
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differentiated biofilms than non mucoid strains (Nivens et al., 2001) and that more 
specifically that it is a result of increased production and acetylation of alginates (a major 
component of P. aeruginosa biofilms).  Mucoid strains and those altered to increase alginate 
production will form mushroom shaped clusters of cells with corresponding water channels.  
Following attachment the algC, algD and algU genes are activated immediately after 
attachment to form the alginate extracellular polysaccharide matrix (Davies and Geesey, 
1995). 
 
As previously described, at an appropriate time, microcolonies will aggregate into true 
differentiated biofilms.  Through cell-to-cell communication P. aeruginosa can form a 
biofilm in as little as 8 hours, following inoculation on rat skin wounds (Kanno et al., 2010).  
However despite this, these acute full thickness wounds still progressed to full healing in 7 
days, as did the uninoculated controls. 
 
P. aeruginosa is an opportunist pathogen and the cause of many infections, both in wounds 
and elsewhere.  It has a high incidence of antibiotic resistance making its eradication 
troublesome.  The ability to detect P. aeruginosa infections early would not only reduce 
time spent in hospital and pharmaceutical requirements but also improve morbidity and 
mortality and help curtail the financial burden of wound infections (Sharp et al., 2010). 
 
Staphylococcus aureus biofilms 
In a study of bacterial genera in diabetic foot ulcers in 2008 staphylococci were found to be 
the primary organism detected (Dowd et al., 2008).  Staphylococci are also potent biofilm 
formers and bring a host of virulence factors and antibiotic resistance genes to a biofilm 
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Studies on porcine wounds showed that S. aureus was capable of forming a biofilm within 
48 hours post inoculation.  Topical antimicrobials (mupuricin cream and a triple antibiotic) 
took in excess of 48 hours to achieve a 2 log reduction in number of these still immature 
staphylococcal biofilms, but was very effective versus planktonic bacteria demonstrating 
that this clinically prevalent biofilm conveys a significant survival benefit to the bacteria 
within it (Davis et al., 2008).  Early and accurate recognition of the presence of staphylococci 
biofilms would also be of huge benefit in reducing morbidity and mortality from chronic 
wounds. 
 
Management strategies for biofilms 
Awareness of biofilms and their structure, virulence, and protective factors inevitably leads 
the clinician to consider various strategies for the management and control of biofilms in 
chronic wounds.  A number of different approaches to this have been adopted and can be 
broadly grouped into the following three categories; prevention of bacterial attachment, 
prevention of biofilm development and treating established biofilms. 
 
Prevention of initial planktonic bacterial attachment 
Lactoferrin inhibits biofilm formation by P. aeruginosa and S. aureus. through inhibition of 
aggregation (Valenti and Antonini, 2005).  In recent studies this was thought to be due to its 
ability to chelate iron, causing an iron deprived state in the bacteria leading to ‘twitching 
behaviour’ in P. aeruginosa causing wandering across the surface instead of forming cell 
clusters which in turn inhibits initial adhesion (Singh et al., 2002). 
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Prevention of biofilm development 
Attempts to prevent biofilm development began in industry with efforts to produce a 
surface that bacteria could not attach to and therefore not develop into biofilms.  However 
all attempts to manufacture such a surface have failed (Costerton et al., 1999).   
 
Bacteriophages have been proposed as one method for prevention of biofilm development.  
Bacteriophages are viruses that propagate in and destroy their bacterial host and some will 
hydrolyse biofilm extracellular polymers (Donlan, 2009).  Bacteriophages appear to 
penetrate biofilms effectively (Doolittle et al., 1996) and due to their replicative nature, a 
single dose could theoretically treat an entire biofilm.  However there are many obstacles to 
the effective use of bacteriophages as a therapy in humans, including bacterial host range, 
development of resistance, incorporation of virulent phage genes into bacteria and 
inactivation by the human immune system (Valenti and Antonini, 2005).  As a consequence 
their potential as therapeutic agents is still being evaluated. 
 
As previously described, QS or cell-to-cell communication is thought to be essential in 
biofilm formation.  Using ribonucleic acid 3-inhibiting peptide (RIP) which inhibits 
phosphorylation of a molecule called TRAP, which is essential in staphylococcal cell to cell 
communications; it was possible to reduce biofilm formation in Dacron grafts (synthetic 
material used to replace normal body tissues) in rats under both flowing and static 
conditions (Balaban et al., 2005).  
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Treatment of an established biofilm 
By the time it is evident that a biofilm will be a problem within a chronic wound the biofilm 
is usually already established, thus the attempted eradication of established biofilms is the 
mainstay of treatment.  Many differing methods have been described, with varying degrees 
of success (Fleck 2006, Donlan 2009, Douglas et al., 2009). 
 
Physical Treatment of an established biofilm 
Regular sharp debridement has long been held by many to be efficacious in promoting the 
healing of chronic wounds.  A sharp debridement down to bleeding tissue physically 
removes the bioburden of a wound, the devitalised tissue, bacterial biofilms and 
inflammatory components.  Similarly to the removal of an implantable device, it physically 
removes the problem.  This strategy whilst reducing bacterial counts also allows the removal 
of fibrinous material and aims to leave a well vascularised wound bed with healthy 
granulation tissue (Davis et al., 2006). However, it is not always possible to completely 
remove all the bioburden from a wound due to pain or time constraints, so other options 
also need to be considered.   
 
Ultrasound Treatment of an established biofilm 
Some studies have shown an increased rate of wound healing following an ultrasonic 
debridement.  It is felt that ultrasound as well as removing tissue may disrupt QS leading to 
a decrease in the virulence of biofilms and an increase in their susceptibility to antibiotics 
(Ennis et al., 2005). 
 
 
49 
 
Dressings and biofilms 
Some wound dressings may have anti-biofilm activity based on their chemical and physical 
attributes.  Iodine and ionic silver impregnated dressings are popular in wound care and 
used extensively in patients with suspected biofilm infection (Percival et al., 2007).  
Dressings should be changed regularly as their active anti-biofilm substances may be 
depleted with time resulting in provision of  another surface of attachment for biofilms. 
 
Antimicrobials and biofilms 
Antimicrobials and antibiotics are generally felt to be effective against metabolically active 
cells in the superficial layers of biofilms but not as effective against deeper persister cells 
(Anderl et al., 2000).  These metabolically active cells are thought to be the most 
detrimental to the host through up regulation of inflammation. Consequently treating 
biofilms with antimicrobials can improve wounds through a limited bactericidal effect 
without eradicating the biofilm.  Systemic antibiotics are used wherever there is suspicion of 
systemic infection or severe localised infection.  Ischemic wounds have a poor blood supply 
and thus antibiotic delivery and the effectiveness of systemic antibiotic therapy is reduced.  
Studies have shown limited effectiveness of antibiotics versus eradication of biofilms for 
reasons already described (Cos et al., 2010), but their effectiveness against planktonic cells 
detached by the biofilm and metabolically active cells on the periphery of biofilms means 
they are still a very useful adjunct in biofilm management. 
 
Antiseptics and biofilms 
Topical antiseptics can be used to suppress the growth of biofilm communities. Antiseptics 
can penetrate biofilms and have a considerable antimicrobicidal effect.  However some 
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antiseptics have been shown to damage human antibodies and cytokines and even kill 
human cells (Wilson et al., 2005).  Hence they are used selectively and sparingly on human 
wounds.   
 
Ionic silver and Biofilms 
It has been recognised for some time that silver can exert an antimicrobial effect at low 
concentrations (Demling and Leslie DeSanti, 2002).  The mechanism of action is through 
damage to the cell membrane, the cell membrane transport system and on the nucleic acid 
and protein function (Fleck, 2006).  Silver is more universal in terms of its activity compared 
with antibiotics being effective against gram-negative bacteria, fungi, yeast and viruses.  
Silver has also been found to have greater efficacy than chlorine (Fleck, 2006).  As with all 
antimicrobials, silver can be cytotoxic if the concentration used is too high.  Some silver 
dressings have been shown to prevent biofilm formation in vitro (Percival et al., 2007) 
although there is controversy over the concentrations required to achieve this. 
 
Polyhexamethylene biguanide and biofilms 
This is a polymeric broad spectrum cationic antimicrobial agent.  The mechanism of action is 
through impairing the integrity of the outer membrane of both Gram positive and negative 
bacteria, and has been used in chronic wounds with considerable success reported in small 
trials (Fleck, 2006). 
 
Iodine and biofilms 
Iodine has long been used to prevent infection and promote wound healing.  However, 
there is some debate as to its effectiveness as an antimicrobial, together with the possible 
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discomfort caused to patients and its toxicity towards host tissues.  In vitro it has been 
shown to impair the function of cells involved in wound healing (Schreier et al., 1997).  It 
does however have a long history of use and established effectiveness in vivo against S. 
aureus and MRSA (Methicillin Resistant S. aureus) (Mertz et al., 1999). 
 
Biomaterials and biofilms 
Large portions of biofilm infections involve implantable biomedical devices.  Various 
attempts have been made to produce a biomaterial that is inhibitory to biofilm formation.  
Liquid/air breaks, antibiotic fills and skin cuffs, tethered antibiotics, silver coatings, slow 
release antiseptics and antibiotics and mechanical design alternatives have all been trialled, 
all with little or no effect (Bryers, 2008). 
 
Iron metabolism interferenc 
Iron is critical for the growth of bacteria and the function of key metabolic enzymes.  The 
sequestration of iron is an evolutionally early host defence mechanism against bacteria 
(Bryers, 2008).  Gallium can be used as an irreversibly binding non-functional competitor to 
iron in many bacterial enzyme systems. Increasing concentrations decrease the growth rate 
of P. aeruginosa in a dose dependent manner and encouragingly it appeared to prevent 
biofilm growth and was bactericidal against mature biofilms when introduced in appropriate 
concentrations (Kaneko et al., 2007).  
   
Rotation of strategies 
Many of the above methods are of merit in particular cases and can, for a short time, be 
effective against biofilms in chronic wounds allowing the underlying wound to improve.  
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However, none of these methods are perfect and often the best strategy for management 
of wounds complicated with biofilm infection is to combine or rotate several methods, 
giving the wound enough respite from the biofilm to progress towards healing. 
 
Wound diagnostics 
Several wound diagnostic methods for bacteria in wounds have been available for a long 
period of time.  All those involved in treating wounds will be familiar with the use of wound 
swabs and classical microbiological tests for bacteria.  While useful for identifying bacterial 
species, classical culture has been shown to identify as little as 5% of bacterial species, 
missing potentially relevant pathogens, whilst also being time consuming and labour 
intensive.  This can be remedied to some extent by the use of molecular approaches such 
PCR.  However these tests cannot given their reductionist nature or provide us with any idea 
of the organisation or structure of the bacterial communities in chronic wounds.   
 
Bacterial staining such as Gram or Ziehl-Neelsen stains are fast and inexpensive and of use in 
giving direct visualisation and crude characterisation, but due to the ‘paucity of 
morphological distinctions among bacteria’ (Moter and Göbel, 2000) do not allow reliable 
identification of species. 
 
The ultimate goal in wound diagnostics would be a rapid acting, economically viable, non 
invasive test giving accurate information concerning bacterial species present, their 
numbers, and their organisation into communities or biofilms. 
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PCR 
Molecular diagnostic techniques based upon PCR can now give us rapid and sensitive 
identification of bacterial species present in a wound independent of their viability in 
culture.  These techniques are however limited in that they give no information on numbers 
present or spatial distribution of bacteria (Amann et al., 2001). 
   
The 16SrDNA gene sequencing tool provides a means of tracing and identifying bacteria 
from various sources by elucidating their phylogenetic relationships.  It is powerful and 
accurate on miniscule sample sizes and for identifying bacteria that are difficult or 
impossible to culture.  Limitations include a lack of information on antibiotic resistance; the 
variability between strains of the same species and the fact the database does not include 
newly discovered microorganisms (Schreier et al., 1997). 
 
Confocal Laser Scanning Microscopy (CLSM) 
Several different microscopy techniques have been evaluated for the observation of 
biofilms.  Light microscopy, transmission electron microscopy and scanning electron 
microscopy have all been used to accurately visualise the structure of biofilms.  These 
techniques suffer severe limitations, either through only allowing surface viewing of the 
biofilms or requiring its dehydration.  Dehydration of biofilms has been shown to account 
for a loss of up to 98% of its in vivo mass (Sutton et al., 1994). 
 
Confocal Laser Scanning microscopy (CLSM) allows three-dimensional imaging of biofilm 
sections without the need for dehydration or physical disruption.  As a consequence CLSM 
has quickly become the ‘gold standard’ for biofilm imaging.  To obtain more detailed 
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analysis of biofilm structure and the species within it, FISH which can provide species 
specific fluorescent labelling, is often used in association with CLSM. 
 
Fluorescence in situ Hybridisation (FISH) 
FISH is a method that can provide more detail to the images obtained on a CLSM, through 
fluorescently labelled probes specific to certain bacteria emitting light of a specific range of 
wavelengths.  FISH is an interesting technique that allows ‘simultaneous visualisation, 
identification, enumeration and localization of individual microbial cells’ (Moter and Göbel, 
2000).  It is hoped that this technique can be culture independent and combine the 
precision of molecular genetics with the visual information of microscopy allowing bacterial 
communities to be accurately characterised in terms of structure and composition. 
 
In Situ hybridisation was first developed by two independent research groups (Pardue and 
Gall 1969, John et al 1969) using radioactive labels.  The method was initially developed to 
allow examination of nucleic acid sequences within cells without altering cell morphology.  
In situ hybridisation was first used on bacterial cells by Giovanni et al. in 1988.  Radioactive 
labels were replaced with fluorescent ones for microbial detection by Delong in 1989.  
Fluorescent dyes were clearly superior in terms of safety, speed of process and allowing 
multiple dyes with different wavelengths to detect several target sequences with a single 
hybridisation step.  FISH has developed in both sensitivity and speed over the last 20 years 
making it a powerful tool in phylogenetics, ecologics, diagnositics and environmental studies 
in microbiology (Amann et al., 2001).  Thurneer et al., 2004, neatly described the use of FISH 
to investigate a mixed species biofilm with simultaneous 16srRNA targeted oligonucleotide 
probes.   
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FISH was originally described with DNA and RNA probes.  However over the last decade PNA 
(Peptide Nucleic Acid) probes have been introduced.  PNA probes are DNA analogues with 
an uncharged polyamide spine instead of sugar phosphates and are stable to degradation.  
These probes hybridise to complementary sequences with a higher affinity and have 
different hybridisation characteristics (Prescott and Fricker, 1999).  PNA probes are superior 
in their penetration of hydrophobic cell walls due to their neutral backbone in contrast to 
oligonucleotide probes. 
   
As with any technique FISH suffers from several limitations.  Auto fluorescence of both 
human and bacterial cells can considerably hamper the gathering of accurate information.  
It also requires very narrow wavelength probes and multiple sections for negative controls 
to avoid false positive results.  Probe specificity and insignificant penetration of the probe 
into a biofilm can lead to falsely negative results as can variability between cells of target 
sequence.  Photo bleaching of the probes under the very high laser energy focused upon a 
small area of the slide requires rapid focusing and data storage and reduces the 
reproducibility of the technique.  FISH also requires specimen processing fixation and 
dehydration, potentially leading to similar problems encountered in Transmission Electron 
Microscopy and Scanning Electron microscopy, thus limiting its utility in the observation of 
dynamic changes in live biofilms.  
 
 
 
 
56 
 
Enzyme-linked immunosorbent assay (ELISA) 
Monoclonal antibodies raised to specific bacterial strains exhibiting immunofluorescence 
can be highly species specific and fast acting allowing rapid identification of bacterial 
species.  Limitations to this method include non-specific binding, and ‘antibody size 
restricting easy access to their target antigens within tissues or biofilms’ (Meyer-Reil et al., 
1980).  This method still requires culture of the bacteria to raise a specific antibody and 
would involve the use of multiple antibodies on single samples, leading to issues of ‘cross-
reactivity of monoclonal antibodies’ (Moter and Göbel, 2000). 
 
Guggenheim et al., (2001) demonstrated that specifically raised monoclonal antibodies to 
Streptococcus mutans could be detected not only in the planktonic phenotype but also 
accurately in a 3 species in vitro biofilm and in an in vivo biofilm.  It was postulated that the 
tight structure of a biofilms EPS could potentially serve as a size exclusion barrier to large 
molecules entering the biofilm.  However immunoglobulin G (IgG) has been shown to be 
small enough to migrate through biofilm matrix (Zhu et al., 2001).  More recent studies 
contradicted this, with Thurnheer et al., (2004) demonstrating that IgG penetrates into the 
biofilm but that movement is impaired by the matrix and possibly blocked in areas with 
smaller pores.   
 
The use of monoclonal antibodies to identify species of bacteria within biofilms by CLSM is 
exciting due to its potential to allow study of a dynamic biofilm.  It does however have 
limitations secondary to increased molecular size versus matrix pore size and durability of 
the associated fluorescent probes. 
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Why further characterisation? 
The microbial communities formed by bacteria present obstacles to the clinician in both 
diagnosis and management.  Biofilms are resistant to many biocides, antibiotics and wound 
care products.  Better characterisation of microbial communities in chronic wounds will 
allow the development of more targeted strategies to combat this problem. 
 
It is important to find new and effective ways to characterise biofilms.  A clinically important 
biofilm may be present without being amenable to culture; it is thought that only 10% of all 
bacteria are culturable (Davies et al., 2004).  Bacteria within a biofilm, such as persisitor cells 
with a slow metabolism, may also be unable to divide sufficiently within 48 hours to be 
cultured.  With more information on biofilm composition and structure we will be able to 
engineer more appropriate treatments. 
 
Knowledge of the exact structural composition of bacterial communities in chronic wounds 
and the metabolism and manipulation of biofilms should aid us in the development of 
improved measures against these common diseases (Thurnheer et al., 2001). 
Investigations in vivo are difficult due to the inability to control variability between patient 
factors, bacteria and the wound environment; no two wounds will be identical, rendering 
any randomised controlled trials difficult, if not impossible.  Further characterisation of the 
bacterial community in chronic wounds may enable the construction of a more accurate 
model for research.  Animals do not suffer chronic wounds and as such provide no suitable 
models. 
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A key goal for management of wound infection is an early warning diagnostic method that 
would allow the non-invasive detection of the early stages of tissue or implant infection 
allowing an expedient response (Parvizi et al., 2006). 
 
Aim of the thesis   
This study aims to demonstrate ways of characterising bacterial communities in chronic 
wounds by identifying bacteria within biofilms, through the collection of appropriate 
microbiological samples from wounds, to build up an accurate pool of clinical samples for 
detection strategies. 
 
The EPSRC project which kindly partly funded this research had developed novel 
Monoclonal antibodies (MABs) to both S.aureus and P.aeruginosa.  This thesis will 
concentrate on efforts to characterise bacterial communities of S. aureus and P. aeruginosa. 
Both of these species are commonly found within chronic wounds, are selectively 
pathogenic, easily culturable and prolific biofilm formers making them ideal candidates for 
demonstrating methods of characterising bacterial communities within chronic wounds. 
 
The following chapters will cover the collection and microbiological typing of chronic wound 
associated specimens. We will also use novel MABs in the detection of bacteria in these 
samples, using fluorescent microscopy, ELISA, FISH and the CLSM to identify bacteria within 
biofilms and demonstrate biofilm architecture.  It is hoped that more accurate 
characterisation of the bacterial communities in chronic wounds will increase our 
understanding of these communities and lead to novel detection and treatment strategies. 
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Chapter Three: Collection and Microbiological Analysis of Wound Samples 
 
Introduction 
Chronic wounds remain an expensive and growing problem worldwide, particularly in the 
industrialised world with its ageing and increasingly obese population.  Chronic wounds 
currently cost 2.3-3.1bn pounds per year in the UK alone (Posnett and Frank 2008) and over 
10bn dollars per annum in the USA (Bickers et al., 2006).  One to two percent of the 
population in developed countries develops chronic wounds, (Fazli et al., 2009) a condition 
associated with severe patient suffering, loss of employment and reduced quality of life 
(Gottrup, 2004).   
 
Whether or not a wound develops chronicity is based upon many factors (Jones et al., 
2004).  It is however, generally agreed that an unfavourable microbial population can be a 
significant causative factor for chronic wounds (Mustoe et al., 2004).  Bacterial damage in 
non healing wounds is mediated through the destructive effects of chronic inflammatory 
reactions inhibiting key processes in wound healing (Jones et al., 2004, Junger and Sorkin 
2000) and the creation of a high protease, high oxidase environment resulting from the 
bacteria and attracted leukocytes.  It has been suggested that maintenance of chronicity 
may be determined by bacterial burden (Bjarnsholt et al., 2008) 
 
In order to better characterise bacterial communities in chronic wounds, it is important to 
collect information on the likely species present in the chronic wound.  It is also pertinent to 
consider the chronic wound environment, as any potential method of characterising 
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bacterial communities will have to operate effectively in an environment containing both 
bacteria and chronic wound fluid. 
 
In order to develop improved methods to characterise bacterial communities in chronic 
wounds, it would be useful to construct a chronic wound model on which these methods 
can be tested.  There is no animal chronic wound model, as animals do not suffer from 
chronic wounds due to effective skin contraction and the relative absence of aged animals 
(Mustoe, 2004).  Methods of wounding animals to try and reproduce in vivo models has 
been attempted using various and ingenious ways, from skin banding in guinea pigs 
(Constantine and Bolton, 1986) to rabbit ear models (Ahn and Mustoe, 1990).  Models to 
reproduce ischaemia have also been trialled ranging from the use of flap surgery (Quirinia et 
al., 1992) to decrease blood supply, to the injection of chemotherapeutic agents into the 
dermis to produce localised ischemia (Rudolph et al., 1979).  In vitro methods include the 
production of biofilms from wound isolates using the Constant Depth Film Fermenter 
(CDFF;Hill et al., 2010) and the Lubbock Chronic Wound Biofilm Model (Sun et al., 2008). 
 
Despite the work outlined above, to date there is no recognised standard model to use for 
the study of chronic wounds.  In this thesis, efforts have been made to collect wound fluid 
eluted from chronic wounds and acute wounds and then characterise the chronic wound 
microflora.  A variety of approaches are used to characterise the bacterial communities, 
with focus on detecting S. aureus and P. aeruginosa within chronic and acute wound fluid.  
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Bacterial species in chronic wounds 
As previously described in the literature review (Chapter 2 section: bacterial colonisation vs. 
wound infection), no chronic wound is sterile; all chronic wounds have a bacterial 
component ranging from simple colonisation to an aggressively invasive biofilm, and 
systemic sepsis (Edwards and Harding 2004).  The diverse microflora present within many 
chronic wounds includes both anaerobic and aerobic species (Price et al., 2009).  These 
bacteria originate from skin, oral mucosa, enteric tract, and the wider environment, and are 
significantly different from populations found on normal skin.  The microbial populations are 
thought to vary between different types of chronic wound (Martin, 2009, Davies et al., 
2004).  The effect of these bacteria is dependent on many factors including species, 
composition, concentration, and host response (Frank et al., 2009).  The role of these 
organisms in impairing wound healing is complex and may include both direct and indirect 
mechanisms (Stephens, et al., 2003, Wall, et al., 2002).  See Chapter 2, (section: Mechanism 
of Bacteria promoting chronicity) for more detail.  
 
Many bacteria have been identified from chronic wounds; and traditionally these have been 
isolated through culture in an agar medium under aerobic and anaerobic conditions, 
however, isolation of bacteria in this manner does not identify the full range of bacteria 
present.  Despite the fact that new organisms are being continuously isolated, it is 
estimated that only a small fraction of all microorganisms have been grown in pure culture 
and isolated (Botarri et al., 2006).  There is a loss of information not just of number of 
species but also their prevalence, and the architecture and structure of the bacterial 
communities being identified.  Indeed some studies using molecular techniques 
demonstrate that only 1% of bacteria can be grown in culture (Martin, 2009) and molecular 
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analysis reveals an average of 10 species per chronic wound, approximately four times more 
than demonstrated with culture (Martin, 2009). Interestingly normally cultured bacteria 
were often found only through molecular methods raising the question of competition and 
overgrowth, with sessile growth states complicating the picture further (Davies et al., 2004).  
 
Chronic wounds support a wide variety of microbial flora due to the different 
microenvironments present within the wound bed and its accessibility to organisms.  A 2007 
study (Davies et al.,) showed that the predominant organisms in chronic wounds from both 
surface swabs and tissue biopsies were Staphylococcus species and P. aeruginosa, present in 
71.2% of patients.  In bacterial profiling studies (Gjodsbol et al., 2006) found that chronic 
venous leg ulcers harboured S. aureus in 93.5% and P. aeruginosa in 52.2% of cases.  In view 
of this predominance, their pathogenicity and biofilm forming ability, it was decided to 
concentrate on these species for identifying ways of better characterising bacterial 
communities in chronic wounds. 
 
Staphylococcus aureus in wounds 
Staphylococcus aureus are characterised by golden yellow circular colonies, and β-
haemolysis of blood agar.  The coagulase-positive, S. aureus is a leading human pathogen 
with infections ranging from minor self-limiting skin infections to invasive and life 
threatening disease. Staphylococcus aureus is recognised to be a prolific biofilm former, and 
widely present within chronic wounds (Oliveira et al., 2003). 
 
Staphylococcus aureus is the most commonly isolated bacteria from chronic wounds (Davies 
et al., 2004, James et al., 2008).  There are varying estimates as to its prevalence ranging 
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from 60% (Kirketerp-Moller et al., 2008) to one study demonstrating S. aureus in 93.5% of 
all investigated chronic venous leg ulcers (Gjodsbol et al., 2006).  
 
Pseudomonas aeruginosa in wounds 
P. aeruginosa is a gram negative rod shaped motile aerobic bacteria.  It is commonly found 
on non-sterile areas of healthy individuals and is a normal constituent of human microflora.  
P. aeruginosa are opportunistic pathogenic bacteria widely known to cause chronic biofilm 
based infections (Fazli et al., 2009); it has been demonstrated to be present in 52.2 % of 
chronic venous leg ulcers. 
 
P. aeruginosa is a recognised prolific biofilm former, most commonly studied in cystic 
fibrosis sufferers (Bjarnsholt et al., 2009) and are very resilient to both host defences and 
antimicrobials (Yang et al., 2008).  The ability of P. aeruginosa to form EPS encapsulated 
biofilms resistant to polymorphonuclearneutrophils (PMNs) is thought to be its main 
survival strategy for hostile human environments (Bjarnsholt et al., 2008) 
  
P. aeruginosa biofilms predominate in those patients who have undergone recent antibiotic 
therapy shifting the profile of relatively diverse wounds to P. aeruginosa dominated colonies 
(Price et al., 2009).  The ability of P. aeruginosa to form biofilms, and be resistant to 
antibiotic eradication, has led to it being hypothesised that P. aeruginosa biofilms are the 
main cause for resistance to host defences and the chronic inflammatory states seen in 
many chronic wounds, and that their ability to neutralise PMNLs lead to a more attractive 
environment for other opportunistic bacteria to thrive within the chronic wound (Bjarnsholt 
et al., 2008). 
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Wound fluid 
Wound fluid or exudate was first described by the Swiss physician Paracelsus in the 
sixteenth century as “nature's balsam” (Haeger, 1925).  Wound fluid is produced as a 
response to the presence of a wound via the inflammatory process, leading to extravasation 
of serum.  It has a high protein count and specific gravity of 1.020 (White and Cutting, 2006).  
The production of exudate is part of the normal wound healing sequence in acute wounds.  
When a wound becomes chronic either through infection or inflammation the exudate has a 
different composition with proteolytic enzymes and components not seen within acute 
wounds (White and Cutting, 2006).  
 
Collecting wound fluid was important in this study in order to investigate the bacterial 
characterisation profiles in more detail; any future bacterial detection system used for 
research or clinical practice would need to operate effectively in an environment dominated 
by wound fluid.    
 
Chronic wound fluid 
Chronic wounds are different to acute wounds; there is an increased inflammatory 
response, vascular permeability, and often an infectious state.  As previously stated it is felt 
that bacteria and especially biofilms can up regulate the inflammatory response increasing 
the volume of exudate considerably.  Therefore it can be expected that chronic wound 
exudate will also be different in both volume and composition to acute wounds. 
Several studies have looked at the composition of chronic wound fluid (Trengrove et al., 
1996, Wysocki et al., 1993).  Prior to these studies it was assumed that fluid consisted 
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entirely of tissue or extracellular fluid and was dismissed as modified serum of little interest 
to wound healing.  Recent studies on the composition of chronic wound fluid have shown it 
is in fact a complex ‘soup’ consisting of electrolytes, glucose, growth factors, cytokines, 
proteinases, and adhesion molecules, bacteria, immunoactive cells, and molecules of the 
extracellular matrix such as MMPs (matrix metalloproteinases) and neutrophil elastase 
(Beidler et al., 2008, Moor et al., 2009).    
 
MMPs influence cellular functions by altering the microenvironment around cells affecting 
cell migration through matrix degradation (Vu and Werb, 2000).  Growth factors are 
released by selected subsets of cells and usually have a trophic effect upon cells in the 
wound, however it has been suggested that they may indirectly mediate the inflammatory 
response, as the many pro inflammatory cytokines do (Baker and Leaper, 2000, Moor, et al., 
2009).  This fluid also contains neutrophils, polymorphonuclear leukocytes, macrophages, 
and foreign body giant cells.  The proteases present in the wound fluid are capable of 
degrading every known constituent of soft connective tissue, and it has been suggested that 
chronic wound exudate can be regarded as a wounding agent in its own right (Moor et al., 
2009, Palolahti et al., 1993).  An imbalance between proteases and their inhibitors may be 
contributory to the chronic wound state (Grinnell and Zhu, 1996, Rao et al., 1995). 
 
Chronic wound fluid also contains bacteria of many different species, the most common of 
which are Staphylococcus and Pseudomonas species. Studies have consistently 
demonstrated colony counts to be higher in wound fluid than in wound tissue from the 
same wound (Breuing et al., 2003).  
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Collection of chronic wound fluid 
Chronic wound fluid is not easy to collect.  Despite a relatively large population of people 
presenting with chronic wounds and a significant proportion of these with heavy exudate 
causing significant excoriation, it has always proved difficult to collect wound fluid in the 
significant quantities required for reproducible experiments.  There is a lack of consensus in 
the many methods of collection of wound fluid with no singular universally accepted 
method (Bowler et al., 2001).  Many methods of collecting wound fluid have been described 
from catching wound fluid dripping from the wound in a sterile container to using occlusive 
dressings, centrifuging them and collecting the supernatant.  Several groups have tried 
aspirating with a sterile needle from under an occlusive dressing (Rayment et al., 2008, He 
et al., 1999).  Typical amounts collected were 50-200µls per wound in recent studies (Moor 
et al., 2009).  In view of these difficulties, it was decided to collect wound fluid from chronic 
wounds using the catch and release system, and to dilute it in processing with TRIS 
(hydroxymethyl aminomethane) buffered saline to ensure the collection of sufficient 
quantities that would allow meaningful and repeatable experimentation, while accepting 
that this fluid was more dilute than concentrated wound fluid collected using alternative 
methods. This process would dilute the numbers of bacteria found with within chronic 
wound samples and the concentration of electrolytes, glucose growth factors cytokines and 
MMPS.  However, this approach would dilute all of these equally and provide enough fluid 
for meaningful repeatable experimentation.  
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Acute Wound Fluid   
In view of the difficulties previously described in collecting large volumes of chronic wound 
fluid, it was felt that a chronic wound fluid substitute would be beneficial for analysis.  Acute 
wound fluid was considered to be sufficiently similar to provide an analogous fluid for 
chronic wound fluid.  The most prolific source of acute wound fluid available was deemed to 
be post mastectomy wound fluid.  Mastectomy is a commonly performed operation, and is 
considered ‘clean’ surgery and representative of an acute wound (Baker et al., 2008).  The 
surgery leaves a relatively large area which is enclosed and can be drained effectively by a 
conventional tube drain, or vacuum drainage system.   Post mastectomy fluid is available in 
large quantities post operatively and for several days/weeks following the procedure.  It is 
worth noting that fluid may be of varied with likely sources being post-operative blood, 
exuded tissue fluid, and lymphatic channel origin (Baker et al., 2008).   
 
The composition of growth factors and MMPs in acute wound fluid has been shown to be 
highly variable between samples (Baker et al., 2008).  Different levels of growth factors have 
been identified on various post operative days, with growth factors peaking on post 
operative day (POD) one and then declining, consistent with the acute inflammatory 
response.  MMPs tended to be lower on POD 1 and peak on POD 2 to 3 (Baker et al., 2008).  
Acute wound fluid can also be described as bloody, serous, as well as ranging between these 
two descriptors, unsurprisingly bloody samples have been shown to contain more growth 
factors.  Interestingly, the more serous samples appear to contain more MMPs (Baker et al., 
2008). 
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Acute wound fluid is not analogous to chronic wound fluid, it is macroscopically different 
and is more likely to be bloody or serosanguineous. Acute wound fluid is also different in its 
composition of growth factors and proteolytic enzymes.  In the first 43-72 hours, platelets 
and fibrin may be present which are not present in chronic wound fluids (White and Cutting, 
2008).  Comparisons have also shown differences in neutrophil activity.  For example, it has 
been demonstrated that fluid from some venous leg ulcer patients (but not fluid from 
mastectomy patients) contain high neutrophil elastase activity (Hoffman et al., 1998). 
Despite not being analogous with chronic wound fluid acute wound fluid is readily available 
in large amounts, and consists of a soup of extracellular fluid growth factors and MMPs, 
whilst far from being identical, this similarity makes it a useful alternative to perfect 
methods prior to chronic wound fluid testing.  
 
Wound imprints 
An imprint of a wound was produced by transfering a dressing which had been placed 
directly on a wound on to a piece of sterile blotting paper. This paper subsequently 
absorbed the wound fluid and debris.  Wound imprints were also collected to allow further 
information for the development of a wound model.  It was considered that the collection of 
wound imprints would also be of value in the development of any future wound diagnostic 
method, which theoretically could be embedded within dressings.  Any diagnostic 
embedded within a dressing would have to be effective in detecting bacteria through the 
fluid and material transferred from the wound to the dressing, therefore wound imprints 
provide an accurate model of conditions in which any potential dressing based diagnostic 
would function. 
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Debrided wound tissue 
In order to provide further detailed characterisation of bacterial presence across a range of 
clinical samples that may be easily collected in an outpatient setting, samples of debrided 
tissue were also collected.  Punch biopsies have previously been utilised for the recovery of 
bacteria (Gardner et al., 2006), and for the detection of biofilms (Malic et al., 2009).  Whilst 
infected wounds are frequently surgically debrided, to the author’s knowledge no previous 
microbiological studies have been performed on these readily available and potentially 
useful tissue samples. 
 
Polymerase chain reaction (PCR) analysis of microbial composition in wounds 
PCR is a molecular technique that can be exploited for the rapid and sensitive detection and 
identification of bacteria in a wound.  The method relies on the use of oligonucleotide 
primer pairs that are specific to bacterial DNA sequences. The targets for the primers are 
selected based on established DNA sequences of target microorganisms or may be generic  
allowing the detection of a wide range of microorganisms.  DNA is extracted from an 
appropriate sample and this provides the template for PCR.  Repeated cycles of primer 
annealing, primer extention (DNA synthesis mediated by Taq polymerase and incorporation 
of nucleotide bases) and DNA denaturation, permits the exponential amplification of the 
targeted DNA.  As a result, even targets that are in low abundance within a sample can be 
amplified to a detectable level, thereby offering great sensitivity.  The fact that bacterial 
detection by PCR is not reliant on cell viability means that even those microorganisms that 
are ‘unculturable’ using conventional methods can be analysed.  This is important as it has 
been estimated that as few as 1-2% (Dowd et al., 2008, Martin, 2009) of bacteria within 
chronic wounds are culturable by conventional methods. Standard PCR techniques are, 
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however, limited as they are not really quantitative and therefore give no information on 
numbers of target microorganisms present nor the spatial distribution of the bacteria within 
the wound (Amann et al., 2001). Other limitations include the lack of information provided 
on antibiotic resistance, potential sequence variability between strains of the same species 
and the fact databases do not include sequences of newly discovered microorganisms 
(Schreier et al., 1997). In this chapter, PCR was performed on chronic wound fluid samples 
specifically targeting P. aeruginosa and S. aureus DNA within the samples. The use of a 
universal bacterial PCR targeting 16S rDNA gene sequences as added confirmation of 
bacterial presence or absence from the collected samples. 
 
Aims 
The aims of the chapter were to provide data on the collection, microbiological typing, and 
storage of clinical samples from chronic and related wounds.  These samples were collected 
to provide a suitable bank of samples to test different methods of characterising bacterial 
communities in chronic wounds and to provide the components to recreate key parts of the 
chronic wound environment.  
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Materials and Methods 
Various sample types were collected for this research.  All sample sources were from unique 
patients, and no patient was sampled more than once in the same category, nor were 
patients sampled in two different categories (such as in chronic wound fluid and debrided 
wound tissue). 
 
Collection of chronic wound fluid  
All samples were taken from a cross section of unique patients with chronic wounds 
presenting with heavy exudate.  Ethical approval was granted and informed consent was 
obtained (see Appendix 1) to collect samples of chronic wound fluid from recruited patients 
from the wound healing department of a large teaching hospital within an NHS Trust.  
Prospective patients were given an information sheet (see Appendix 2) and an appointment 
was made for them to attend the research clinic at the University Hospital.  After 
information about the study was presented and full written informed consent was obtained 
(Appendix 1), the wounds were then dressed with RELEASETM (Systagenix Wound 
Management Limited, Gatwick, UK) dressings and wrapped in cling film, to prevent moisture 
loss, for four hours.  RELEASETM (Johnson and Johnson Medical Limited, Ascot, UK) dressings 
were used as these consist of gauze with a non-adherent layer, and have no reported 
evidence of bacterial sequestration.  Dressings were placed into sterile containers using 
sterile forceps and these were in turn placed in a secure and appropriately labelled icebox 
for transportation to the laboratory.  The majority of samples were collected in the 
outpatient clinic, however, three samples were collected from patients at home, as this was 
more convenient for the patients concerned.  All samples collected in and out of the 
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hospital environment were transported in sealed sterilised containers within iceboxes 
containing carbon dioxide pellets for no longer than 30 minutes until processing in the 
laboratory. 
   
On arrival in the laboratory, the samples were removed from the sterile containers and the 
dressings were cut into 5 cm x 5 cm squares, these were placed in a sterile Petri dish with 
12.5 ml of TRIS (hydroxymethyl aminomethane) buffered saline with Tween (Wound fluid 
elution buffer; 0.1M Tris-HCl buffer, pH 7.4, containing 0.1% Triton X-100) and agitated on a 
tilt board at a medium speed for at 4°C for 4 hours.  The samples were then returned to the 
laboratory and with sterile forceps the fluid was squeezed out of each dressing; the eluted 
fluid was then recombined in a sterile bottle. A 100 µl volume of the chronic wound fluid 
was serially diluted and plated out on blood, MSA (Mannitol Salt Agar), and Pseudomonas 
agar.  These plates were incubated for 24 hours at 37°C and colonies counted to give a 
reading of bacterial load in each sample.  Each isolate was then subjected to classical 
microbiology and PCR to aid speciation. The remaining fluid was then aliquoted into falcon 
tubes for storage at -80°C in a locked Human Tissue Authority approved freezer. For a full 
flow chart of chronic wound fluid collection please see fig 3.0 below.   
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Fig 3.0 Flow chart of collection of chronic wound fluid 
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Collection of acute wound fluid  
Ethical approval was granted and informed consent obtained to collect samples of post 
mastectomy drain fluid from patients in a large NHS teaching Hospital under the care of a 
single consultant breast surgeon (Appendix 3).  Patients were approached prior to their 
mastectomies; patient information sheets were given (Appendix 4) and questions answered.  
On postoperative day one appropriate patients were approached, information reiterated, 
and written informed consent taken.  All patients were sampled on day one and day two 
post operatively.   
 
Inclusion criteria consisted of a consecutive cohort of patients undergoing mastectomy by a 
consultant breast surgeon in a large NHS teaching hospital between May and December 
2008.  No one was excluded except at their own request.  Acute wound fluid samples were 
taken from nine patients on post operative day one and post operative day 2 following 
mastectomies performed.  Most patients had 2 drains and therefore two samples were 
collected on day one labelled A and B, and 2 samples on day 2 labelled C and D.  Patient 4 
only had one drain and was therefore only labelled A for day one and B for post operative 
day 2.  One patient refused on moral grounds to enter the study, as antibodies to be used 
later on the fluid were developed in animals. She has been referred to as patient number 10 
in all the tables for comparison to the selected group and her samples safely discarded 
according to her wishes.   
 
Mastectomy drain fluid bags were removed from the drains, the amount of collected fluid 
was recorded in the medical and nursing notes, and empty bags fitted to the drains with 
aseptic technique.  The wound fluid bags were then placed in a secured labelled transport 
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container chilled with dry ice to approx 4°C.  On return to the laboratory these samples 
were decanted into falcon tubes in 5-ml aliquots and stored in a locked -80°C Human Tissue 
Authority approved freezer. 
 
For the purposes of identification in analysis, samples were labelled 1-9 (patient number 10s 
samples were not analysed).  Most patients had 2 drains so samples from these on post 
operative day one were labelled A and B, and on post operative day 2, labelled C and D. 
Therefore, samples for each donor were divided into A, B, C and D except sample 4 in which 
the donor had one drain only and thus only A and B samples, a total of 34 samples.   
 
Acute wound fluid (100 µl) from each sample was serially diluted and plated on to blood 
agar, MSA, and Pseudomonas agar.  These agars were then incubated for 24 hours at 37°C 
and resulting colonies enumerated to determine bacterial load in each sample.  Each isolate 
was then subjected to traditional microbiological identification procedures and PCR to allow 
identification. 
 
Collection of wound imprints and swabs 
Inclusion criteria included a wound duration of greater than one year, and all wounds would 
have been dressed with simple hydrofibre dressing, so no dressing components would be 
present to affect the imprints. 
 
Wound dressings were collected from patients attending the wound healing outpatient’s 
clinic in a major NHS teaching hospital in accordance with the ethical approval.  An 
information sheet was given and full informed consent taken (Appendix 2).  Only patients 
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with plain Hydrofibre*(Convatec Limited, Uxbridge UK) dressings that were soaked through 
with exudate were approached to participate in the study.  Wound imprints were collected 
exclusively from patients with chronic wounds which were judged to have dressings which 
were wet secondary to high exudate, and would give a good imprint onto blotting paper.  
These wounds were all dressed with plain Hydrofibre dressings as this retains a large 
amount of wound fluid and is amenable to imprint.  Each patient’s wound(s) was swabbed 
and samples placed in a labelled sterile dry-ice filled secure container and transported to 
the laboratory.  
 
Dressings were imprinted on to clean filter paper in sterile conditions; the dressings were 
then appropriately discarded.  The filter paper was dried overnight in a sealed container and 
stored in a -80°C freezer in accordance with the Human Tissue Act.  Only filter paper, which 
had become saturated on both sides was removed with the hole punch for further testing 
from the frozen samples. 
 
Swabs were used to inoculate Blood agar, MSA and Pseudomonas agar and incubated at 
37°C overnight.  Colonies were then Gram-stained and tested for catalase, oxidase and 
coagulase activity as previously described.  Bacterial isolates were then stored as described 
previously. 
 
Collection of debrided wound tissue and swabs 
Debrided tissue was collected from patients attending the wound healing outpatients clinic 
in a major NHS teaching hospital in accordance with the ethical approval obtained (see 
Appendix 5).  An information sheet was given and fully informed written consent taken.  
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Only patients with infected wounds at the time of review requiring sharp debridement in 
the normal course of treatment were considered for participation in this part of the study.  
No patient underwent sharp debridement solely for the purposes of this study.  
Debridement occurred following the application of a topical local anaesthetic 
EMLA (Eutectic Mixture of Local Anaesthetics containing lidocaine and prilocaine, APP 
Pharmaceuticals) for thirty minutes; debridement was sharp to bleeding tissue.  Each 
patient’s wounds were swabbed prior to application of local anaesthetic and debridement.  
Swabs were placed in an ice filled labelled secure container and transported to the 
laboratory.  Debrided tissue was placed straight into formalin for fixation prior to paraffin 
embedding by standard histological technique. 
 
Method of Microbiological Identification 
AGARs: the following standard methods were used to ensure that the samples were treated 
in a systematic and consistent way. 
MSA-OXOID Mannitol Salt Agar - 111g was suspended in 1 L of distilled water and brought 
to the boil to dissolve completely.  The resultant liquid was sterilised by autoclaving for 
15minutes at 121°C and then cooled in a water bath (Laboratory thermal engineering) at 
56°C.  It was then poured into aseptic Petri dishes and cooled further, stored at 4°C. 
PSEUD-LAB M LAB 108 Pseudomonas agar base- 48.4g was suspended in 1 L of distilled 
water soaked for 10 minutes- swirled to mix and added to 10 ml of glycerol sterilised by 
autoclaving for 15 minutes at 121°C cooled to 47°C and 2 vials of LABM supplement X107 
(Cetrimide, Nalidixic acid) diluted in 5 ml of sterile water, and the solution then aseptically 
dispensed into Petri dishes. 
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BLOOD-LAB M Blood agar base- 39.5g was dispersed in distilled water soaked for 10 
minutes, and swirled to mix, then autoclaved for 15 minutes at 121°C, cooled to 47°C in a 
water bath, and 5% of defibrinated sheep blood, was mixed in and the solution then 
aseptically dispensed into Petri dishes. 
 
Gram Stain-protocol 
A loop of the liquid culture was transferred to the surface of a clean glass slide, and spread 
over a small area.  For staining of material from a culture growing on solid media, a loop of 
sterile water was placed on a slide; using a sterile cool loop transfer a small sample of the 
colony was added to the drop, and emulsified.  The film was allowed to air dry. The film was 
then fixed by passing it briefly through the Bunsen flame two or three times without 
exposing the dried film directly to the flame. The slide was kept cool so as to not be 
uncomfortable to the touch. 
The slide was flooded with crystal violet solution for 1 min and washed briefly with tap 
water (no longer than 5 seconds). The slide was then flooded with Gram's Iodine solution, 
which was allowed to act (as a mordant) for 1 min and then washed off with tap water. 
Excess water was removed from the slide and the slide blotted, so that alcohol used for 
decolourisation was not diluted. The slide was then flooded with 95% alcohol for 10 s and 
washed with tap water. The slide was then flooded with safranin solution and allowed to 
counter stain for 30 seconds, and washed off with tap water. The slide was then drained and 
blotted dry with bibulous paper.  Slides were were examined by standard light microscopy 
under oil immersion lens (x1000). 
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Coagulase test 
Coagulase-Oxoid Diagnostic reagents staphylase test (Oxoid Limited Basingstoke, United 
Kingdom) was used in detecting free and bound coagulase (or clumping factor) which is 
characteristic of Staphylococcus aureus. 
Test and control reagents were shaken vigorously to obtain a homogenous suspension. Any 
reagent cells that were trapped in the dropping pipette were mixed into the suspension.  A 
loop was used to smear 1 to 3 of the suspect colonies on a test circle and a control circle on 
the Reaction Card.  One drop of the Test Reagent was added to the test circle and 1 drop of 
Control Reagent to the control circle.  The contents of the test circle were mixed using a 
loop.  The loop was flamed and then used to mix the contents of the control circle.   The 
circles were observed for agglutination while mixing and the results were recorded.  The 
Reaction Card was safely disposed of in to disinfectant. A positive result was obtained if 
clumping of the test cell suspensions occurred during mixing and a presumptive 
identification of Staphylococcus aureus was then made.  Results were not interpreted if 
there was any clumping of the control cell suspension.  
 
Oxidase Test 
The Oxidase Test (Sigma-Aldrich) consisted of: N,N,N,N,-tetramethyl-p-phenylenediamide 
dihydrochloride (minimum 95%)- diluted in phosphate buffered saline to 1% concentration 
on filter paper strips.  A sterile inoculating loop was used to transfer a portion of an isolated 
colony from the agar on to the oxidase disk provided. The reaction was observed within 2 
minutes at 25-30°C.  If P. aeruginosa was present a positive reaction was observed with the 
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disc changing colour to a deep purple.  The result was recorded after 2 minutes of 
observation. 
Catalase Test 
A solution of 3 % aqueous hydrogen peroxide, protected from light, on a glass microscope 
slide was used.  Catalase converts hydrogen peroxide into water and oxygen.  The catalase 
test is commonly used to differentiate streptococci (negative) from staphylococci (positive). 
Using a sterile loop, cells from an isolated colony were transferred to a glass slide.  One to 2 
drops of 3% hydrogen peroxide was added.  Positive results for the presence of catalase 
were evident by the rapid and sustained appearance of effervesence, 2 minutes after 
addition of bacterial cells.  Positive S. aureus, and negative Streptococcus sp. controls were 
used as references for the experiment. 
Storage of microbial wound isolates 
Microbial Wound isolates were stored using a solution of 25 coloured beads packed in cryo 
preservative (microbank Pro-lab diagnostics).  Fresh monocultures (<36 h) were cultured on 
Pseudomonas agar and MSA, and incubated at 37°C.  Using a permanent marker the vials 
were coded with the origin of the specimen and microorganism to be stored.  Under aseptic 
conditions microbank beads were inoculated with a single colony of pure growth bacteria.  
Vials were then closed tightly and inverted 4-5 times to emulsify the organisms, at this point 
the microorganism would have been bound to the porous beads.  The vial was reopened 
and the excess cryopreservative aspirated using a pipette and sterile tip.  The inoculated 
microbank beads were then stored at -80°C. .  
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Polymerase chain reaction for detection of S. aureus and P. aeruginosa in chronic wound 
fluids 
Samples of chronic wound fluid collected and stored as previously described were subjected 
to PCR to identify the presence or absence of S. aureus and P. aeruginosa.  Total DNA 
extraction was based on the use of the PUREGENE DNA Purification Kit with DNA 
purification from 1 ml Gram-positive bacteria with an expected yield 6-60 μg DNA. 
 
Cell Lysis 
Chronic wound fluid (1-ml) was added to a 1.5 ml tube on ice.  This was then centrifuged at 
13,000-16,000 x g for 5 s to pellet cells (for some species, centrifugation for up to 60 s was 
required to obtain a tight cell pellet).  As much supernatant as possible was removed using a 
pipette.  Six hundred μl of Cell Suspension Solution was added to the cell pellet and gently 
resuspended using a pipette. 3.0μl of Lytic Enzyme Solution was added and the tube 
inverted 25 times to mix.  The solution was then incubated at 37°C for 30 min to digest cell 
walls.  The sample was inverted occasionally during the incubation period.  The solution was 
then centrifuged at 13,000-16,000 x g for 1 min to pellet the cells.  The supernatant was 
removed and 600 μl of Cell Lysis Solution was added to the cell pellet and gently 
resuspended using a pipette to lyse the cells.  
 
RNase Treatment 
RNase A Solution (13.0 μl) was added to the cell lysate and the sample mixed by inverting 
the tube 25 times. The preparation was then incubated at 37°C for 15-60 min. 
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Protein Precipitation 
The sample was cooled to room temperature and 200 μl of Protein Precipitation Solution 
was added to the cell lysate.  The sample was then vortexed at a high speed for 20 s to mix 
the protein precipitation solution uniformly with the cell lysate (for species with a high 
polysaccharide content, placing the sample on ice for 15-60 min was required).  The sample 
was then centrifuged at 13,000-16,000 x g for 3 min. The precipitated proteins formed a 
tight white pellet (if the tight protein pellet was not formed, Step 3 was repeated followed 
by repeated incubation).  The sample was then placed on ice for 5 min and then 
recentrifuged at 13,000-16,000 x g for 3 min.  
 
DNA Precipitation 
The supernatant containing the DNA was decanted (leaving behind the precipitated protein 
pellet) into a clean 1.5 ml microfuge tube containing 600 μl 100% isopropanol (2-propanol).  
The sample was mixed by inverting gently 50 times.  The sample was then centrifuged at 
13,000-16,000 x g for 1 min; at which point the DNA became visible as a small white pellet.  
The supernatant was removed and the tube drained briefly on clean absorbent paper. 
Ethanol (600 μl of 70%) was added, and the tube inverted several times to wash the DNA 
pellet.  The solution was then centrifuged at 13,000-16,000 x g for 1 min, and the ethanol 
carefully removed. The tube was inverted and drained on clean absorbent paper and 
allowed to air dry 10-15 min. 
 
DNA Hydration 
DNA Hydration Solution (200 µl) was added (200 μl will give a concentration of 100μg/ml if 
the yield is 20μg DNA).  The DNA was then rehydrated by incubating the sample for 1 h at 
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65°C and/or overnight at room temperature.  The tube was tapped periodically to aid in 
dispersing the DNA; the DNA was then stored at 4°C.   
 
Detection of bacterial species by species specific PCR 
 
Species-specific PCRs was used to detect two opportunistic pathogens, Staphylococcus 
aureus and Pseudomonas aeruginosa.  PCR was undertaken in volumes of 25 µl.  In the case 
of S. aureus, Each reaction consisted of PCR buffer (x10), template DNA (5 µl), Taq 
polymerase (1.5 units), and 5 µM of each PCR primer. The primers for S. aureus were Vick1 
and Vick2 Primer designs taken from Liu et al, 2007.   
o S.aur_vicK1: 5’-CTA ATA CTG AAA GTG AGA AAC GTA-3’ 
o S.aur_vicK2: 5’-TCC TGC ACA ATC GTA CTA AA-3’ 
The reaction mix was denatured for 5 min at 94oC, before undergoing 35 cycles of 94oC for 
40 s, 50oC for 40 s and 72oC for 1 min, prior to a final single 10 min cycle at 72oC. For P. 
aeruginosa, the reaction mix was identical but included the primer pair of ECF1 and ECF2 
Primer designs taken from Lavenir et al, 2007  
o Ps.aeru_ECF1: 5’-ATG GAT GAG CGC TTC CGT G -3’ 
o Ps.aeru_ECF2: 5’-TCA TCC TTC GCC TCC CTG -3’ 
 (Lavenir et al., 2007; Table 10).  PCR cycling consisted of a single denaturation cycle of 95oC 
for 5 min, before undergoing 35 cycles of 94oC for 45 s, 58oC for 45 s and 72oC for 1 min, 
before a final 5 min at 72°C.  
The subsequent PCR products were electrophoresed in a 1.5% (w/v) agarose gel containing 
1 μl of ethidium bromide within a 1× Tris-acetate-EDTA (TAE) buffer comprising 40 mM Tris, 
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20 mM acetic acid and 1 mM EDTA buffer at 40 V/cm2 for 45 min.  The products were run 
alongside a standard 100 base pair marker DNA ladders (Promega).  PCR products were then 
visualised using ultraviolet light in a GelDoc system (Bio-Rad, Hemel Hempstead, UK).  PCR 
for S. aureus and P. aeruginosa in chronic wound fluids were repeated 3 times to ensure 
reproducibility.   
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Results 
Overview of collected samples 
Table 3.0 summarises the clinical samples used in this research.  All of these samples were 
subjected to microbiological testing specifically to identify the presence and absence of our 
target bacteria S. aureus and P. aeruginosa as is illustrated later in this section.  
Sample type 
Number 
collected 
Label used to 
identify Applied analysis 
Chronic wound fluid 10 CHR1- CHR10 
Competitive ELISA 
DNase Agar 
Acute wound fluid 9 
Acute wound 
fluid 1-9 Competitive ELISA 
Debrided chronic wound 
tissue 3 DWT 1- DWT3 PNA CLSM FISH 
Chronic wound imprints 5 WD1-WD5 Modified competitive ELISA 
 
Table 3.0 Demonstrating samples collected, nomenclature and experiments utilised in 
throughout the thesis. 
 
Chronic wound fluid collection 
In total 10 chronic wound fluid samples were taken.  The participants ages ranged from 64 
to 90 years (table 3.1), with a mean age of 75.4 years being largely representative of the 
ageing population most commonly affected by chronic wounds.  For purposes of 
identification of samples they were labelled CHR1-10.  Duration of these chronic wounds 
ranged from 10 months to 27 years (table 3.1), with a mean duration of 99.5 months (8.3 
years)  
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Study number Age in years Location of wound Size of wound Cause of wound 
Duration of Wound 
in Months 
CHR1 90 Right ankle Semi Circumferential Unknown 36 
CHR2 67 Right ankle Circumferential Unknown 13 
CHR3 85 Right legs Circumferential 
trauma-burns in 
accident 216 
CHR4 64 Both legs Circumferential Unknown 18 
CHR5 69 Left ankle Circumferential 
insect bite, venous 
disease 216 
CHR6 80 Both legs Medial malleolus venous disease 180 
CHR7 81 Right leg Circumferential Arterial 10 
CHR8 64 Both legs Semi Circumferential venous disease 48 
CHR9 75 Both legs Semi Circumferential venous disease 17 
CHR10 79 Right leg Semi Circumferential venous disease 138 
Table 3.1 Chronic wound Fluid donor patient information 
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The wounds were all located on the lower legs with 1 being confined to the malleolus, 4 
were semi-circumferential and 5 were circumferential wounds (table 3.1).   Of these 
wounds, 4 were bilateral, 5 were right leg only and 1 was left leg only (table 3.1).  The 
aetiology of the ulcers was venous disease in 4, traumatic in 2, arterial in 1, and 3 of 
unknown aetiology (table 3.1).  Despite an N of only 10, the donor’s wounds were 
representative of those most often seen in clinical practice in terms of wound location and 
aetiology. 
 
Of these wounds, 3 were assessed using an experienced wound healing clinician as being 
currently locally infected, and the other 7 were not considered locally infected (table 3.2).  
All three of the patients whose wounds that had been assessed as infected were taking oral 
antibiotics at the time of wound fluid sampling; the antibiotics taken were as listed in table 
3.2.  The time of the last course of antibiotics taken was recorded as it is possible that this 
could have affected the wounds ecology (table 3.2).  It must be noted that this information 
was based on patient recollection and may be unreliable.  Prior use of antibiotics was a 
median of 56 days and mean of 74 days previous to sampling.  It should be noted that 
participant CHR2 was also using potassium permanganate soaks, a topical treatment 
effective against Pseudomonas species, and CHR8 was using Betaine Polyhexanide irrigation 
solution and gel with antibacterial and antiseptic properties, both of which could be 
considered likely to affect the wounds ecology. 
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Study 
number 
Currently 
Infected Most recent antibiotic 
CHR1 No 10 weeks ago - unsure what antibiotic. 
CHR2 Yes Currently- Augmentin and Potassium Permanganate. 
CHR3 No 3 weeks ago – Ciprofloxacin 
CHR4 Yes Currently on Ciprofloxacin 
CHR5 No 34 weeks ago -  Flucloxacillin 
CHR6 No 8 weeks ago – Trimethoprim 
CHR7 Yes Flucloxacillin 
CHR8 No 
3 weeks ago - intravenous Cefuroxime, Vancomycin, 
and Teicoplanin 
CHR9 No 8 weeks ago -  Cefuroxime, and metronidazole 
CHR10 No 8 weeks ago - Flucloxacillin, and Benzyl penicillin 
Table 3.2 Antibiotic use in patients donating chronic wound fluid 
 
The patients’ concomitant medications were recorded as various medications are known to 
effect wound healing directly or indirectly.  It was immediately obvious (table 3.3) that the 
majority of the patients exhibited polypharmacy, the mean number of medications taken 
was 8.1, with a range from 3-13 oral medications prescribed (table 3.3). The cohort was also 
taking large amounts of analgesics ranging from simple paracetamol to strong opiates such 
as Morphine Sulphate tablets, Oxycodeine tablets and Fentanyl patches (table 3.3).  The 
patient CHR8, was also taking Pregabalin and Amitryptaline for neuropathic pain (table 3.3).  
Patient CHR4 was taking oral hypoglycaemics; indicating NIDDM (Non insulin dependent 
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diabetes mellitus) and patient CHR8 was taking both oral hypoglycaemics and insulin 
indicating IDDM (Insulin dependent Diabetes mellitus) (table 3.3). 
 
Study number  
 
Medications 
CHR1 Tramadol, Clonidine, Lisinopril, Asprin 
CHR2 Simvastatin, Losaratan, Frusomide, Levothyroxine, Symbicort, 
Tramadol, Paracetamol, Diazepam, Oramorph 
CHR3 Cyclizine, Oxycontin, Paracetamol, Omeprazole, 
Chloramphenicol eye drops 
CHR4 Paracetamol, Tramadol, Metformin, Spironolactone, 
Frusemide, Salbutamol, Perindopril, Simvastatin, Asprin, 
Lansoprazole, Novorapid, GTN spray 
CHR5 Loperamide, Warfarin, Oxycodone, Ascorbic acid, 
Paracetamol, Tramadol, Buprenorphine patches,   
Esomeprazole, Domperidone, Chlorpheniramine 
CHR6 Bendroflumethazide, Asprin, Prednisolone 
CHR7 Isosorbide Mononitrate, Quinine Sulphate, Atorvastatin, 
Temazepam, Alphacalciferol, Asprin, Bisoprolol, MST, 
Perindopril, Bisoprolol, Frusemide 
CHR8 Metformin, Calcichew, Ensure, Paracetamol, Ferrous 
Sulphate, Fentanyl, Insulin, Ibersartan, Pregabalin, 
Amitryptaline, Bisoprolol, Lidocaine, Epiderm, Warfarin, 
Betaine Polyhexanide  
CHR9 Salbutamol, Fluticasone, Salmeterol, Fentanyl patches, 
Tramadol, Paracetamol, Naproxen, Moxonidine 
CHR10 Ramapril, Simvastatin, Tamsulosin, Quinine Sulphate, Co-
codamol 
Table 3.3 Concomitant medication of chronic wound fluid patients 
 
 
 
Volumes of collected chronic wound fluids  
Despite the difficulties experienced in other studies collecting chronic wound fluid, it was 
possible to collect reasonable amounts using the dilution method described in the preceding 
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materials and methods section.  These were stored in 5 ml aliquots and where necessary in 
smaller quantities.  The mean amount collected was 94.95 ml with a range from 45 ml to 
230 ml (table 3.4)  
Study Number Volume and number of aliquots 
CHR1 9 x 5 ml 
CHR2 13 x 5 ml 
CHR3 11 x 5 ml 
CHR4 46 x 5 ml 
CHR5 13 x 5 ml 
CHR6 14 x 5 ml 
CHR7 22 x 5 ml, 1 x 3.5ml 
CHR8 22 x 5 ml 
CHR9 19 x 5 ml, 1 x 1 ml 
CHR10 20 x 5 ml 
Table 3.4 Volumes of chronic wound fluid collected 
 
 
Acute wound fluid 
Significant quantities of acute wound fluid were collected in comparison to chronic wound 
fluid samples.  It was not unusual to collect over 200 ml (×4) from each patient.  A and B 
samples were empirically serosanguineous whereas C and D samples tended to be more 
serous as would be expected for fluid collected a further day post operatively. 
The patients were exclusively female, consisting of three left mastectomies, four right 
mastectomies and two bilateral mastectomies.  Mean age was 60.7 years old, and median 
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age of 64 years old.  Two of the patients had IDDM.  In terms of previous antibiotic 
exposure, one patient had had a recent course of topical antibiotics (table 3.5), one had a 
one week long course for a urinary tract infection and three patients had been given a single 
dose of antibiotics at induction of anaesthesia as a prophylactic measure. 
 
All mastectomies were performed for confirmed breast cancer, except patient 8 who 
underwent bilateral mastectomy (surgical removal of both breasts) aged 31 as a 
prophylactic measure following diagnosis of a genetic predisposition, skewing our mean age 
range slightly.  Interestingly no patients developed any post operative wound complications, 
such as infection, seroma or breakdown. 
 
Patient 
Number 
Ag
e Mastectomy  Recent Antibiotics 
Diabet
es 
 
Rheumato
id 
 
complicatio
ns  
1 74 Left Metronidazole gel-  for acne rosacea IDDM Nil Nil 
2 63 Right Nil Nil Nil Nil 
3 82 Left Augmentin at induction Nil Nil Nil 
4 50 
Right- (Latissimus Dorsi 
flap+implant) Augmentin at induction Nil Nil Nil 
5 60 Bilateral Nil IDDM Nil Nil 
6 64 Right Nil Nil Nil Nil 
7 72 Right Nil Nil Nil Nil 
8 31 Bilateral Nil Nil Nil Nil 
9 51 Left 
Cefalexin 1/52 (UTI)- Augmentin at 
induction Nil Nil Nil 
10 77 Right Nil Nil Nil Nil 
Table 3.5 Acute wound fluid donor information  
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Wound Imprints 
Five patients’ dressings were sampled; the majority of the wounds (80%) were located on 
the lower limbs, but one (20%) abdominal wound was also utilised.  The cause of these 
wounds was 3 venous, 1 arterial, and 1 surgical (table 3.6).  Samples WD1, WD2, WD4, and 
WD5 were all judged to be infected and as such various antimicrobials were used; topically 
Flamazine, Pronotosan and Trimovate, were all used (table 3.7).  WD1 had also undergone a 
2-week course of oral Augmentin as treatment for a localised wound infection (table 3.6). 
Sample Number Location of wound Wound Duration Wound Cause 
WD1 Left leg and thigh 1 year Arterial 
WD2 Right  Leg over 1 year Venous 
WD3 Abdomen over 1 year Surgical  
WD4 Right Leg over 1 year Venous 
WD5 Left  leg  over 1 year Venous 
Table 3.6 wound dressing donor information 
 
Sample number Infected 
Topical 
treatments Antibiotics Dressing  
WD1 Yes Flamazine 
Co-amoxiclav 2 
weeks Hydrofibre* 
WD2 Yes 
Betaine 
Polyhexanide Nil Hydrofibre* 
WD3 No Trimovate Nil Hydrofibre* 
WD4 Yes Nil Nil Hydrofibre* 
WD5 Yes Aquafoam Nil Hydrofibre* 
Table 3.7 Wound dressing donor wound information 
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Debrided wound tissue 
Only 3 patients were recruited due to the small number of patients seen in the clinic 
requiring sharp surgical debridement; all of these patients were considered to have grossly 
locally infected wounds with probable biofilm formation.  All patients were female and all 
were suffering from leg wounds secondary to venous disease (Table 3.8).  Four separate 
samples were collected from DWT1, 2 from DWT2, and 3 from DWT3 
 
Patient Sex 
Wound 
duration Location DM/RA Smoker Dressings 
DWT1 F Unknown 
Right 
circumfential No No 
Hydrofibre* 
Ag 
DWT2 F 7 years 
Left medial 
and lateral 
malleolus No Yes 
Hydrofibre* 
Ag 
DWT3 F 3years 
Left 
circumfential No No 
Hydrofibre* 
Ag 
       
Table 3.8 Debrided wound tissue donor information 
 
Microbiological analysis 
Chronic wound Fluid 
The results of analysis of the chronic wound fluid samples through traditional 
microbiological analysis using Blood agar, MSA, and Pseudomonas agar are summarised in 
table 3.9 and Appendix 6. 
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CHR sample S. aureus P. aeruginosa Other 
1 Yes Yes Corynebacterium 
2 No Yes CNS 
3 Yes Yes CNS 
4 Yes Yes CNS 
5 Yes Yes No 
6 Yes Yes No 
7 No Yes CNS 2 strains 
8 No Yes CNS 
9 Yes Yes Corynebacterium 
10 No Yes CNS 
Table 3.9 Culture analysis of chronic wound samples  
 
Acute Wound Fluid 
As expected the results of the microbiology for the acute wound fluid were very different 
from chronic wound fluid;  For the purpose of analysis, each patient’s samples were split 
into 4 groups, referred to as A, B, C and D.  Groups A and B were from separate drains in the 
same patient on post operative day one, and groups C and D from day two.  None of the 
samples grew P. aeruginosa, so the Pseudomonas agar which all demonstrated no growth 
after 24 h have been excluded from the table of results (Appendix 6).  As can be seen from 
table 3.10, the predominant organisms were CNS (coagulase negative staphylococci) with 
occasional S. aureus cultured.  The colony numbers were very low ranging from 0 cfu/ml to 
2.7×104 cfu/ml, with a median of 50 cfu/ml indicating that the fluid was, as might have been 
expected, mostly clean with only light skin commensal contamination.  
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Sample Oxidase Catalase Coagulase Conclusion 
1A Negative Positive Negative 
CNS (both clear 
and pale) 
B Negative Positive Negative CNS 
C Negative Positive Negative CNS 
D Negative Positive Negative CNS 
2A Negative Positive Positive S. aureus 
B Negative Positive Positive S. aureus 
C Negative Positive Positive S. aureus 
D N/A N/A N/A Nil 
3A Negative Positive Negative CNS 
B Negative Positive Negative CNS 
C Negative Positive Negative CNS 
D Negative Positive Negative CNS-haemolytic 
4A Negative Positive Negative CNS 
B Negative Positive Negative 
CNS- (white and 
yellow colonies) 
5A Negative Positive Negative CNS 
B Negative Positive Negative CNS 
C Negative Positive Positive S. aureus 
D Negative Positive Negative CNS 
6a Negative Positive Negative 
CNS- (white and 
yellow colonies) 
B Negative Positive Negative CNS 
C Negative Positive Negative CNS 
D Negative Positive Negative CNS 
7A Negative Positive Negative CNS 
B Negative Positive Negative CNS 
C Negative Positive Negative CNS 
D Negative Positive Negative CNS 
8A NA NA NA NA 
B NA NA NA NA 
C NA NA NA NA 
D NA NA NA NA 
9A Negative positive 
MSA→positive 
Blood → 
negative 
MSA→S. aureus 
Blood → CNS 
B NA NA NA NA 
C NA NA NA NA 
D NA NA NA NA 
Table 3.10  Microbiological analysis and speciation of bacteria present in acute wound fluid 
samples  
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Wound imprints 
Traditional microbiology results from the wound dressing imprints were similar to those for 
the chronic wound samples, with CNS present in all samples, P. aeruginosa present in three 
and possibly in the remaining two, but these were obscured by swarming Proteus making 
definitive identification very difficult.  Staphylococcus aureus was only present in one 
sample in WD1 (Table 3.11)  
Wound Dressing Agar 
Colony 
appearance Gram stain Coagulase Catalase Oxidase Identity 
1 Blood 
Green 
colonies 
Negative 
bacilli - + + P. aeruginosa 
 MSA 
Yellow 
colonies with 
mannitol 
fermentation 
Positive cocci- 
clumps - + - 
CNS/S. 
aureus 
2 Blood 
Proteus 
swarming 
Positive cocci, 
Negative 
bacilli    Proteus 
 MSA 
White 
colonies 
Positive cocci 
in chains, 
Negative 
bacilli - 
+ 
- CNS 
3 Blood 
White 
Colonies  
Negative 
bacilli - 
+ 
+ P. aeruginosa 
 MSA White small Positive cocci - + - CNS 
4 Blood 
Proteus 
swarming 
Negative 
bacilli and 
cocci    Proteus 
 MSA white small Positive cocci - + - CNS 
5 Blood White/green  Negative rods - + + P. aeruginosa 
 MSA 
1 colony 
yellow Positive cocci - 
+ 
- CNS 
MSA, mannitol salt agar; CNS, coagulase negative staphylococci 
Table 3.11 Wound dressing culture microbiology and speciation 
 
 
 
Debrided wound tissue 
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Classical microbiology demonstrated the presence of P. aeruginosa in all 3 samples, S. 
aureus in two out of three and Proteus spp in 2 out of three, with a CNS also cultured from 
sample one (table 3.12).  
 
 
 
Sample Morphology Gram stain Coagulase Catalase Oxidase Conclusion 
DWT1 White colonies Positive cocci Negative + Negative CNS 
 Green colonies Negative bacilli Negative + + P. aeruginosa 
DWT2 Swarming Negative bacilli Negative 
 
+ Negative Proteus 
 Yellow colonies Positive cocci Positive 
 
+ Negative S. aureus 
 White/Green  Negative bacilli Negative 
 
+ + P. aeruginosa 
DWT3 Swarming Negative bacilli Negative 
 
+ Negative Proteus 
 Yellow colonies Positive cocci Positive 
 
+ Negative S. aureus 
 White/green  Negative rods Negative 
 
+ + P. aeruginosa 
Table 3.12 Debrided wound tissue, culture, microbiology and speciation 
  
Polymerase chain reaction 
Chronic wound fluid samples were analysed using species specific PCR and each PCR was 
repeated on three occasionsTypical results of PCR (Fig 3.1 and 3.2) are shown for wound 
fluid extracts 1- 10.   Pseudomonas aeruginosa was detected in chronic wound fluids 
numbers 3, 6 and 7, whilst S.  aureus was detected in chronic wound fluids numbers 1, 3, 4, 
6 and 8 (table 3.1).   
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Fig 3.1 PCR of chronic wound isolates for detection of P. aeruginosa. Lanes 1-10 represent 
chronic wound fluid samples CHR1- CHR10.  Lane 11 contains P. aeruginosa DNA (positive 
control), Lane 12 is negative control (absence of template)  P. aeruginosa was detected in 
chronic wound fluids 3,6 and 7. Lane 3 was positive on all gels but unfortunately too faint to 
appear in the picture. Left side 100 base pair marker DNA ladders (Promega). 
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Fig 3.2  PCR of chronic wound isolates for detection of S. aureus. Lanes 1-10 represent 
chronic wound fluid samples CHR1- CHR10.  Lane 11 contains S. aureus DNA (positive 
control), Lane 12 is negative control (absence of template), Ladder = 100 base pair marker 
DNA ladders (Promega) to left and right.   
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Sample P. aeruginosa 
cfu/ml 
S. aureus 
cfu/ml 
Target species 
detected by PCR  
CHR 1 Unknown 1.3 x 105 S. aureus  
CHR2 6.3 x 106 Not detected ND 
CHR3 6.5 x104 1.6 x 104 P. aeruginosa,  
S. aureus  
CHR4 3.4 x 109 2.4 x 107 S. aureus  
CHR5 4.5 x 106 3.3 x 104 ND 
CHR6 4.2x106 Not detected 
 
P. aeruginosa,  
S. aureus  
CHR7 1.02x103 Not detected P. aeruginosa,  
CHR8 4.8 x 105 Not detected S. aureus  
CHR9 1.6 x 106 7.2x104 ND 
CHR10 7.8x106 Not detected ND 
ND, not detected 
Table 3.13 Results of traditional microbiology and PCR for enumeration and detection of P. 
aeruginosa and S. aureus. 
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Discussion 
Chronic wounds remain a significant and increasing problem worldwide; one factor strongly 
linked to the development of wound chronicity is bacterial colonisation, infection and 
biofilm formation. The bacterial flora of chronic wounds has been studied both through 
culture and molecular methods and consists of bacteria from skin, oral mucosa, enteric tract 
and the wider environment. Wound microflora is deemed significantly different from that 
found on normal skin and indeed appears to be different even for different types of chronic 
wounds (Martin, 2009, Davies et al., 2004). 
 
In order to complete an in-depth study into bacterial communities within chronic wounds it 
was decided to focus on S. aureus and P. aeruginosa.  It is well recognised that the 
microflora of chronic wounds is polymicrobial (Fazli et al., 2009).  Pseudomonas aeruginosa 
and S. aureus are both frequently isolated from chronic wounds and these species are 
prolific biofilm formers, making them ideal for further characterisation. 
 
Both traditional microbiology and molecular microbiology were used to characterise the 
bacterial species present within chronic wounds and to provide a bank of acute and chronic 
wound fluid, debrided wound tissue and wound imprints for the further study and 
characterisation of bacterial communities within chronic wounds. 
 
Using the dilutional methods previously described, significant volumes of chronic wound 
fluid were collected, stored and typed in comparison with other studies, which although 
diluted still contained bacteria of many different species.  The chronic wound fluid took a 
long time to collect (approx 3 months to obtain all 10 samples) even in a large university 
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wound healing unit.  This was due to the limited number of patients with wounds with 
heavy exudate and the rather onerous 4 h of collection followed by redressing required.  It 
would be very difficult to regularly reproduce this for a diagnostic test.  This wound fluid 
provides a bank of fluid to be utilised in controlled studies for assessing the bacteria within 
chronic wounds, as any detection system will have to work in the hostile environment that 
is dominated by wound fluid.   
 
It was possible to collect, store and microbiologically analyse large volumes of acute wound 
fluid from post mastectomy patients, which although rather sanguineous, provided further 
fluid for controlled testing of the components of a proposed diagnostic system prior to their 
use on chronic wound fluid samples.  The collection of acute wound fluid was far easier and 
only limited by the number of patients having mastectomies; it involved no discomfort to 
the patient and would be easily reproducible in any hospital setting. 
 
Wound imprints successfully obtained from patients with chronic wounds, giving a valuable 
bank of wound fluid impregnated samples, which can be used to demonstrate the utility of 
methods of characterising chronic wounds in differing environments.  Any dressing based 
detection system would work on the basis of detecting chronic wound fluid absorbed into 
the dressing.  This was the easiest sample bank to collect as it merely entailed collecting 
discarded dressings of a commonly used type and imprinting them on blotting paper.  As a 
simple non invasive method of sampling, this could be applied to any patient group and 
would be the most appropriate to convert to a diagnostic test. 
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Debrided wound tissue was taken from patients with infected leg wounds and its bacterial 
communities analysed.  Sharp debridement of infected wounds while a well recognised 
treatment is not common and it was difficult to recruit patients to this group leading to the 
small number of samples collected.  The use of debrided wound tissue for a diagnostic tool 
would not be convenient, well tolerated, or desirable.  
 
Acute Wound Microbiology 
There is currently no data in the literature to compare with the microbiological findings of 
this study in the mastectomy wound fluid.  However, the microbiological results for the 
acute wound samples were as would be expected following ‘clean’ surgery with no open 
wounds or history of infection.  Bacteria were isolated in the majority of acute wound fluid 
samples, the numbers were, however, relatively low.  Each of the nine samples was split 
into 4, except sample 4 which was split into 2 giving 34 samples in total.   
 
Of this bank of samples all showed no growth on Pseudomonas agar, but only 8 showed no 
growth in all agars (samples 2D, 8A, B, C, D, 9B, C, and D).  Of the others that yielded 
bacterial growth, the numbers were low with a median of 50 cfu/ml.  The majority of 
bacteria isolated were CNS, however S. aureus was isolated in samples 2 A, B, and C.  The 
bacteria isolated were all normal skin microflora and most likely contaminated the wound in 
very low numbers during surgery.   
 
It would be expected that samples taken on day two would have a higher bacterial content; 
however this did not prove to be the case with no significant differences in bacterial counts 
observed between the days.  It is postulated that the large numbers of red blood cells 
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obviously present in the fluid may have had an antibacterial effect along with the white 
blood cells and cytokines undoubtedly present.  There was no significant difference in 
bacterial concentrations identified, despite the administration of prophylactic antibiotics at 
induction, as were given to patients 3, 4 and 9.  There were also no significant differences in 
the concentration of bacteria found or the diabetic status of the patients.  On reflection it 
may have been useful in the creation of a chronic wound model to collect fluid for more 
days post operatively, as on days one and two there was still a significant red blood cell 
component to the fluid which becomes more serous, and less sanguineous and therefore 
would be expected to be more similar to chronic wound fluid over time.   
 
Chronic wound fluid 
Chronic wounds are known to support a far more diverse microflora than acute wounds, 
due to their duration they are exposed to the environment for longer and their microflora 
changes over time.  The patients were fairly typical in age range for chronic wounds with a 
mean age of 74.1 years, and a range of 62- 88 years at the time of sampling, reflecting that 
the aging population is most commonly affected.  The causes of these chronic wounds were 
also fairly typical with 40% venous disease, 10% arterial disease, 20% attributed to trauma 
and 30% of unknown aetiology.  The wound locations, exclusively on the lower limbs, were 
also very typical of the chronic wound population, as was the mean duration of 8.3 years.  It 
was worthy of note, and typical of this population, that patients were on a large number of 
regular oral medications.  Three of these wounds were assessed as currently infected and 
these patients were on oral antibiotics, and 2 were using topical antimicrobials, again very 
typical of this group of patients.  It was particularly noticeable that 8 out of 10 patients in 
this group required strong analgesia to help manage the pain of their chronic wounds and 5 
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of these required controlled drugs, indicating the significant long term reductions in health 
related quality of life for this cohort. 
 
Chronic wound fluid microbiology 
Pseudomonas aeruginosa was successfully cultured and identified in 100% of the chronic 
wound fluid samples, while S. aureus was demonstrated in 70%.   CNS were also isolated in 
50% of cases and coryneforms in 20%.  This is a higher than expected frequency for P. 
aeruginosa than normally cited in the literature, with Fazli et al., (2009) describing them as 
isolated in only 53.5% of chronic wounds.  It is possible that this preponderance of P. 
aeruginosa occurred through selection following the high frequency of antibiotic 
prescription.  As has been described in Table 3.2, all patients had antibiotics of various kinds 
within a prior timescale ranging from 0- 32 weeks and a mean of 8 weeks.  Thus fitting with 
the evidence of Price et al., (2009) that P. aeruginosa biofilms predominate in those patients 
who have undergone recent antibiotic therapy shifting the profile of relatively diverse 
wounds to P. aeruginosa dominated.  This may also be a factor explaining the relative 
paucity of S. aureus, 70% as opposed to the expected 93.5% (Gjodsbol et al., 2006).  As seen 
in Table 3.2, patient CHR4 was on Ciprofloxacin at the time of sampling, for eradication P. 
aeruginosa infection and patient CHR3 had finished the same antibiotics just 2 weeks 
previously.  Patient CHR 7 was undergoing a course of Flucloxacillin, and patient CHR2 was 
taking Co-amoxiclav at the time of sampling, presumably to counter S. aureus infection, 
which may well account for the lack of S. aureus in those samples and bringing the results 
more into line with expectations. 
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It must also be considered that 10 samples were of a relatively small sample size and though 
interesting to speculate, no definitive conclusions can be drawn regarding the microflora 
without larger studies. 
 
Potassium permanganate topical preparation were being used by patient CHR2, and CHR4 
was taking Ciprofloxacin to counter P. aeruginosa, while CHR3 was 3 weeks post a course of 
Ciprofloxacin.  It would be expected that levels of P. aeruginosa in these samples would be 
lower than those of the other chronic wound fluid samples containing P. aeruginosa.  This 
however was manifestly not the case (Appendix 6).  This may be due to the fact that in those 
undergoing treatment the antibiotics had yet to be fully bactericidal as the course was not 
completed and in the case of CHR3 due to regrowth post antibiotics.  It must also be 
considered that P. aeruginosa is very difficult to eradicate and the antibiotics may be 
ineffective due to a biofilm phenotype or the development of Ciprofloxacin resistance. 
 
Staphylococcus aureus was isolated in 50% of the 10 sampled patients by culture, with a 
discrepancy from expected rate of around 90% (Gjodsbol et al., 2006).  There appeared to 
be no relationship between wound duration, causation, or timing of antibiotic courses and 
the presence or absence of S. aureus in the wound fluid samples.  However, it should be 
noted that wound fluid is not a swab or a biopsy and it is possible that some bacteria were 
not cultured or were adherent to a biofilm and did not survive as well suspended in a wound 
fluid environment as others. 
 
The results from the PCR (Fig 3.1 and 3.2) of the chronic wound fluid interestingly showed 
significant discrepancies from those found in the culture of chronic wound fluids (Table 
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3.13).  Pseudomonas aeruginosa was only detected in three samples using PCR as opposed 
to all ten by culture.  It is therefore likely that despite selective agars and positive oxidase 
tests these isolates were not P. aeruginosa but related Pseudomonas species.  
Staphylococcus aureus was present in 50% of samples using conventional testing and 50% of 
samples by PCR.  However, three of these samples correlated, two samples of wound fluid 
were found to contain S. aureus by culture but not by PCR and vice versa.  It is important to 
note that PCR is considered definitive, whereas culture on selected agars and oxidase, 
catalase and haemolysis tests provide only a presumptive identification.  As for those S. 
aureus detected by PCR and not culture, it is possible that these represent non-viable 
organisms or those in a quiescent non culturable state. 
 
While disappointing that the molecular biological detection methods and classical 
microbiological methods did not match entirely, this is not uncommon in microbiology and 
the study of wound ecology, for the reasons mentioned above (Dowd et al., 2008).  It has 
been stated that ‘Discrepancies between culture and molecular data were numerous and 
demonstrate that accurate identification remains challenging’ (Bittar et al., 2008, pg 1). 
  
Wound Fluid Quantity 
Significant quantities of chronic wound fluid were collected (Table3.4).  In those studies that 
use methods for concentrated wound fluid only small quantities are collected whilst the 
dilution method results in large volumes suitable for use in multiple confirmatory 
experiments.  The dilution of the chronic wound fluid samples in Tris-HCl was expected to 
have caused a dilution in the final bacterial counts per ml and may possibly account for 
some discrepancies in the microbiology with that found in the literature.  However, the 
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large quantities of wound fluid collected allows repeated experiments to be undertaken in 
order to find effective ways of identifying bacteria within chronic wounds.  Bacterial isolates 
from chronic wounds were stored for use in future experiments.   
 
Wound imprints 
Wound imprints were collected from patients recruited on the basis of their highly 
exudating chronic wounds.  The patients selected were typical of the population with 
chronic wounds in terms of their wound aetiology and location (Table 3.7).   There were five 
patient samples collected and they were labelled WD1-5; four of these wounds were 
considered to be locally infected and four were on topical antimicrobials with one also on a 
course of oral antibiotics.   
 
Following analysis by traditional microbiology, the species listed in Table 3.13 were 
identified. It was interesting to note the presence of Proteus in two of these wounds and the 
presence of CNS in swabs from all patients.  Staphylococcus aureus was again under 
represented, present in only one of the samples and P. aeruginosa was present in three of 
the five samples and possibly in the other two, but was impossible to identify secondary to 
the swarming of Proteus.  It was interesting to note the presence of Proteus in 40% of 
wounds with high levels of exudate, and the possibility that Proteus may be related to this 
should be considered.  Pseudomonas aeruginosa species were again commonly found (60% - 
100%), which correlates well with our previous findings, if not the literature, which suggests 
a prevalence of approximately 50%. 
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Debrided wound tissue 
Debrided wound tissue was collected from three patients with infected wounds that were 
clinically considered to require sharp surgical debridement.  All of these patients had chronic 
leg wounds of venous aetiology; although the population was small the location of the 
wounds, causation and age range of the population suffering from chronic wounds was 
typical. 
In keeping with the other chronic wound samples, three were positive for P. aeruginosa, 
showing it to be almost ubiquitous in chronic wounds.  Two were positive for S. aureus, with 
the remaining containing CNS.   Interestingly two samples were positive for Proteus species 
which had not been isolated from any other chronic wound fluid samples analysed.  These 
were patients considered to be so badly locally infected that the treatment of choice was 
sharp debridement, all were felt to have a macroscopically visible biofilm in situ.  In view of 
this, it was interesting that S. aureus occured with a greater frequency in these patients than 
in the other chronic wound samples and that Proteus (Appendix 7) was present in 3 of the 
wounds selected either for excessive exudate of severe local infection, perhaps secondary 
to the virulence factors present within these species. 
 
The strengths of collecting debrided wound tissue in this manner include the fact that it was 
readily available and as an accepted treatment modality the patients were put through no 
extra discomfort in sampling.  Weaknesses include the fact that EMLA has some 
antibacterial properties and that the tissue collected is necessarily disordered giving little 
information on tissue and biofilm architecture. 
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Conclusion 
All sample sources were unique patients, and no patient was sampled more than once in the 
same category.  No patient was sampled in two different categories.  Whilst it could have 
been useful to compare the microbiology of the same patient sampled in different 
modalities i.e. Chronic wound fluid, wound dressing imprint, and debrided tissue all from 
the same patient, this idea was discounted.  As the wounds would need to be sampled at 
different times, this would be of uncertain significance, and impractical for the individual 
patient given the time involved in sample collecting.  It was considered that whilst multiple 
sampling of individuals would increase sample number, it was more useful and more ethical 
to have unique patients for each sample taken. 
 
Following the collection, microbiological typing and storing of acute wound fluid, chronic 
wound fluid, wound imprints and debrided wound tissue a large bank of varied 
microbiologically typed specimens has been built up to allow further experimentation on 
methods of identifying bacteria in chronic wounds as both individual species and biofilm 
communities.  The bacterial characterisation achieved while not exhaustive could broadly be 
described as typical of the microflora of the chronic wound population with respect to 
populations of S. aureus and P. aeruginosa.  
  
As previously mentioned there are many unculturable bacteria within chronic wounds 
possibly as many as 98-99% of chronic wound flora are unculturable, therefore to fully 
characterise bacterial communities in chronic wound molecular methods such as PCR, the 
use of monoclonal antibodies and ELISA and CLSM FISH are of likely value.  The following 
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chapters involve the application of these methods to further characterisation of bacterial 
communities in chronic wounds. 
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Chapter 4: The use of monoclonal antibodies in the detection of 
specific bacteria in chronic wounds biofilms 
 
Introduction 
The microbiology of chronic wounds, as determined both through culture and 
molecular methods, has continually demonstrated the presence of a diverse 
microflora (Bowler and Davies, 1999, Davies et al., 2007).  This microflora is 
frequently found to be polymicrobial and comprised of both aerobic and anaerobic 
bacteria with a significant anaerobic population present in up to 45% of non-infected 
venous leg ulcers (Bowler and Davies, 1999, Edwards and Harding 2004).  Although 
many studies have examined the microbiology of chronic wounds, a large number of 
these have classified the various patient groups insufficiently or have not done an 
adequate or robust microbiological analysis of the microflora itself and subsequently 
have frequently failed to report any strict anaerobes at all (Davies et al., 2007).   
 
The bacterial species present in chronic wounds have been implicated in impaired 
wound healing and the development of chronic wound states.  A number of 
mechanisms have been postulated for this bacterial mediated delayed healing, 
particularly the promotion of a pro-inflammatory state and the direct effects of 
bacterial exotoxins as discussed previously in the Literature Review of this thesis 
(Wall et al., 2002; Stephens et al., 2003).  Reliable and rapid detection methods for 
such microorganisms are therefore important in terms of management of these 
wounds. 
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Chronic Wounds-current characterisation of microflora 
As previously discussed (Literature Review; Bacterial colonisation and wound 
infection) a wound is considered to be locally infected, or a source of systemic 
infection, following review by an experienced wound healing medical practitioner, 
this diagnosis is purely clinical.  When making the diagnosis, wound swabs are often 
sent for microscopy analysis, microbial culture and antimicrobial sensitivity testing of 
the recovered microorganisms.  Microbiological culture of wound samples often 
requires 1-2 days incubation for aerobic species and between 7-10 days for slow-
growing, strictly anaerobic bacteria (Davies et al., 2007).  Since clinical treatment of 
patients cannot be delayed for accurate microbiological typing and antibiotic 
sensitivity determination prior to treatment, most antibiotic prescribing for these 
patients is empirical.  Broad-spectrum antibiotics are often therefore the preferred 
course of treatment.  As a result of both a lack of accurate diagnosis of infective 
states and a limited knowledge of the bacterial sensitivities of the species present, 
over-prescribing of antibiotics for this particular patient group is frequent (Howell-
Jones et al., 2005 and 2006).   
 
Indiscriminate antibiotic therapy, whilst possibly being effective for an individual 
patient, can be problematic as it increases the risk of antibiotic resistance 
development, thus creating future problems at both a patient and population level 
(Knox and Holmes, 2002).  An accurate and rapid method of determining the 
presence, species and antibiotic sensitivities of wound pathogens would therefore be 
beneficial to patient, clinician and the population at large and would allow rapid and 
appropriate antibiotic use when necessary. 
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Chronic wound bacteria targeted for detection 
As previously discussed (Literature Review; Significance of bacteria in chronic 
wounds), aerobic bacterial species that are frequently isolated from wounds include 
both S. aureus and P. aeruginosa (Davies et al., 2004; 2007) with detection rates as 
high as 93.5% and 52.2%, respectively (Gjodsbol et al., 2006).  Staphylococcus aureus 
is present as a part of the normal skin flora and P. aeruginosa can also be found on 
the skin of healthy individuals (Cogen et al 2008), but in chronic wounds both are 
also opportunistic pathogens, expressing significant virulence factors.  In this present 
study, these two species were targeted for detection due to their high incidence in 
chronic wounds, association with wound infection and delayed wound healing.  The 
approach used for detection was based on the use of MABs (monoclonal antibodies) 
that had previously been developed against targets specific for these bacterial 
species.  Following the development of an effective method of detection of these 
bacteria, this approach would have potential to be extended to the detection of 
other bacterial species.  
 
Staphylococcus aureus 
Staphylococcus species can partly be characterised by their ability to produce 
deoxyribonuclease (DNase), an enzyme which catalyses hydrolytic cleavage of 
phosphodiester links of DNA.  It is one of several hydrolytic enzymes produced by S. 
aureus and indeed, testing for DNase is often used as a tool in the identification of 
this species.  Importantly, S. aureus produces a heat-stable or thermostable DNase 
referred to as thermonuclease (TNase), which is encoded by the nuc gene (Chesneau 
1992).  Given TNase’s previously cited high specificity and sensitivity of 97% and 
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100%, respectively, for detection in routine blood culture (Lagace-Wiens et al., 2007) 
and food bacteriology (Brakstad et al., 1995), TNase was selected as a suitable target 
antigen for monoclonal antibody (MAB) production.   
 
TNase has successfully been used in identifying S. aureus from blood cultures as far 
back as 1983 (Madison and Baselski, 1983).  Nevertheless, it must still be recognised 
that there is no single diagnostic test that can confirm the presence of S. aureus 
despite the seeming high specificity of TNase (Kateete et al., 2010).  To highlight this, 
although initially considered unique to S. aureus, it is now thought that some strains 
of the species Staphylococcus schleiferi, Staphylococcus carnosus, Staphylococcus 
intermedius, Staphylococcus hyicus, Staphylococcus caprae and Staphylococcus 
capitis may also produce a TNase (Kloos and Bannermann, 1994), along with some 
streptococci and bacilli (Park et al., 1980).  It must also be recognised that TNase is 
generated intracellularly and may therefore remain protected from interaction with 
extracellular detection systems, or be excreted and detected following the demise of 
the bacteria. 
 
Pseudomonas aeruginosa 
The opportunistic Gram-negative bacterium, P. aeruginosa, is frequently isolated 
from chronic wounds and this species is known to be a prolific biofilm former (Eberl 
and Collinson 2009).  Pseudomonas aeruginosa is often considered to be an infecting 
organism in chronic wounds and populations of this organism recover quickly 
following antibiotic administration.  For such reasons, P. aeruginosa often becomes 
the dominant bacterial species within chronic wound environments (Flanagan, 
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2007).  Pseudomonas aeruginosa causes severe infections in hosts with weakened 
defence mechanisms (Bystrova et al., 2004).  The outer component of the P. 
aeruginosa cell wall is predominantly LPS (lipopolysaccharide), which is highly 
antigenic and plays an important role in the interaction of the bacterium with its 
host (Pier, 2007).  LPS consists of three parts; a lipid component (lipid A), a core of 
oligosaccharide and an O-polysaccharide chain or O-antigen attached, this antigen 
defines the immuno-specificity of the bacterium, there have been 11 major O-
antigen groups identified (Pier, 2007; Fig. 4.1) 
 
 
Figure 4.1 Schematic representations of LPS (Picture courtesy of Jones M.D., 
University of British Colombia Wikipedia 2011) 
 
The structure of P. aeruginosa LPS has been fully elucidated (Bystrova et al., 2004); it 
is located on the outer wall of the bacteria and thus readily exposed to MABs.  The 
O-polysaccharide region is unique to the bacterial species making it an ideal and 
specific target for the production of MABs to detect P. aeruginosa. 
  
Many antigens have previously been used for the detection of S. aureus and P. 
aeruginosa previously using differing methodologies for detection.  A small selection 
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of recent commonly used antigens for the development of monoclonal antibodies to 
S. aureus and P. aeruginosa is shown in tables 4.1 and 4.2. 
 
 
Table 4.1 Antigens for S. aureus that have been used in previous diagnostic studies 
(Varshney et al 2011), (Ebert et al 2010), (Provenza et al 2010), (Matsui et al 2011), 
(Lorenz et al 2011), (Patti, 2004).  
 
Antibody Study title and year 
Staphylococcal 
enterotoxin B (SEB) 
Generation, characterization, and epitope mapping of 
neutralizing and protective monoclonal antibodies against 
staphylococcal enterotoxin B-induced lethal shock. 2011 
Iron regulated 
surface determinant 
B (IsdB) of 
Staphylococcus 
aureus 
A fully human monoclonal antibody to Staphylococcus 
aureus iron regulated surface determinant B (IsdB) with 
functional activity in vitro and in vivo. 2010 
Staphylococcus 
aureus Fibronectin-
binding proteins A 
and B  
  
Functional analysis of a murine monoclonal antibody 
against the repetitive region of the fibronectin-binding 
adhesins fibronectin-binding protein A and fibronectin-
binding protein B from Staphylococcus aureus.  2010 
Staphylococcus 
aureus penicillin-
binding protein 2' 
Development of an immunochromatographic strip for 
simple detection of penicillin-binding protein 2'. 2011 
IsaA of 
Staphylococcus 
aureus 
Functional antibodies targeting IsaA of Staphylococcus 
aureus augment host immune response and open new 
perspectives for antibacterial therapy. 2011 
Staphylococcus 
aureus MSCRAMM® 
(Microbial Surface 
Components 
Recognizing 
Adhesive Matrix 
Molecules) 
A humanized monoclonal antibody targeting 
Staphylococcus aureus 2004 
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Antibody Study title and year 
O-polysaccharide 
moiety of 
Pseudomonas 
aeruginosa serotype 
O11. 
Pharmacokinetics and safety profile of the human anti-
Pseudomonas aeruginosa serotype O11 immunoglobulin 
M monoclonal antibody KBPA-101 in healthy volunteers. 
2009 
 
highly 
phosphorylated and 
7-O-carbamoyl-l-
glycero-alpha-d-
manno-
heptopyranose 
(CmHep) of the 
inner core of LPS 
Monoclonal antibody S60-4-14 reveals diagnostic potential 
in the identification of Pseudomonas aeruginosa in lung 
tissues of cystic fibrosis patients. 2010 
 
Pseudomonas 
Aeruginosa serotype 
O11 LPS 
Preclinical in vitro and in vivo characterization of the fully 
human monoclonal IgM antibody KBPA101 specific for 
Pseudomonas aeruginosa serotype IATS-O11. 2010 
 
acyl homoserine 
lactones (AHL) used 
by Pseudomonas 
aeruginosa 
Generation of quorum quenching antibodies, 2011 
MAbs against wild-
type amidase from 
Pseudomonas 
aeruginosa 
Chromatographic behaviour of monoclonal antibodies 
against wild-type amidase from Pseudomonas aeruginosa 
on immobilized metal chelates. 2011 
 
Outer membrane 
protein F (OprF) of 
P. aeruginosa, 
3C3B5 
Development of a colloidal gold-based 
immunochromatographic test strip for the rapid, on-site 
detection of Pseudomonas aeruginosa in clinical samples. 
2011 
 
Table 4.2 Antigens for P. aeruginosa utilised in previous studies (Lazar et al 2009), 
(Schmengler et al 2010), (Horn et al 2010), (Kaufmann et al 2011), (Martins et al 
2011), (Wang et al 2011). 
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Monoclonal antibodies (MABs) 
MABs are identical mono-specific, reproducible antibodies which can be produced in 
unlimited quantities to almost any antigen.  MABs are identical, since they are 
generated by the same immune cells (B lymphocytes) found within the spleen, which 
are in turn, clones of a unique parent cell.  This cell is then fused with a myeloma cell 
to make an immortal cell line.  As such, MABs already have an extensive range of 
clinical uses in diagnostic systems and in the treatment of human disease.  For the 
purposes of this project, MABs had previously been raised against S. aureus TNase 
and P. aeruginosa LPS as part of an EPSRC (Engineering and Physical Sciences 
Research Council) project.  These antibodies were utilised in the present study for 
bacterial detection.   
 
Immunofluorescent microscopy 
The use of species-specific MABs attached to fluorescent labels for the detection of 
bacteria by fluorescent microscopy (immunofluorescent microscopy) has been 
widely reported (Gu et al., 2002).  More recently, expansion of this technique to 
detect bacteria within biofilms using confocal laser scanning microscopy (CLSM) has 
been described (Gu et al., 2005). This method of study is significant as it allows 
imaging of biofilms without altering structure and allows analysis over extended 
periods of time.  Despite initial concerns about molecular penetration into biofilms, 
it is now thought that immunoglobulin G (IgG) is a small enough molecule to migrate 
through the extracellular matrix of biofilms unimpeded (Zhu et al., 2001).  This 
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process has previously been successfully utilised to allow real-time characterisation 
of species both within and outside of a biofilm (Gu et al., 2005). 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Enzyme-Linked Immunosorbent Assay (ELISA) is a biochemical technique used to 
detect the presence of an antibody or an antigen within a sample.  In its basic form, 
the principle of ELISA is the use of a captured antigen (immobilised to a solid 
surface), to which a labelled antibody is then applied, allowing it to bind with the 
antigen.  The reporter label on the antibody is often an enzyme with which an added 
substrate reacts (usually causing a colour change) yielding a detectable signal.  There 
are several variations of ELISA and these include indirect, sandwich and competitive 
formats. 
 
ELISA was first described in 1971, and replaced forerunner assays that utilised 
radioactive labels with the incorporation of ‘safer’ colour change signals (Engval et 
al., 1971, Van Weemen and Schuurs, 1971).  ELISAs are now widely used in medicine 
for detection of host antibodies to viruses and in the food industry for detecting food 
allergens.  For the detection of P. aeruginosa in cystic fibrosis patients there is a 
commercially available ELISA to detect IgG antibodies formed as a result of exposure 
to P. aeruginosa (Douglas et al., 2009).  ELISAs have also been used in chronic 
wounds to quantify levels of matrix metalloproteinases (MMPs) (Barone et al., 1998) 
and cytokines (Secor et al., 2011, Pukstad et al., 2010), but to date have not been 
employed to detect bacteria within chronic wounds. 
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Aims of study 
The aim of this present study was to use developed MABs against P. aeruginosa and 
S. aureus to detect these bacterial species in chronic wounds.  Prior to application to 
clinical specimens it was first necessary to demonstrate specificity and sensitivity of 
these antibodies in pure culture against planktonic and biofilm growth states, and in 
testing on previously microbiologically typed wound samples utilising fluorescent 
microscopy and ELISA, both indirect and competitive.   
 
Materials and Methods 
 
Monoclonal antibodies used in this study 
Antibodies had previously been prepared in a separate Engineering and Physical 
Sciences Research Council funded grant (Grant Number EP/D505437/2) aiming to 
develop diagnostic systems for wound pathogens.  MABs against S. aureus TNase 
had previously been raised by murine BALB/c immunisation with a commercially 
available TNase preparation (Toxin Technology Inc, Sarasota, Florida, USA) purified 
from S. aureus strain FRI 1151M (Kokan and Bergdoll, 1987).  In the case of P. 
aeruginosa, antibodies were raised against the LPS O-antigen portion by murine 
BALB/c immunisation with phenol chloroform extracted lipopolysaccharide (LPS) 
from P. aeruginosa PAO1 strain (Sigma).  Immunisation was done using 10 μg of 
commercial antigen on alum adjuvant intra-peritoneally.  Immunisations were done 
every 7 days for 4 weeks, with a final immunisation at week 8.  Blood serum levels 
were monitored periodically over time for antigen presence by indirect ELISA and 
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spleen cells harvested 4 days after the last immunisation.  The spleen cells were used 
to prepare monoclonal antibodies as detailed below.  Briefly, murine splenocytes 
from the immunisations were fused with SP2/0 myeloma cells.  Cultured cells were 
screened for antibodies against commercial antigen (TNase, LPS) using culture 
supernatants which were tested by indirect ELISA for recognition of TNase antibodies  
Cultures which appeared positive for antigen production were cloned by limiting 
dilution.  Cultures showing monoclonal growth were tested by indirect ELISA and 
frozen for long term storage.  Large scale antibody production was done by bulk 
culture in growth medium.  Secreted antibodies were enriched and purified by 
affinity chromatography of culture supernatant on Hitrap protein G HP columns (GE 
Healthcare Biosciences AB) after centrifugation to remove cells (Randle et al., 2004). 
 
Detection of target bacteria by immunofluorescent microscopy 
Preparation of microorganisms 
Pseudomonas aeruginosa D10 and S. aureus FRI 1151M were cultured from stock 
isolates on Pseudomonas agar (LabM UK) and Blood agar (LabM UK), respectively.  
Colonies of these bacteria were then resuspended in phosphate buffered saline (PBS) 
and washed twice by centrifugation (2500g) and resuspension of the pellet in fresh 
PBS.   
 
Immunofluorescent staining of bacteria 
A human serum block (Sigma, Poole, UK; 1% of volume of the resuspended culture) 
was added to the cell suspension and the resulting solution was incubated at room 
temperature for 1 hour.  The primary mouse antibodies used were either anti-P. 
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aeruginosa LPS (A56) or anti-S. aureus TNase (B34).  These antibodies were 
previously stored at a stock concentration of 1 mg/ml and added to the cell 
suspension at a 10% concentration (100 µg/ml) and incubated at room temperature 
for 30 minutes.  The culture was then centrifuged at 600g (Heraeus Pico 17 
centrifuge) for 1 minute, and washed twice with PBS as described earlier.  Secondary 
antibody (goat anti-mouse IgG FITC (fluorescein isothiocyanate)-conjugated 
antibody) (Sigma-Aldrich UK) was then added to the culture and allowed to incubate 
in the dark at room temperature for 30 minutes.  This preparation was centrifuged at 
2500g and washed twice as before.  The culture was re-suspended in PBS and 
smeared on to a microscope slide; the suspension was maintained in a hydrated 
state under a cover slip and imaged by fluorescent microscopy at the appropriate 
excitation wavelength for FITC (494 nm) on a Nikon microscope. 
 
Appropriate controls for immunofluorescence included either omission of the 
primary or secondary antibodies as well as replacement of the primary antibody with 
an isotype IgG antibody (Sigma-Aldrich UK) not raised against TNase. 
 
Production of Constant Depth Film Fermenter (CDFF) generated biofilms 
The CDFF was prepared as previously described (Hill et al., 2010) using S. aureus FRI 
1151M and P. aeruginosa PAO1.  Overnight cultures of both bacterial strains 
incubated in BHI on a shaking incubator at 37°C were used, the bacterial growth was 
harvested by centrifugation (8000g, for 10 minutes) to produce a cell pellet.  The 
culture medium was circulated through the CDFF for 30 min prior to inoculation and 
rotated with a turntable speed of 20 rev/min.  Five µl of each wound isolate was 
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added separately to BM medium (1000 mL) and was then recirculated through the 
CDFF for 24 h to ‘seed’ the system. The inoculum was then disconnected and fresh 
non inoculated medium was fed into the CDFF.  The CDFF waste was collected in a 
separate bottle.  The growth medium was delivered at a rate of 30 mL/h using a 
peristaltic pump (Watson–Marlow). Biofilms were cultured in a CDFF maintained at 
37°C with plug inserts recessed to a depth of 400 µm.  CDFF pans were removed 
after 7 days and biofilms from 4 plugs were pooled and harvested (Hill et al., 2010).  
Harvested plugs with biofilms were then embedded in paraffin wax blocks. 
 
 
Fig 4.2 Constant depth film fermenter 
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 a  b c 
Fig 4.3 (a, b and c) internal components of CDFF 
a. Turntable with components in situ 
b. Plug  
c. Sweeper  
 
 
Preparation of biofilms on Recombinant Human Epithelium (RHE)  
Cultivated reconstituted human epidermis (RHE; 0.5 cm2) was obtained from 
SkinEthic Laboratories Lyon France.  These tissues had previously been cultured for 
10 days in a chemically defined culture medium containing 5 µg insulin ml-1 and 1.5 
mM calcium chloride as well as various growth factors, but with no antibiotics 
(SkinEthic Laboratories).  The RHE consisted of normal human keratinocytes (human 
foreskin-derived) with a well-differentiated epidermis consisting of basal layers, 
spinous layers, granular layers and a stratum corneum Fig 4.4. 
 
Fig 4.4 The in vitro reconstructed human epidermis (RHE).  RHE consists of normal 
human keratinocytes cultured on an inert polycarbonate filter. This model is 
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histologically similar to that of the in vivo human epidermis. (Image and text courtesy 
of SkinEthic.com/RHE.asp 4-12-2011) 
 
Bacterial strains were inoculated into 5 ml of BHI (brain heart infusion broth BHI, 
Oxoid) and incubated with shaking at 37°C for 18 hours.  Bacteria were harvested by 
centrifugation at 600g (Heraeus Pico 17 centrifuge) for 1 minute and washed three 
times with PBS.  The pelleted bacteria were then resuspended in 1.5 ml of RHE 
culture medium.  The RHE inoculum was 500 μl of the bacterial suspension and this 
was deposited centrally on to the surface of the RHE tissues.  When dual species 
inocula were used, supernatants from 2 strains of equal volumes (250-μl) of each 
was applied.   
 
The infected RHE was incubated for 24 hours at 37°C in a humidified atmosphere, 
enriched with 5% CO2.  The RHE conditioned growth media was then removed and 
stored at -20°C until required for detection of target S. aureus TNase antigen.  A non-
infected control was included for comparison.  The tissue itself was used for 
immunofluorescent staining and detection of target bacteria (P. aeruginosa and S. 
aureus). 
 
Immunofluorescent staining of infected RHE and CDFF generated biofilms 
Both RHE and CDFF generated biofilms were fixed in formalin 10% (v/v) overnight 
and embedded in paraffin wax.  The fixed material was then sectioned using a 
microtome to generate 10 µm sections and these were mounted on poly L-lysine 
coated microscope slides.  Processing of these sections on the slides involved 
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treating with xylene to remove the paraffin wax, and then rehydration of the 
specimens through decreasing concentrations of alcohol back to water.  The RHE 
sections were delineated using a wax pen and blocked with 20 µl/sample of 10% 
(w/v) BSA (bovine serum albumin) in PBS (Phosphate Buffered saline) for 10 minutes, 
which was then removed by gentle washing.  Primary antibody was then added at a 
concentration of 100 µg/ml was added to the tissue and incubated at room 
temperature for 1 hour.  The section was then gently washed with PBS to remove 
the primary antibody.  Initially, washing of the sections was performed using water 
bath with agitation, however due to the loss of contact of several sections from the 
slide the method was refined to three washes by gentle pipetting of PBS. FITC 
conjugated goat anti-mouse IgG antibody at a concentration of 1mg/ml was then 
added and incubated on the section in the dark at room temperature for 1 hour. The 
section was then washed with PBS and resuspended in 20 µl of PBS and maintained 
under a coverslip and imaged as previously described.  Consecutive sections were 
then imaged by fluorescent microscopy (Olympus Provis AX70).  Controls used were 
the substitution of the monoclonal antibodies (i.e. P. aeruginosa MAB challenged 
with S. aureus and vice versa), and the substitution of the FITC conjugated anti-
mouse IgG antibody with a similarly conjugated anti-goat antibody.  Light microscopy 
was also used to examine Gram-stained sections to demonstrate the presence of 
bacterial biofilms. 
 
Enzyme Linked Immunosorbent Assay (ELISA)  
For the purpose of ELISAs it was decided to focus on the B34 antibody for S. aureus 
only.  An enzyme linked immunosorbent assay (ELISA) was initially developed to 
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determine the optimal concentrations of biotinylated TNase for use in antigen 
detection using a competitive ELISA.  To achieve this result the following competitive 
ELISA method was followed but with no addition of competitor to biotinylated 
TNase. The sample added to the ELISA contained only dilutions of biotinylated TNase 
from an initial concentration of 10 µg/ml in doubling dilutions through to 0.005 
ng/ml.      
 
Development of a competitive ELISA protocol for detection of S. aureus TNase in 
bacterial supernatants 
The wells of a microtitre plate (96-well PVC) were coated with 50 µl of 10 µg/ml of 
goat anti-mouse IgG (Fc specific) antibody (Sigma) in coating buffer 
(Carbonate/bicarbonate 0.1M pH 9.6, Sodium carbonate 1.59g/L, Sodium hydrogen 
carbonate 2.93g/L). This was incubated overnight at 4°C.  The antibody coating was 
then removed and the plate blocked with 100 µl/well of 10% (w/v) bovine serum 
albumin (BSA) in PBS for 2 hours at room temperature with gentle agitation.  The 
plate was then washed twice with 150 µl/well of 0.05% Tween 20 in PBS (Wash 
buffer).  The anti-S. aureus TNase (B34) antibody was prepared at 4 µg/ml in protein 
buffer (Appendix 1) and added to the plate at 50 µl/well, this was left to incubate at 
room temperature for 1 hour with gentle agitation. The plate was then washed twice 
with 150 µl wash buffer. 
 
Competitor antigen samples (unlabelled) were prepared in 35-µl volumes a separate 
96 well microtitre plate (Corning, Amsterdam, The Netherlands) in a doubling series 
of dilutions in protein buffer, a control of protein buffer alone was included.  TNase 
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conjugated to biotin (previously prepared as part of a separate research project) was 
used at a previously determined 80 ng/ml concentration (determined by the 
experiment listed above).  This was prepared in protein buffer and 35 µl of the 
biotinylated TNase was added to the competitor antigen preparations in the replica 
plate wells.  The contents of the replica plate were transferred to the washed ELISA 
plate (50 µl) and allowed to incubate at room temperature for 1 hour with agitation.  
The antigen mix was then removed and the plate washed twice with wash buffer.  A 
500-fold dilution of avidin alkaline phosphatase (AVAP, Sigma, Poole, UK) in protein 
buffer was then added at 50 µl/well (to bind to any captured biotinylated TNase) and 
the plate incubated at room temperature for 15 minutes.  The AVAP was then 
removed and the plate washed 3 times with 150 µl wash buffer.  Any bound alkaline 
phosphatase enzyme was then detected by adding 50 µl/well of 1 mg/ml para-
nitrophenol phosphate in diethanolamine buffer 0.1M pH 9.6 (Appendix 1). The plate 
was then incubated in the dark for 5-15 minutes and the developed colour from the 
enzyme-substrate reaction was read on a microplate reader (Fluostar Optima BMG 
Labtech, Offenburg, Germany) at 405 nm. 
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Fig 4.5 Schematic of competitive ELISA 
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Competitive ELISA for detection of S. aureus TNase in artificially contaminated 
wound fluid  
Wound fluid was artificially contaminated with TNase at a concentration of 1 μg/ml 
to produce samples of chronic wound fluid with a known quantity of TNase.  These 
samples were mixed in a microfuge tube and subjected to the competitive ELISA as 
described above. 
 
Competitive ELISA for detection of S. aureus TNase in wound fluid samples 
Wound fluid samples (chronic and acute) were vortexed to maintain consistency of 
sample constituents.  These wound samples were then subjected to the competitive 
ELISA as described above. 
 
Detection of Staphylococcus aureus TNase in chronic wound fluids using DNA agar  
An agar test was also used to determine the presence of TNase within chronic 
wound fluid samples.  DNase Test Agar (Oxoid), incorporating DNA into Trypticase 
Soy Agar, was used as a TNase test for the chronic wound samples collected in the 
study.  Chronic wound samples (1 ml) were heated at 80°C for 30 min to denature 
any heat-sensitive DNase.  A 6 mm punch biopsy was then used to produce a well in 
the centre of DNA agar plates, to which heat-treated chronic wound fluid samples 
were added at a volume required to fill the well.  The plates were then incubated for 
4 h at 37°C before flooding with HCl (1 M).  TNase activity was evident through the 
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presence of a zone of clearing in the agar around the well of any TNase-positive 
isolates.  Positive controls of S. aureus FRI 1151M supernatants (previously 
incubated in BHI) were also tested and uninoculated BHI served as a negative 
control. 
 
 
Competitive ELISA for detection of bacterial antigens in culture supernatants 
Supernatants from RHE incubated 24 hour biofilms of P. aeruginosa and S. aureus 
were extracted using a pipette and subjected to the competitive ELISA as described 
above. 
 
Sensitivity of the competitive ELISA with respect to Staphylococcus aureus FRI 
1151M cell number 
These experiments aimed to determine the amount of S. aureus (colony forming 
units/ml) required to generate sufficient levels of TNase to be detected by ELISA 
using the MAB (B34) specific to S. aureus TNase. 
 
BHI broth was inoculated with S. aureus FRI 1151M using colonies from a blood agar 
plate and incubated overnight at 37°C with agitation.  S. aureus FRI 1151M culture 
(10 ml) was centrifuged, and the resulting cell pellet (estimated at 108 CFU/ml) was 
washed twice in 10 ml of PBS to remove any TNase generated overnight in the 
culture.  A ten-fold dilution series of this cell suspension was then prepared in BHI.  
The broths were then incubated at 37°C.  Using a spiral plater system (Don Whitley 
Scientific, Shipley, UK), the CFU/ml present in preparation was determined on MSA 
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at hourly intervals between 0 and 12 h at and also at 16 h and 24 h.  All plates were 
incubated for 24 hours at 37°C and resulting colonies were enumerated.  In addition, 
at each time point a sample was also stored at -70°C for later analysis by competitive 
ELISA as described earlier.  Uninoculated BHI was used for controls. 
 
Concentrating chronic wound fluid  
An 11.25-ml volume of each chronic wound fluid sample (Materials and Methods in 
Chapter 3) was centrifuged at 600g for 10 minutes to remove large particulate 
material and the samples were then filtered using a 0.22 μm syringe filter.  Salt and 
small solutes were removed by dialysis against 10 L of distilled H2O at 4°C overnight 
using visking tubing size 1.  The contents of the dialysis tubing were transferred to 30 
ml universal containers freeze dried for approximately 3 days to remove the water 
thus concentrating the samples.  Resulting samples were resuspended in 150 μl of 
protein buffer (1% BSA, 1% HEPES in PBS) a concentration of the chronic wound fluid 
sample of x75, and subjected to the competitive ELISA as previously described. 
 
Filter paper ELISA 
A falcon 96-well PVC microtitre plate was coated with 50 µl/well of anti-S. aureus 
TNase B34 antibody at a concentration of 1 µl/ml and the plate was incubated 
overnight at 4°C.  The plate was then washed using wash solution as previously 
described.  To each well a volume of 10% foetal calf serum diluted in PBS was added 
and incubated for 1 hour at room temperature.  The plate was again washed with 
wash solution. 
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The chronic wound dressing imprints were produced by pressing saturated dressings 
against filter paper.  Completely saturated filter paper containing this absorbed 
wound fluid was then stored.  Three samples of the filter paper were cut with a hole-
punch to 4 mm discs from each wound dressing sample stored. 50µl of Protein buffer 
was added to the appropriate wells.  Three samples of clean filter paper which had 
not been in contact with wound fluid or dressings were then added as a control to 
other wells and 50 µl protein buffer added.   
 
A control of serial dilution of stock TNase was then added to generate a standard 
curve and allow quantitative values of TNase to be determined for the chronic 
wound fluids.  The plate was then incubated for 2 hours on a shaking plate.  The 
layer was removed (including filter paper) and the plate was then washed three 
times with wash solution.  Fifty µl of biotinylated B34 at a concentration of 1.2µl/ml 
of protein buffer was added to each well and incubated at room temperature for 2 h. 
The plate was washed as described previously and a 500-fold dilution of avidin 
alkaline phosphatase (AVAP) in protein buffer was added at 50 µl/well.  The plate 
was incubated at room temperature for 15 minutes.  AVAP was then removed and 
the plate washed 3 times with wash buffer.  Alkaline phosphatase activity was 
detected by adding 50 µl/well of 1mg/ml para-nitrophenol phosphate in 
diethanolamine buffer 0.1M pH 9.6 (Appendix 1).  The plate was then incubated in 
the dark for 5-15 minutes and optical density read on a microplate reader (Fluostar 
Optima BMG Labtech, Offenburg, Germany) at 405nm. 
 
135 
 
 
Fig 4.6 The use of a filter paper collection method for chronic wound dressings. 
 
Pressure 
Proteins in the fluid 
collected on the 
dressing are eluted from 
the filter paper and bind 
to B34.  
Chronic wound dressing Saturated filter paper 
Cut circle 3mm diameter  
from filter paper 
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Results 
 
Immunofluorescent microscopy 
Immunofluorescent staining of S. aureus FRI 1151M with anti-TNase B34 antibody 
followed by anti-mouse IgG conjugated with FITC was positive (Fig. 4.7).  Controls 
without inclusion of the primary antibody were negative for S. aureus detection, 
although weak background fluorescence was evident on occasion.  
 a)  b) 
Fig 4.7 Detection of S. aureus using a) mouse anti-TNase (B34) antibody and anti-
mouse IgG conjugated FITC; (positive) b) control with omission of primary B34 
antibody (negative).  Original magnification ×1000. 
 
In the case of immunofluorescence staining of P. aeruginosa with mouse anti-LPS 
(A56) antibody and anti-mouse IgG conjugated FITC, cells were visible as small rod 
shape cells with slightly increased fluorescence evident in the MAB treated specimen 
compared with controls (Fig. 4.8).  Rapid quenching of FITC staining was however 
evident and coupled with autofluorescence of P. aeruginosa made interpretation of 
reactivity problematic.  
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 a) b) 
Fig. 4.8 Detection of Pseudomonas aeruginosa using a) mouse anti-LPS (A56) 
antibody and anti-mouse IgG conjugated FITC; (positive) b) control with omission of 
A56 antibody (negative).  Original magnification ×1000.  
 
Detection of S. aureus and P. aeruginosa in CDFF and RHE biofilms by 
immunofluorescent microscopy  
The presence of biofilms on both the PTFE plugs from the CDFF and the RHE was 
confirmed by light microscopy and Gram-staining with appropriate controls.  
Immunofluorescent staining of biofilms prepared in these systems all demonstrated 
significant autofluorescence which precluded bacterial detection (as demonstrated 
in fig 4.9). 
 
 
 
138 
 
 
Fig. 4.9 Pseudomonas aeruginosa CDFF generated biofilm with omission of A56 
antibody demonstrating autofluorescence of the biofilm. Original magnification 
×1000. 
 
Development of a competitive Enzyme Linked Immunosorbent Assay (ELISA) for 
detection of S. aureus TNase 
Initially, the chosen MAB developed for detection of S. aureus TNase was used in an 
ELISA against two-fold serial dilutions of biotinylated TNase antigen.  These 
experiments allowed the optimal concentration of biotinylated TNase for 
subsequent use in a competitive ELISA format.  As a result of these experiments, 
standard curves were generated (Fig. 4.10).  Optimal biotinylated TNase 
concentration was deemed to be the level that gave 80% of signal in the competitor 
ELISA format.  As can see from figure 4.10, this concentration was approximately 78 
ng/ml of biotinylated TNase. 
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Concentration 
in  ng/ml 
Biotinylated 
TNase 
Biotinylated 
TNase 
Mean  of 
Biotinylated 
TNase 
SD Blank 
corrected 
Mean 
10000 3.193 3.712 3.453 0.367 3.214 
5000 3.168 3.598 3.383 0.304 3.144 
2500 3.281 3.598 3.439 0.224 3.200 
1250 3.207 3.536 3.371 0.233 3.132 
625 3.193 3.411 3.302 0.154 3.063 
312.5 2.996 3.110 3.053 0.081 2.814 
156 2.542 2.691 2.616 0.105 2.377 
78 1.949 2.055 2.002 0.075 1.763 
39 1.360 1.424 1.392 0.045 1.153 
19.5 0.896 0.943 0.919 0.034 0.680 
9.8 0.610 0.606 0.608 0.002 0.369 
4.88 0.419 0.423 0.421 0.003 0.182 
2.44 0.334 0.356 0.345 0.015 0.106 
1.22 0.315 0.307 0.311 0.006 0.072 
0.61 0.304 0.288 0.296 0.011 0.057 
0.3 0.258 0.264 0.261 0.004 0.022 
0.15 0.258 0.275 0.266 0.016 0.027 
0.08 0.250 0.264 0.257 0.010 0.018 
0.04 0.262 0.249 0.256 0.009 0.017 
0.02 0.246 0.239 0.242 0.005 0.000 
Table 4.3 Absorbance values for biotinylated TNase in serial twofold dilutions in 
competitive ELISA without competitor. 
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Fig. 4.10 Showing detection of biotinylated TNase using anti-S. aureus TNase 
antibody (B34) by competitive ELISA format, but without competitor. These values 
are a mean of two runs, further see table, this was completed 3 times (total of six 
runs) please see Appendix 8 for further data tables. 
 
Detection of TNase in S. aureus culture supernatants using the competitive ELISA 
It was decided to test the ability of the competitive ELISA developed to detect TNase 
in the supernatants of different strains of S. aureus.  It was also felt pertinent to test 
the ELISA against filtered and unfiltered supernatants of S. aureus cultures to 
ascertain if the debris and cells present in a supernatant significantly affected the 
ELISA, as demonstrated in Fig 4.11 showing detection of the S. aureus produced 
TNase from FRI strain supernatant to a sensitivity of 62.5ng/ml. 
 
 
 
 
 
141 
 
Dilutions (two 
fold serial) 
No 
Competition 
S.aureus B2 
supernatant 
S. aureus 
FRI115M 
supernatants 
TNase 
1 2.218 0.733 1.465 0.230 
0.5 2.234 1.920 2.190 0.539 
0.25 2.239 2.175 2.228 0.921 
0.125 2.261 2.265 2.296 1.496 
0.062 2.243 2.274 2.310 1.917 
0.032 2.251 2.298 2.305 2.146 
0.016 2.247 2.320 2.299 2.214 
0.008 2.248 2.313 2.306 2.258 
0.004 2.266 2.295 2.316 2.256 
0.002 2.215 2.292 2.287 2.268 
0.001 2.202 2.289 2.289 2.246 
Table 4.4 Absorbance values for S. aureus supernatants in competitive ELISA with 
positive and negative controls. 
 
 
Fig. 4.11 Detection of S. aureus TNase in S. aureus culture supernatants. A positive 
control of purified TNase was included, together with an uninoculated BHI broth 
(negative control).  An increased level of competition occurred with S. aureus FRI 
1151M supernatant compared with supernatants from other strains of S. aureus. 
This data was compiled from the mean of two runs, the full data tables for which can 
be found in Appendix 8. 
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Dilution (two 
fold serial) 
S. aureus 
FRI115M 
supernatant 
S. aureus 
FRI115M 
supernatant 
and cells 
P. aeruginosa 
supernatant 
No 
competition 
1 0.2625 0.11615 1.4012 1.5623 
0.5 1.1004 0.8413 1.42 1.658 
0.25 1.23555 1.14385 1.46035 1.5623 
0.125 1.29285 1.2819 1.3943 1.658 
0.062 1.3112 1.3382 1.46035 1.5623 
0.032 1.3959 1.3864 1.51675 1.658 
0.016 1.4442 1.4452 1.54055 1.6451 
0.008 1.43745 1.45535 1.50745 1.65195 
0.004 1.4513 1.44575 1.51365 1.58695 
0.002 1.46 1.4503 1.48535 1.6234 
0.001 1.412 1.4201 1.382 1.616 
Table 4.5 Absorbance values for S. aureus and P. aeruginosa supernatants in a 
competitive ELISA with negative control.  
 
 
Fig. 4.12. Detection of TNase in S. aureus FRI 115M culture supernatants by 
competitive ELISA using filtered and unfiltered culture medium.  Controls included a 
P. aeruginosa culture supernatant and an uninoculated BHI broth showing no 
competition. This data was compiled from the mean of two runs, the full data tables 
for which can be found in Appendix 8. 
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Specificity of competitive ELISA for S. aureus TNase  
The specificity of the S. aureus TNase MAB (B34) for its target (S. aureus TNase) in a 
competitive ELISA was assessed by challenge with different bacterial supernatants 
from infected RHE utilising purified S. aureus TNase as a positive control (Fig. 4.13, 
4.14).   
Dilution  1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
TNase control 0.016 0.026 0.074 0.182 0.343 0.515 0.639 0.659 0.689 0.703 0.673 
RHE S. aureus 
supernatants 1.  
0.146 0.240 0.434 0.562 0.608 0.619 0.638 0.647 0.630 0.620 0.620 
 RHE S. aureus 
supernatants 2 
0.122 0.233 0.415 0.549 0.620 0.663 0.667 0.684 0.680 0.678 0.686 
 RHE S. aureus 
supernatants 3 
0.150 0.261 0.442 0.555 0.633 0.695 0.688 0.668 0.682 0.676 0.657 
 RHE S. aureus 
supernatants 4 
0.283 0.470 0.613 0.677 0.733 0.769 0.763 0.816 0.806 0.774 0.747 
RHE S. aureus 
supernatants 5 
0.086 0.173 0.339 0.523 0.644 0.835 0.821 0.860 0.861 0.864 0.869 
Table 4.6 Absorbance values for Recombinant human epithelium S. aureus biofilm 
supernatants in a competitive ELISA with positive control of TNase. 
 
 
Fig. 4.13. Competitive ELISA demonstrating competition by S. aureus RHE biofilm 
supernatants indicating the presence of TNase in these samples. This data is not a 
mean and was not repeated. 
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Dilution  1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 1.000 0.500 
TNase control 0.047 0.088 0.189 0.467 0.774 0.934 0.996 1.112 1.151 0.047 0.088 
RHE P.aureginosa 
supernatants 1.  
0.874 0.829 0.885 0.892 0.877 0.934 0.886 0.866 0.874 0.874 0.829 
RHE P.aureginosa 
supernatants 2.  
0.909 0.916 0.983 0.969 1.029 1.028 1.070 1.128 1.053 0.909 0.916 
RHE P.aureginosa 
supernatants 3.  
0.963 1.034 0.975 1.045 1.053 1.040 1.072 1.052 1.096 0.963 1.034 
RHE P.aureginosa 
supernatants 4.  
0.961 1.130 1.157 1.152 1.170 1.108 1.113 1.098 1.132 0.961 1.130 
RHE P.aureginosa 
supernatants 5.  
0.865 0.854 0.845 0.836 0.827 0.817 0.832 0.837 0.840 0.865 0.854 
Table 4.7 Absorbance values for Recombinant human epithelium P. aeruginosa 
biofilm supernatants in a competitive ELISA with positive control of TNase. 
 
 
Fig. 4.14 Competitive ELISA for S. aureus TNase demonstrating no competition using 
P. aeruginosa RHE biofilm supernatants. This data is not a mean and was not 
repeated. 
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Detection of S. aureus TNase in wound fluids using DNA agar  
Prior to assessing TNase presence by ELISA in chronic wound fluid samples, these 
were first subjected to agar testing for TNase.  Using this detection method all 
samples were negative (fig4.15 b).  When the wound fluids were artificially 
contaminated with S. aureus FRI 1151M positive results were evident (fig4.15 a).    
 a)  b) 
Fig. 4.15 Detection of S. aureus TNase activity using DNA agar; a) example of positive 
result, and b) a negative result for detection of TNase. 
 
Sensitivity of competitive ELISA for S. aureus TNase with respect to cell numbers of 
S. aureus FRI 1151M 
To give an indication of the numbers of colony forming units per ml of S. aureus 
required to produce enough TNase for detection utilising the competitive ELISA 
developed it was decided to produce a growth curve of S. aureus  (fig4.16)  and take 
supernatants and a series of time points for competitive ELISA. 
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Time in 
hours 
0 1 2 3 4 5 6  
CFUs/ml 4.8x102 6.4x102 8.8x102 2.0x103 1.7x104 3.0x104 6.8x104  
         
         
Time in 
hours 
7 8 9 10 11 12 16 24 
CFUs/ml 6.535x105 2.25x106 1.4x107 4.6x107 1.4x108 3.35x107 2.55X108 9.75X108 
 Table 4.8 colony forming units per ml recorded over time. 
 
Fig. 4.16 Growth curve (CFU per ml) of S. aureus FRI 1151M over 24 hours at 15 
different time points. Non measured time points in red. 
 
A satisfactory growth curve for S. aureus FRI 1151M was obtained with levels of 480 
CFU/ml at time 0 to 9.75 x 109 CFU/ml at 24 hours.  At each time point (excluding 
those in red), supernatants were obtained and subjected to the competitive ELISA as 
previously described. 
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BHI 
negative 
control 
1.887 1.886 1.944 1.948 1.924 2.034 1.986 2.039 1.939 
TNase 
Positive 
control 
1.029 1.583 1.721 1.933 1.986 2.032 2.126 2.084 2.059 
0hrs 1.825 1.867 1.837 2.021 1.959 1.921 1.936 1.87 1.965 
1hrs 1.856 1.959 1.863 2.011 1.912 1.909 1.864 1.873 1.889 
2hrs 1.818 1.925 1.945 1.977 1.957 1.946 1.955 1.879 1.871 
3hrs 1.876 1.916 2.038 2.128 2.027 2.077 2.016 1.99 1.904 
4hrs 1.843 1.927 1.999 2.063 2.058 2.079 2.004 1.998 1.933 
5hrs 1.882 2.001 1.922 1.838 1.898 1.915 1.903 1.946 1.996 
Table 4.9 Mean absorbance values for FRI115M S. aureus supernatants collected at 
different time points in the growth curve in a competitive ELISA against biotinylated 
TNase, with positive control of TNase and a negative control of Brain heart infusion 
(BHI). 
 
 
Fig. 4.17 Mean results of competitive ELISAs run on supernatants collected from 
hours 0 to 5 plus a control of purified TNase- red. This ELISA was repeated a twice 
further (see Appendix 8 for data tables). 
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BHI 
negative 
control 
1.901 1.958 1.925 1.93 1.937 1.957 1.927 1.856 1.888 
TNase 
Positive 
control 
1.069 1.471 1.736 1.793 1.859 1.858 1.893 1.905 1.934 
6hrs 1.825 1.867 1.837 2.021 1.959 1.921 1.936 1.87 1.965 
7hrs 1.856 1.959 1.863 2.011 1.912 1.909 1.864 1.873 1.889 
8hrs 1.818 1.929 1.945 1.977 1.957 1.946 1.955 1.879 1.871 
9hrs 1.876 1.916 2.038 2.128 2.027 2.077 2.016 1.99 1.904 
10hrs 1.843 1.927 1.999 2.063 2.058 2.079 2.004 1.998 1.933 
11hrs 1.882 2.001 1.922 1.838 1.898 1.915 1.903 1.946 1.996 
Table 4.10 Mean absorbance values for FRI115M S. aureus supernatants collected at 
different time points in the growth curve in a competitive ELISA against biotinylated 
TNase, with positive control of TNase and a negative control of Brain heart infusion 
(BHI). 
 
 
Fig. 4.18 Mean results of competitive ELISAs run on supernatants collected from 
hours 6 to 11 plus a control of purified TNase- red. This experiment was repeated 
twice further (see Appendix 8 for data tables). 
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BHI 
negative 
control 
2.074 2.136 2.148 2.265 2.206 2.272 2.287 2.202 2.129 
TNase 
Positive 
control 
1.104 1.712 2.038 2.089 2.124 2.086 2.112 1.976 1.955 
12hrs 1.535 1.839 1.823 1.936 2.008 1.929 1.972 1.984 2.016 
16hrs 0.768 1.292 1.487 1.803 1.756 1.803 1.898 1.915 2.052 
24hrs 0.539 1.063 1.127 1.462 1.731 1.916 2.059 2.04 2.111 
Table 4.11 Mean absorbance values for FRI115M S. aureus supernatants collected at 
different time points in the growth curve in a competitive ELISA against biotinylated 
TNase, with positive control of TNase and a negative control of Brain heart infusion 
(BHI). 
 
Fig. 4.19  Mean results of three competitive ELISAs run on supernatants collected 
from 12 h, 16 h, and 24 h plus a positive control of purified TNase and uninoculated 
BHI.  Showing competition at all three time points with increasing quantities of 
TNase with time.  This experiment was repeated twice further (see Appendix 8 for 
data tables). 
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There was a trend of increased competition in the ELISA as the number of S. aureus 
CFU/ml increased with time.  There was no competition over the first five time 
points(fig 4.17) (or up to a S. aureus concentration of 3.0x104 CFU/ml).  Clear 
competition was evident between 12 and 24 h time points (fig 4.19) or 
concentrations of S. aureus in excess of 3.35x108 CFU/ml.  The 16 and 24 h time 
points appeared to contain a higher concentration of TNase than the positive control 
(1µg/ml). 
 
Detection of S. aureus TNase in wound fluid artificially contaminated with S. 
aureus TNase to determine the ability of the MAB to function in a wound fluid 
environment 
Following confirmation of the ability of the competitive ELISA to detect S. aureus 
TNase, and therefore the likely presence of S. aureus in both bacterial and RHE 
biofilm supernatants, it was decided to test the antibodies in a wound fluid 
environment.   
Two fold 
serial 
dilutions  
 
Wound 
fluid  
Wound 
fluid spike 
(1:1) with 
TNase 
Wound 
fluid 
spiked 
(1:2) with 
TNase  
S.aureus 
supernatant  
No 
competition 
1 1.543 0.890 0.737 0.573 1.922 
0.5 1.584 1.244 1.161 1.109 1.959 
0.25 1.624 1.439 1.244 1.365 1.797 
0.125 1.624 1.534 1.385 1.494 1.773 
0.062 1.666 1.514 1.506 1.569 1.674 
0.032 1.691 1.511 1.471 1.587 1.780 
0.016 1.780 1.546 1.577 1.681 1.868 
0.008 1.731 1.565 1.505 1.558 1.896 
0.004 1.788 1.605 1.537 1.632 1.838 
0.002 1.755 1.619 1.565 1.688 1.834 
0.001 1.803 1.652 1.598 1.762 1.756 
Table 4.12 Absorbance values for wound fluid spiked with TNase in a competitive 
ELISA with positive and negative controls. 
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Fig. 4.20.  Competitive ELISA for the detection of S. aureus TNase within chronic 
wound fluids artificially and deliberately contaminated with TNase. S. aureus culture 
supernatant was used as a positive control and PBS as a negative control.  This data 
was compiled from the mean of two runs (full data tables for which can be found in 
Appendix 8). 
Detection of S. aureus TNase in acute and chronic wound fluids by competitive 
ELISA 
Following the preceding results demonstrating the ability of the MAB (B34) to detect 
S. aureus TNase in a competitive ELISA using artificially contaminated chronic wound 
fluid, it was decided to test all of the acute and chronic wound fluid samples (Fig. 
4.12).   
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Dilution Acute 3b Acute 4a Acute 2b TNase 
1 0.814 0.947 0.941 0.035 
0.5 0.965 1.164 0.903 0.108 
0.25 1.124 1.279 1.047 0.073 
0.125 1.207 1.303 1.168 0.243 
0.062 1.338 1.362 1.295 0.672 
0.032 1.340 1.455 1.474 0.918 
0.016 1.477 1.480 1.511 1.008 
0.008 1.519 1.456 1.486 1.145 
0.004 1.531 1.429 1.471 1.203 
0.002 1.489 1.430 1.482 1.431 
0.001 1.554 1.469 1.512 1.447 
Table 4.13 Absorbance values for acute wound fluids in a competitive ELISA with a 
positive control of TNase. 
Fig. 4.21 Competitive ELISA for detection of TNase in acute wound fluid samples 
previously shown to contain S. aureus by culture.  These samples were negative for 
TNase. This data was compiled from the mean of two runs, (full data tables can be 
found in Appendix 8). 
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Dilution 
 
Chronic 
1 
Chronic 
2 
Chronic 
3 
Chronic 
4  
Chronic 
5 
TBS TNase 
1 1.204 1.102 0.919 1.344 1.379 1.272 0.136 
0.5 1.312 1.146 1.021 1.388 1.462 1.392 0.305 
0.25 1.282 1.091 1.097 1.478 1.329 1.345 0.569 
0.125 1.262 1.183 1.135 1.477 1.406 1.359 0.811 
0.062 1.276 1.235 1.190 1.420 1.397 1.310 1.022 
0.032 1.219 1.179 1.191 1.396 1.353 1.353 1.113 
0.016 1.206 1.136 1.147 1.380 1.315 1.300 1.224 
0.008 1.190 1.050 1.124 1.390 1.332 1.358 1.274 
0.004 1.283 1.130 1.167 1.353 1.382 1.355 1.316 
0.002 1.256 1.159 1.149 1.345 1.357 1.346 1.318 
0.001 1.248 1.089 1.101 1.354 1.310 1.287 1.392 
Table  4.14 Absorbance values for chronic wound fluids in a competitive ELISA with 
positive and negative controls. 
 
 
Figure 4.22 Competitive ELISA of chronic wound fluid  samples 1-5 demonstrating no 
TNase detection, with a positive control of purified TNase.  A pattern repeated in all 
chronic wound samples and concurring with the DNA agar results. This data was 
compiled from the mean of two runs, (full data tables can be found in Appendix 8). 
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Serial two 
fold 
dilutions 
Chronic 
6 
Chronic 
7 
Chronic 
8 
Chronic 
9 
Chronic 
10 
TBS 
negative 
control 
TNase 
positive 
control 
1 1.139 1.220 1.058 1.082 1.176 1.272 0.024 
0.5 1.087 1.025 0.823 1.125 1.224 1.392 0.053 
0.25 1.087 1.025 0.778 0.901 1.004 1.345 0.066 
0.125 1.098 1.073 0.852 0.939 0.928 1.359 0.098 
0.062 1.295 1.160 1.004 1.006 1.210 1.311 0.196 
0.032 1.288 1.149 1.063 1.204 1.258 1.353 0.399 
0.016 1.326 1.181 1.113 0.967 1.148 1.300 0.494 
0.008 1.265 1.206 1.036 0.960 1.132 1.358 0.856 
0.004 1.317 1.209 1.187 1.053 1.220 1.355 0.934 
0.002 1.363 1.334 1.301 1.272 1.256 1.346 1.143 
0.001 1.372 1.276 1.319 1.188 1.340 1.287 1.221 
Table  4.15 Absorbance values for Chronic wound fluids in a competitive ELISA with 
positive and negative controls. 
 
Figure 4.23 Competitive ELISA of chronic wound fluid  samples 6-10 demonstrating 
no TNase detection, with a positive control of purified TNase.  A pattern repeated in 
all chronic wound samples and concurring with the DNA agar results. This data was 
compiled from the mean of two runs (full data tables can be found in Appendix 8). 
 
Concentration of wound fluid samples and application of ELISA 
The results appeared to demonstrate definitive TNase detection in chronic wound 
samples 2-6 and 9 (fig 4.25, fig 4.26, fig 4.27, fig 4.28, fig 4.29, fig 4.32) and possible 
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detection in samples 10 and 8 (fig 4.31, fig 4.33), with no discernable competition in 
sample 1 (fig 4.24) figures 4.24-4.34 below illustrate the results of ELISA on these 
samples. 
Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
1.061 1.020 0.929 0.963 0.997 0.944 0.961 1.012 1.009 1.078 1.046 
TNase 
positive 
control 
0.021 0.046 0.110 0.213 0.377 0.533 0.695 0.799 0.821 0.906 0.984 
1X 
concentration 
(mean) 
1.021 0.996 0.954 0.962 0.985 0.961 0.960 0.977 0.935 0.985 1.010 
75X 
concentrated 
(mean) 
0.661 0.817 0.846 0.890 0.931 0.909 0.942 0.957 0.916 0.915 0.943 
Spiked chronic 
wound fluid 
0.016 0.014 0.091 0.201 0.362 0.572 0.731 0.827 0.871 0.938 0.973 
  
Table 4.16 Absorbance values for wound fluid 1 and concentrated x75 chronic 
wound fluid 1 in a competitive ELISA with positive and negative controls. 
 
 
Fig 4.24 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR1).  1x concentration, 75x concentration and artificially 
contaminated are mean of two runs, controls one run only, (for full data see 
Appendix 8) 
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
1.002 1.102 1.080 1.047 1.018 0.927 0.988 0.984 0.954 0.987 1.027 
TNase 
positive 
control 
0.014 0.057 0.127 0.254 0.365 0.506 0.693 0.775 0.835 0.905 0.920 
1X 
concentration 
(mean) 
0.856 0.841 0.934 0.933 0.942 0.889 0.901 0.893 0.886 0.917 0.924 
75X 
concentrated 
(mean) 
0.080 0.207 0.385 0.630 0.735 0.773 0.818 0.829 0.834 0.895 0.864 
Spiked chronic 
wound fluid 
0.019 0.062 0.152 0.276 0.448 0.587 0.742 0.791 0.848 0.870 0.884 
  
Table 4.17 Absorbance values for wound fluid 2 and concentrated x75 chronic 
wound fluid 2 in a competitive ELISA with positive and negative controls. 
 
 
 
 
 
Fig 4.25 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR2).  1x concentration, 75x concentration and spiked are mean of 
two runs, controls one run only (for full data see Appendix 8). 
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
1.428 1.292 1.297 1.312 1.255 1.208 1.250 1.200 1.181 1.270 1.219 
TNase 
positive 
control 
0.045 0.060 0.153 0.307 0.457 0.605 0.772 0.911 0.961 0.898 1.071 
1X 
concentration 
(mean) 
1.045 1.058 1.098 1.135 1.131 1.146 1.174 1.182 1.161 1.197 1.189 
75X 
concentrated 
(mean) 
0.148 0.210 0.284 0.484 0.671 0.847 1.006 1.066 1.063 1.028 1.069 
Spiked chronic 
wound fluid 
0.009 0.035 0.136 0.215 0.415 0.611 0.791 0.898 0.954 0.955 1.014 
  
Table 4.18 Absorbance values for wound fluid 3 and concentrated x75 chronic 
wound fluid 3 in a competitive ELISA with positive and negative controls. 
 
 
Fig 4.26 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR3).  1x concentration, 75x concentration and artificially 
contaminated are means of two experiments, controls one experiment only  
(for full data see Appendix 8). 
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
1.353 1.354 1.286 1.330 1.324 1.327 1.302 1.247 1.349 1.398 1.341 
TNase 
positive 
control 
0.014 0.063 0.139 0.255 0.467 0.688 0.829 0.957 1.073 1.122 1.223 
1X 
concentration 
(mean) 
1.109 1.225 1.220 1.265 1.221 1.205 1.220 1.200 1.231 1.160 1.301 
75X 
concentrated 
(mean) 
0.374 0.454 0.564 0.700 0.797 0.954 1.027 1.151 1.184 1.127 1.211 
Spiked chronic 
wound fluid 
0.008 0.002 0.089 0.193 0.404 0.689 0.868 0.986 1.077 1.123 1.230 
Table 4.19 Absorbance values for wound fluid 4 and concentrated x75 chronic 
wound fluid 4 in a competitive ELISA with positive and negative controls. 
 
 
 
Fig 4.27 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR4).  1x concentration, 75x concentration and artificially 
contaminated are mean of two runs, controls one run only (for full data see 
Appendix 8).  
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
1.478 1.430 1.602 1.521 1.456 1.473 1.533 1.413 1.434 1.526 1.343 
TNase 
positive 
control 
0.012 0.054 0.155 0.323 0.506 0.807 1.033 1.296 1.296 1.418 1.287 
1X 
concentration 
(mean) 
1.278 1.280 1.245 1.222 1.274 1.269 1.289 1.329 1.292 1.241 1.423 
75X 
concentrated 
(mean) 
0.115 0.282 0.442 0.821 1.069 1.221 1.298 1.361 1.330 1.272 1.236 
Spiked chronic 
wound fluid 
0.003 0.044 0.163 0.321 0.559 0.800 1.088 1.286 1.375 1.414 1.229 
  
Table 4.20 Absorbance values for wound fluid 5 and concentrated x75 chronic 
wound fluid 5 in a competitive ELISA with positive and negative controls. 
 
 
 
Fig 4.28 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR5).  1x concentration, 75x concentration and artificially 
contaminated are means of two experiments, controls one experiment only (for full 
data see Appendix 8). 
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
0.667 0.782 0.731 0.715 0.675 0.676 0.710 0.709 0.679 0.619 0.662 
TNase 
positive 
control 
0.024 0.089 0.175 0.270 0.362 0.450 0.486 0.549 0.586 0.645 0.630 
1X 
concentration 
(mean) 
0.482 0.542 0.576 0.419 0.591 0.497 0.609 0.581 0.618 0.614 0.600 
75X 
concentrated 
(mean) 
0.094 0.172 0.188 0.302 0.369 0.416 0.466 0.531 0.581 0.574 0.560 
Spiked chronic 
wound fluid 
0.017 0.097 0.221 0.302 0.417 0.494 0.519 0.556 0.591 0.607 0.582 
  
Table 4.21 Absorbance values for wound fluid 6 and concentrated x75 chronic 
wound fluid 6 in a competitive ELISA with positive and negative controls. 
 
 
 
Fig 4.29 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR6).  1x concentration, 75x concentration and artificially 
contaminated are mean of two experiments, controls one experiment only(for full 
data see Appendix 8).  
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
0.783 0.783 0.728 0.781 0.788 0.761 0.769 0.763 0.764 0.759 0.687 
TNase 
positivel 
0.039 0.110 0.236 0.381 0.521 0.636 0.681 0.716 0.727 0.696 0.719 
1X 
concentration 
(mean) 
0.673 0.723 0.789 0.780 0.790 0.809 0.812 0.802 0.797 0.770 0.768 
75X 
concentrated 
(mean) 
0.575 0.624 0.633 0.648 0.648 0.708 0.752 0.791 0.766 0.728 0.742 
Spiked chronic 
wound fluid 
0.039 0.100 0.259 0.384 0.534 0.627 0.687 0.703 0.721 0.696 0.694 
  
Table 4.22 Absorbance values for wound fluid 7 and concentrated x75 chronic 
wound fluid 7 in a competitive ELISA with positive and negative controls. 
 
 
 
 
Fig 4.30 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR7).  1x concentration, 75x concentration and artificially 
contaminated are means of two experiments, controls one experiment only (for full 
data see Appendix 8). 
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
0.859 0.853 0.795 0.797 0.801 0.764 0.804 0.812 0.800 0.769 0.803 
TNase 
positive 
control 
0.045 0.114 0.227 0.403 0.535 0.629 0.685 0.751 0.765 0.754 0.803 
1X 
concentration 
(mean) 
0.588 0.707 0.627 0.793 0.784 0.797 0.763 0.770 0.782 0.773 0.820 
75X 
concentrated 
(mean) 
0.312 0.315 0.370 0.433 0.471 0.543 0.635 0.699 0.727 0.728 0.758 
Spiked chronic 
wound fluid 
0.019 0.054 0.196 0.282 0.431 0.605 0.651 0.700 0.696 0.722 0.771 
  
Table 4.23 Absorbance values for wound fluid 8 and concentrated x75 chronic 
wound fluid 8 in a competitive ELISA with positive and negative controls. 
 
 
Fig 4.31 Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR8).  1x concentration, 75x concentration and artificially 
contaminated are means of two experiments, controls one experiment only (for full 
data see Appendix 8). 
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Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
0.925 0.951 0.884 0.899 0.877 0.883 0.896 0.822 0.820 0.830 0.786 
TNase 
positive 
control 
0.052 0.135 0.240 0.383 0.511 0.654 0.658 0.718 0.726 0.740 0.727 
1X 
concentration 
(mean) 
0.725 0.793 0.810 0.836 0.798 0.846 0.827 0.845 0.842 0.823 0.772 
75X 
concentrated 
(mean) 
0.071 0.165 0.260 0.434 0.556 0.621 0.661 0.714 0.758 0.743 0.757 
Spiked chronic 
wound fluid 
0.031 0.110 0.224 0.354 0.544 0.660 0.715 0.751 0.731 0.733 0.460 
  
Table 4.24 Absorbance values for wound fluid 9 and concentrated x75 chronic 
wound fluid 9 in a competitive ELISA with positive and negative controls. 
 
Fig 4.32  Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR9).  1x concentration, 75x concentration and artificially 
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contaminated aremeans of two experiments, controls one experiment only (for full 
data see Appendix 8). 
 
 
Two fold 
serial dilution 
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 
Negative 
control 
1.062 1.031 1.111 1.114 1.060 1.092 1.104 1.134 1.136 1.082 1.051 
TNase 
positive 
control 
0.052 0.185 0.193 0.457 0.647 0.809 0.884 1.032 0.993 1.046 1.022 
1X 
concentration 
(mean) 
0.910 1.008 1.075 1.089 1.062 1.073 1.025 1.103 1.112 1.025 0.989 
75X 
concentrated 
(mean) 
0.590 0.650 0.615 0.720 0.785 0.796 0.842 0.951 0.947 0.964 0.992 
Spiked chronic 
wound fluid 
0.040 0.187 0.195 0.447 0.648 0.761 0.859 0.940 0.970 1.011 1.002 
  
Table 4.25 Absorbance values for wound fluid 10 and concentrated x75 chronic 
wound fluid 10 in a competitive ELISA with positive and negative controls. 
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Fig 4.33  Competitive ELISA for detection of S. aureus TNase in concentrated wound 
fluid sample (CHR10).  1x concentration, 75x concentration and artificially 
contaminated are means of two experiments, controls one experiment only (for full 
data see Appendix 8). 
Detection of S. aureus TNase using a modified ELISA format applied to chronic 
wound dressings 
Filter paper from all six patients was assayed using the sandwich ELISA technique.  
Six samples were taken from each patient and compared to blank filter paper.  TNase 
was not detected in any samples using this method. 
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Discussion 
 
Monoclonal antibody targets 
In this study, LPS present from the cell wall of P. aeruginosa was one target for MAB 
development.  LPS consists of three components, the hydrophobic membrane 
anchoring lipid, a conserved oligosaccharide core region and an O-antigen section 
distally (Fig. 4.1).  The O-antigen is a major component of the outer cell surface of 
the Gram-negative bacterial cell wall and is a well-established virulence factor of 
bacteria (Jamasbi and Taylor, 2009) to which patients will commonly develop 
antibodies.  The O-antigen is however a variable molecule with most clinical isolates 
being classifiable into 10 varieties or serogroups (Hatano and Pier, 1998).  A recent 
study of 16 P. aeruginosa strains demonstrated three differing O-antigen 
components and varying levels of expression within the same serotype (Jamasbi and 
Taylor, 2009). 
 
LPS has been used as a target for MAB production for bacterial detection in other 
studies including that of Weisner et al., 2007 who detected LPS in the sputum of 
patients with cystic fibrosis by various methods including ELISA.  Lam et al., 1987 
developed two MABs to the O-antigen of P. aeruginosa LPS and studied binding by 
scanning electron microscopy secondary labelled antibodies with gold markers.  
Despite promising results with one strain, this was not replicated with a further ‘wild 
type’ strain of P. aeruginosa, possibly highlighting differing O-antigen regions.  To 
counter this variation, previous studies have been attempted to utilise antibodies 
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raised against 8 of the most common O-antigens rather than just one (Kusama, 
1983).  
 
TNase is a thermostable nuclease produced by S. aureus and some other species of 
bacteria and this was also used as an antigen to generate MABs.  TNase is a 5’-
diphosphodiesterase which yields DNA or RNA hydrolysis products, predominately 
3’-mono and dinucleotides (Yazdankhah et al., 1999).  TNase is the target of 
detection in several commercial tests for S. aureus with sensitivity rates as high as 
96.7% at 2 hours and is the favoured microbiological test for rapid identification of S. 
aureus (Lagace-Wiens et al., 2007). 
 
Recent advances in the understanding of the methods used by neutrophils to 
combat bacterial infection have led to the discovery of neutrophil extracellular traps 
(NETs) (Brinkmann et al., 2004).  These traps consist of a DNA backbone with 
associated antimicrobial peptides, histones and proteases.  These NETs have been 
shown to form in response to S. aureus infection (Berends et al., 2010).  It has also 
been reported that TNase producing S. aureus reduce entrapment in NETs, whereas 
non-TNase producing S. aureus does not, indicating possible strain differences for 
TNase production. 
 
TNase is also not entirely specific for S. aureus with some TNase negative S. aureus 
strains having reported (Neville et al., 1991).  The number of false negatives is likely 
however to be low with a recent study, Gonano et al 2008, demonstrating no TNase 
production in only one out of 48 strains isolated from human wounds.  However, a 
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study by Chesneau et al., (1993) demonstrated TNase production in nine of twenty 
eight staphylococcal species studied.   
 
Previous studies utilising TNase as a target antigen for MABs have shown sensitivity 
rates as low as 1 ng/ml of TNase (Yazdankhah et al., 1999) when utilised in ELISA 
with magnetic beads, which they estimated as corresponding to the amount of 
TNase produced and secreted by 105 CFU/ml of S. aureus. 
 
TNase has successfully been used as a marker for the identification of S. aureus.  In 
previous studies, detection of this antigen has shown a high positive identification 
rate, with low numbers of false negatives (<1%) (Gonano et al., 2009).  However, it is 
clear from this, and other studies, that false-positive results can also occur due to 
TNase activity in some strains of coagulase negative staphylococci (CNS) (Chesneau 
et al., 1993).  Hence, MABs developed against TNase would appear to be good 
identifiers for S. aureus strains, although they show similar limitations, and some 
false positives may be expected.   
 
Interestingly, previous studies utilising MABs raised to TNase produced by S. aureus 
have demonstrated that some of these antibodies are specific to S. aureus TNase 
whilst some detect all TNase produced by different species of bacteria.  This is 
almost certainly as a function of the binding site of the antibody as there may only 
be slight differences in TNase configuration between species (Brakstad et al., 1995).  
It is therefore possible to produce S. aureus TNase specific MABs, as although the 
activity of TNase is not specific to S. aureus the nuc encoding gene has S. aureus 
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specific sequences leading to minor differences between S. aureus TNase and those 
produced by other bacteria.  MABs specific to S. aureus TNase were previously 
produced by (Brakstad et al., 1995).  Unfortunately this information or epitope 
mapping was not available for the antibody used in the present study.    
 
 
 
Monoclonal antibodies for use in the detection of target bacteria 
MABs and the ELISA methods allow the rapid and effective detection of bacteria 
within a few hours (Yazdankhah et al., 1999).  The O-antigen of the LPS is expressed 
on the cell wall of the bacterium and should therefore be easily available for 
presentation to the antibody and subsequent detection through fluorescent 
microscopy of ELISA.  However the O-antigen of the LPS has variable regions with 11 
commonly recognised variants.  It was anticipated that the antibody used would be 
specific to a constant epitope, however it was possible that specificity was to a 
variable epitope of O-antigen particular to the LPS of the PAO1 strain P. aeruginosa.  
If the latter was the case then use of the antibody would be limited to selected 
strains of P. aeruginosa.  
 
TNase is manufactured intra-cellularly and then secreted by S. aureus at which point 
it is available for presentation of the antigen and subsequent detection through 
fluorescent microscopy of ELISA.  TNase is not specific to S. aureus and is expressed 
by other species such as. S. schleiferi, S. carnosus, S. intermedius, S. hyicus, S. caprae 
and S. capitis (Kloos and Bannermann, 1994), along with some streptococci and 
170 
 
bacilli (Park et al., 1980).  One other potential problem of using TNase as an antigen 
was that there is no reliable data as to when it is produced and expressed.  If it is 
constitutively expressed by all strains of S. aureus then it would be an advantageous 
choice of antigen, however if it is produced only at times of stress or when the 
bacteria are above a certain cell density then variability in the test would be 
encountered.  In the case of the latter this could also be an advantage when testing 
for S. aureus in chronic wounds as undoubtedly a relatively high cell density would 
be synonymous with the pathogenic state.   
 
Immunofluorescent microscopy 
Immunofluorescent microscopy utilising MABs and FITC labelled conjugated anti-
mouse antibodies was successful in a limited manner in detection of P. aeruginosa 
and S. aureus planktonic bacteria (Fig. 4.7 and 4.8).  However, interpretation of these 
results was difficult due to auto-fluorescence and quenching which was particularly 
evident with P. aeruginosa as well as biofilm specimens (fig 4.9).  The use of an 
alternate non-quenching fluorescent marker (e.g. Alexa 594) may have negated this 
risk of false negatives.  If this molecule could have been attached directly to the MAB 
rather than a secondary antibody a simpler method could have produced more 
reliable results.  There appears to be no reliable method for reducing 
autofluorescence in bacteria or tissue and therefore no current way of reducing the 
risks of false positives in this technique. 
  
A very similar method was used by Gu et al., 2002 using MABs to Streptococcus 
mutans which was then treated with FITC-conjugated goat anti-mouse antibodies to 
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detect the bacteria in salivary samples.  This study did not mention FITC quenching 
or the problems of auto fluorescence and claimed 100% sensitivity and specificity in 
detecting S. mutans. 
 
Immunofluorescence microscopy of CDFF and RHE generated biofilms 
The methods for visualising bacteria within biofilms developed in the CDFF and on a 
RHE model were very similar, both were paraffin embedded and then cut into 10 µm 
sections and mounted on slides prior to processing.  Both had biofilms evident 
through Gram-staining but the RHE exhibited autofluorescence thus preventing 
bacterial detection.  The biofilms generated in the CDFF autofluoresced to a lower 
extent and although there were some possible positive results particularly with the 
P. aeruginosa biofilms (fig 4.9), the interpretation of these results was again 
compromised by rapid quenching.  Fluorescent microscopy, depending on observer 
interpretation of light levels, suffers from autofluorescence particularly when used in 
conjunction with tissue samples and highly fluorescent bacteria such as P. 
aeruginosa.   
 
Previous studies identifying bacterial species in biofilms using fluorescently labelled 
MABs (Gu et al., 2005) directly conjugated their MABs to fluorescent labels that did 
not quench and utilised a CLSM rather than a light microscope to successfully 
visualise individual bacteria within biofilms.  In view of the difficulties with 
immunofluorescence microscopy it was decided to proceed to an ELISA method for 
detection of targets in which would negate the problems of autofluorescence and 
quenching previously encountered. 
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ELISA for the detection of S. aureus TNase 
Initial experiments were undertaken to establish the optimal amount of biotinylated 
S. aureus TNase to use in competitive ELISAs.  The results indicated that 80% of the 
maximal ELISA response was generated by ~78 µg/ml of biotinylated TNase (see fig 
4.10).  This was the concentration used in all subsequent competitive ELISAs and 
enabled competition with S. aureus TNase to be reliably detected.   
 
The competitive ELISA sensitivity and specificity 
Using the competitive ELISA, competition was as expected, demonstrated with 
purified S. aureus TNase.  The sensitivity of S. aureus TNase detection was deemed to 
be ~62.5 ng/ml.  Similarly, competition was evident with S. aureus culture 
supernatants and also supernatants from S. aureus biofilms on RHE (Fig. 4.11).   
 
Further ELISAs indicated (Fig. 4.11) that as expected the highest competition 
occurred using purified S. aureus TNase, followed by S. aureus FRI 115M culture 
supernatants (NB it was from this strain that the purified TNase was obtained and to 
which the MAB was raised) and then S. aureus SaB2 supernatant.  No competition 
was evident in the uninoculated BHI control.   
 
It is possible that S. aureus FRI 115M strain produces more TNase than SaB2 strain or 
alternatively that the MAB was more specific to the TNase from S. aureus FRI 115M.  
Additional studies on S. aureus FRI 115M supernatant (Fig. 4.12) using filtered and 
unfiltered supernatants showed little difference in detection, thus indicating that the 
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cells and other debris within the unfiltered supernatant were not interfering with the 
ELISA.  Using the competitive ELISA no cross reaction between the B34 antibody to S. 
aureus TNase and P. aeruginosa RHE biofilm supernatants was evident (Fig. 4.14). 
These results indicated a high level of sensitivity and specificity and a lack of cross 
reaction of bacterial products and cells affecting the competitive ELISA developed. 
 
Detection of S. aureus TNase using DNA agar  
Before using the competitive ELISA chronic wound samples were crudely screened 
for S. aureus TNase using DNA agar.  All chronic wound fluids tested were negative in 
these tests for TNase.  This was perhaps surprising given that previous 
microbiological and PCR analysis had shown the presence of S. aureus within some of 
these samples. The failure of the DNA agar to detect S. aureus TNase most likely 
reflects the low concentration of the enzyme following dilution during wound fluid 
collection (see methods chapter 1). It was also possible that the S. aureus present 
within these fluids had not secreted TNase and thus the TNase may have been 
present intracellularly and not available for detection.   
 
Competitive ELISA on wound fluids artificially contaminated with S. aureus TNase  
To ensure there would be no interference of the ELISA by wound fluid components it 
was decided to use the competitive ELISA on wound fluids artificially contaminated 
with S. aureus TNase (fig 4.20).  Wound fluid, and particularly chronic wound fluid is 
a complex mix of cells, proteins and growth factors which could inhibit a MABs 
action through preventing it reaching its target antigen. Chronic wound fluid not 
previously shown to contain S. aureus by culture or PCR was artificially contaminated 
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with purified S. aureus TNase and subjected to competitive ELISA.  The TNase in 
these samples was reliably detected in these assays, indicating that the components 
of the chronic wound fluid did not inhibit the ELISA.   
 
Wound fluids and the competitive ELISA 
All acute wound fluids analysed by competitive ELISA demonstrated no competition, 
indicating the absence of S. aureus TNase.  This was expected given that all acute 
wound samples except sample 2a, b, and c were negative for S. aureus, and the 
amount of CFU/ml cultured within samples 2a, b, and c was low (<833.3 CFU/ml).  All 
chronic wound fluid samples were negative for S. aureus TNase by ELISA (fig 4.22, fig 
4.23), including the samples from which S. aureus was isolated (counts as high as 
2.4x107 CFU/ml).  Two possibilities for these results were considered, the first was 
again due to sample dilution during collection resulting in a S. aureus TNase 
concentration below the sensitivity of the ELISA (<62.5 ng/ml), or that S. aureus was 
present and not secreting TNase, as previously postulated.  Further studies, using a 
more sensitive analysis e.g. surface plasmon resonance may be of value in 
establishing the presence of TNase in these samples.    
 
Correlation between TNase detection and S. aureus cell number using ELISA 
As the competitive ELISA detects TNase effectively in a wound fluid environment, 
and the samples had been shown to contain S. aureus it was necessary to accurately 
determine of the levels of S. aureus required to produce detectable levels of TNase.  
It is not known when S. aureus produces TNase, and it is possible that this occurs 
constitutively, however given the nature of the enzyme it is more likely that this 
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occurs when populations reach a certain density and the supply of available 
nutrients become deficient. 
 
To determine the number of S. aureus required to produce detectable TNase, a S. 
aureus FRI 115M growth curve was produced (fig 4.16) and the culture supernatants 
at measured time points were subjected to the competitive ELISA (fig 4.17, fig4.18, 
fig4.19).  The results first suggested TNase presence at 12 hours and clear detection 
occurred at 16 and 24 hours.  A cell concentration 3.35x108 CFU/ml was considered 
necessary to produce TNase at the necessary detectable level.  Interestingly this 
density of S. aureus far exceeds that detected within our chronic wound fluid 
samples, providing a likely explanation that out MAB was not sensitive enough to 
detect any TNase that may have been produced within our samples.  Of course a 
lower cell number might be able to generate detectable concentrations of TNase 
provided a sufficient period of time was available and that the TNase remained 
stable in the environment. 
 
 
Concentration of chronic wound fluid samples 
Diluted chronic wound fluid samples were concentrated in order to improve 
sensitivity of the assay.  After concentration S. aureus TNase was detected in 
samples 2-6 and 9, with possible detection in samples 8 and 10.  No TNase was 
detected in sample 1 see fig 4.24-Fig 4.33 inclusive. 
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It should be noted that the positive results on these concentrates did not correspond 
exactly to the cultural and molecular findings for the presence of S. aureus.  False 
positives could occur due to the presence of other TNase producing bacterial species 
such as CNS.  However, more likely is the presence of TNase which could persist after 
the loss of S. aureus from the environment (Yazdankhah et al., 1999).  When ELISA 
was negative but culture positive for S. aureus, an additional explanation could be 
the persistence of S. aureus within epithelial cells (Yazdankhah et al., 1999) where 
any secreted TNase may be unavailable for subsequent detection.    
 
ELISA application to chronic wound dressings 
An attempt to modify the ELISA format and apply it to filter paper imprints of chronic 
wound dressings was undertaken.  It was hoped that since these imprints were 
directly from the dressing and not subjected to dilution then greater sensitivity of 
detection would occur. 
 
The results of the chronic wound dressing ELISAs showed no detectable TNase within 
the tested samples including WD1 where S. aureus had been detected by 
culture/PCR.  The fact that these samples were negative may indicate absence of 
TNase.  Further work is however needed in this area to create a reliable filter paper 
based ELISA. 
 
Summary  
The approach of using MABs and fluorescent microscopy to directly detect bacterial 
species in clinical samples is of great value as this would greatly reduce the period 
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required for detection compared with traditional culture.  Furthermore, previous 
studies using permanent non quenching markers directly linked to the antibody and 
CLSM rather than standard fluorescent microscopy (Gu et al., 2005) hold great 
promise for the dynamic investigation of bacteria within biofilms. 
 
The method of utilising MABs and ELISA to rapidly detect bacteria is well established 
and offers a rapid, efficient and reproducible testing format that could be simply 
translated into a bedside or simple laboratory test.  The novel MABs and competitive 
ELISA used in this present study reliably detected purified S. aureus TNase from S. 
aureus culture supernatants, RHE culture medium and artificially contaminated 
wound fluids.  Unfortunately, S. aureus TNase was not detected initially from chronic 
wound fluid samples, which was consistent with the screening analysis using DNA 
agar.  However, concentrating the collected wound fluids did overcome potential 
problems of low levels of TNase in the samples.  Further study in optimising the 
ELISA and sample collection/processing would be recommended.  Possible other S. 
aureus specific targets for future study include the recently described extracellular 
adherence protein (EAP) (Hussain et al., 2008) which showed 100% specificity to S. 
aureus with no false-positives. It would also be of value to consider MABs developed 
against antibiotic resistance pumps in Methicillin Resistant S. aureus.  Antigens 
developed to a constant and specific cellular wall protein or even the mobile 
extracellular flagella would be useful in further studies of P. aeruginosa. 
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Chapter Five:  Characterisation of biofilms on tissues using fluorescent 
in situ hybridisation 
 
Introduction 
Previous investigations in this thesis have characterised the bacterial communities in 
chronic wounds using species-specific monoclonal antibodies raised against P. 
aeruginosa, and S. aureus (Chapter 4).  This chapter focuses upon the analysis of 
bacterial biofilm communities colonising surfaces of Reconstituted Human 
Epithelium (RHE) and human debrided wound tissue using molecular probes.  
Specifically, studies aimed to determine the type and quantity of bacteria present, 
together with the structure of the biofilm typical of chronic wounds.  An approach 
based on Fluorescent in situ Hybridisation (FISH) utilising bacterial specific Peptide 
Nucleic Acid (PNA) probes and Confocal Laser Scanning Microscopy (CLSM) was used. 
 
Traditional analysis of microbial communities   
A wide range of techniques can be used to identify bacterial species in different 
fields of microbiology.  Simple bacterial culture is routinely employed for the 
isolation of microorganisms from clinical origin, including chronic wounds.  Culture 
methods are of benefit in the identification of culturable bacteria that commonly 
cause wound infection.  However, the approach clearly requires an ability of the 
microorganisms to grow on the selected agar medium together with the 
atmospheric conditions employed.  The existence of unculturable microorganisms is 
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widely recognised, and it has been estimated that for many microbial populations, 
culturable organisms represent only a small proportion (only 2-3%) of the total 
bacterial population (Amman et al., 2001, Moter and Göbel, 2000).  Cultural analysis 
can also be time-consuming (Amman et al., 2001) and even in instances where 
differential agar media are used, supplementary testing including biochemical and 
serological analysis is required for definitive identification. Traditional 
microbiological analysis is often limited in terms of the information generated on the 
bacterial phenotype and structural composition of bacterial communities, when 
compared with other methods (Thunheer et al., 2004)   
 
Bacterial staining approaches such as Gram-staining coupled with light microscopy 
can provide detail on bacterial cell walls and a limited amount of information 
regarding the structure of biofilms.  The method broadly delineates two groups of 
bacteria (Gram-positive and Gram-negative) but does not permit species 
identification (Moter and Göbel, 2000).  Molecular microbiological methods based 
on the analysis of DNA/RNA extracted from microbial populations can be very 
effective at species identification, but in mixed communities PCR bias can 
theoretically occur and the processing steps involved in the nucleic acid extraction 
methods will generally destroy any structural detail of the bacterial community 
(Amann et al., 2001).  
 
Analysis of biofilm composition and structure  
A more detailed characterisation of biofilms is important since identification of 
pathogenic bacteria and their quantity and location within biofilms can aid in 
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assessing the risk status of any infection (Gu et al., 2005).  This is perhaps best 
demonstrated by studies on dental plaque (a well-recognised and studied biofilm) 
where a correlation between the relative proportion of certain bacteria and the 
occurrence of dental caries has been established (Marsh, 2003).  It is highly probable 
that the same principle applies to biofilms in other clinical environments.  For 
example in chronic wounds it has been shown that some wounds heal when a 
biofilm is present (Leaper 1994, Kanno et al., 2010), whilst others have their healing 
arrested and will deteriorate (Schierle et al., 2009).   Marsh (2003) also hypothesised 
that changes in the oral environment (pH, nutrition, oxygen concentrations, 
medications) could alter gene expression within oral microflora, increasing the 
competitiveness of pathogenic bacteria, whilst decreasing the competitiveness of 
the normal microflora, thus promoting disease.  This view has been termed the 
‘environmental plaque hypothesis’ (Marsh, 2003).  It would seem logical to 
extrapolate this hypothesis to chronic wound microflora and if demonstrable may 
lead to new strategies for altering wound environment to maximise beneficial or 
non-harmful species within the biofilm allowing a ‘healing biofilm’ to develop rather 
than focusing on biofilm eradication.  This approach would, however, require an 
accurate assessment of biofilm structure, distribution and numbers of species 
involved. 
 
The ideal method for characterisation of bacterial communities within chronic 
wounds would be one that combines the species specificity of the molecular 
techniques together with staining and microscopy, allowing the analysis of the 
biofilm structure.  Biofilms communities are dynamic, with continuous changes 
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occurring in structure and species composition and an appropriate method would 
facilitate observation of this dynamic biofilm without killing the microbial cells. 
 
Structure of biofilms  
As previously discussed (Chapter 1) biofilms occur ubiquitously where 
microorganisms and a surface come into contact with sufficient nutrition to support 
microbial growth.  Biofilms can be polymicrobial and are structurally organised into 
multiple microcolonies with interspersed water channels.  As such, biofilms consist 
of bacterial cells, water, and cell aggregates embedded into an exopolysaccharide 
(EPS) matrix (Costerton, 1999 and 1995). 
  
 
Figure 5.1. Schematic representation of a biofilm (courtesy of Bozeman- Centre for 
Biofilm Engineering Montana State University) 
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Fluorescence in situ hybridisation (FISH)  
In situ hybridisation (ISH) is a technique that was first developed in 1969 (Pardue and 
Gall, 1969) and allowed nucleic acid sequences to be detected inside cells using 
radioactive labels without altering the cell morphology or integrity of various 
components (Moter and Göbel, 2000).  The approach was not applied to bacterial 
cells until 1988 (Giovannoni et al., 1988).  Radioactively labelled probes have since 
been replaced in many applications by fluorescent probes, leading to the 
development of the fluorescent in situ hybridisation (FISH). 
 
FISH detects nucleic acid sequences using a fluorescently labelled oligonucleotide 
probe that hybridises specifically to its complementary target sequence within the 
intact cell (Moter and Göbel, 2000).  The procedure includes several universal stages 
(Fig 5.2).  Specimens are first fixed prior to exposure to any necessary pre-treatment 
steps.  Hybridisation of the oligonucleotide probe to the target molecule is followed 
by washing to remove unbound probe.  Mounting and imaging of the specimen are 
the final stages of the process.  Fluorochromes with different excitation and emission 
spectra allow for the simultaneous detection of multiple probes within a single 
specimen, and therefore the potential to visualise several microbial species.  This 
adaptation is frequently termed as multiplex staining (Thurnheer et al., 2004). 
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Figure 5.2. Schematic illustrating typical stages involved in FISH (Courtesy of Dr S. 
Malic, Ph.D. thesis (2008) ‘The In Vitro Development and Characterisation of Two 
Clinically Important Biofilms’). 
 
FISH has been used for direct imaging of microorganisms since 1999 (Sekiguchi et al., 
1999).  The method initially targeted 16S ribosomal RNA (rRNA) sequences and was 
applied to a variety of diverse bacterial systems, such as microbial isolates (Mignard 
and Flandrois, 2006) and dental plaque (Thuneer et al., 2001).  Probes were selected 
that targeted rRNA sequences because the encoding gene regions are often 
functionally conserved as well as being abundant (usually more than 10000 per cell) 
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(Perry-O'Keefe et al., 2001) throughout the genome thus allowing a high degree of 
sensitivity and specificity.   
 
The 16S rRNA gene sequences for a wide range of bacteria are readily available 
within genomic databases and this allows the design of probes to target specific 
species or groups of bacteria.  The probes used in FISH are typically 15-30 
nucleotides long and are covalently bound at the 5’ end to a single fluorescent dye 
molecule (Helmer-Madhok et al., 2002).  Whilst useful, FISH does, like all methods of 
characterisation have some limitations.  DNA probes can bind to intracellular 
proteins and due to the thick cell wall of Gram-positive bacteria there is sometimes 
insufficient probe penetration (Malic et al., 2009). 
 
Peptide Nucleic Acid (PNA) probes  
Peptide Nucleic Acid (PNA) probes have over the last few years been incorporated 
into FISH (Malic et al., 2009).  PNA probes are DNA analogue molecules consisting of 
an uncharged polyamine backbone instead of conventional sugar phosphates.  These 
DNA analogues hybridise with DNA sequences through complimentary base pairing 
(Moter and Göbel, 2000, Pardue and Gall, 1969).  As PNA probes have an uncharged 
backbone, they tend to have superior hybridisation characteristics with higher 
specificity and exhibit more rapid hybridisation compared with equivalent DNA 
probes.  It has also been proposed that PNA probes can more readily diffuse through 
hydrophilic cell walls allowing hybridisation to occur without the need for stringent 
pre-treatment stages (Moter and Göbel, 2000, Pardue and Gall, 1969).  As a result, 
hybridisation with PNA probes can be performed in a low salt buffer and reduced 
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stability of the rRNA secondary structure can be achieved, allowing PNA probes to 
hybridise to otherwise less accessible target pairings (Moter and Göbel, 2000, Pardue 
and Gall, 1969).  It could therefore be argued that PNA probes have considerable 
advantages over DNA probes, although the former are very expensive to synthesise 
and this does limit their use in routine clinical applications.  
 
The use of PNA probes in bacterial studies is increasingly being reported as the 
advantages of the technique become more widely recognised.  Recent studies have 
successfully and rapidly differentiated between Enterococcus species (Wellinghausen 
et al., 2007) and allowed the rapid (in less than 2.5 h) identification of S. aureus in 
blood culture bottles with 100% specificity and sensitivity (Oliveira et al., 2003).  
Recently, a PNA probe was used successfully to detect Helicobacter pylori in paraffin 
embedded gastric biopsy specimens enabling its easy and rapid detection with 100% 
specificity (Guimarães et al., 2007).  Further PNA/FISH work has allowed the 
definitive detection of Candida species cultured from solid and liquid media in 1 h, 
whilst claiming a specificity and sensitivity of 100% (Trnovsky et al., 2008).  Whilst 
these studies have demonstrated the rapid and specific identification of pure 
microbial species in culture media, further work by Malic and colleagues (Malic et al., 
2009) have showed the effectiveness of the PNA/FISH technique in the analysis of 
multispecies communities allowing the detection of both S. aureus and P. aeruginosa 
strains, both planktonically and within a biofilm.   
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Aims 
The aim of the work described in this Chapter was to use PNA-FISH as an approach to 
further characterise chronic wound biofilm populations.  Detection of S. aureus and 
P. aeruginosa was the focus of study, as both of these species are prevalent in 
chronic wounds and recognised as prolific biofilm formers.  As previously mentioned 
(Literature review) it is important to remember that the presence or absence of S. 
aureus and P. aeruginosa biofilms have not been definitively shown to be related to 
chronicity or healing of wounds. 
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Materials and Methods 
 
Peptide Nucleic Acid (PNA) Probes  
Three PNA probes were used in this present study and consisted of the universal 
bacterial probe (Bac-UniCY3), P. aeruginosa specific probe (PsaerFITC) and a S.  
aureus specific probe (Sta 16S03).  Details of these probes are provided in Table 5.1.  
The sequences of these probes were partially adapted from Perry-O’Keefe et. al, 
(2001).  The probes were manufactured by Boston Probes (Foster City, USA) for 
Applied Biosystems  (Warrington, UK) and were labelled either with FITC, Cyanine 5 
(CY5) or Cyanine 3 (CY3) and designed to target the 16s rRNA gene of bacteria.  All 
probes were pre-validated using the PNA designer software (Applied Biosystems) 
before synthesis.  
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Table 5.1 summary of the properties of the PNA probes used in this study 
Probes Target Nucleotide 
sequence 
Hybridisation 
conditions 
Fluorescent 
Label 
Working 
concentration 
(nM) 
Excitation 
wavelengths 
Refs. 
Psaer PNA 
P. aeruginosa 
5’-
OOAACTTGCTG
AACCAC-3’ 
55°C 
No Formamide 
FITC 300 488 (Coull and hyldig- 
Nielsen 2003) 
Sta 
16S03 
PNA 
S. aureus 
5’-
OOGCTTCTCGTC
CGTTC-3’ 
55°C 
30% 
Formamide 
CY5 500 633 (Perry-O’Keefe e al 
2001) 
Bac Uni1 PNA 
Universal probe  
(eubacteria) 
5’-
OOCTGCCTCCCG
TAGGA-3’ 
55°C 
No Formamide 
CY3 150 561 (Perry-O’Keefe e al 
2001) 
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To confirm the PNA probes were indeed functional and specific to the target 
bacterial species and that the probes functioned in a ‘fixed’ preparation of mixed 
bacteria, initial studies were undertaken using planktonic suspensions of bacteria.  
These included pure cultures of P. aeruginosa and S. aureus species and mixed 
preparations of these species.  These preparations were prepared from pure isolates 
as previously described in Chapter 2.   
 
Cell fixation and PNA-FISH was performed as described by Perry-O’Keefe et. al., 
(2001).  Bacterial cultures were grown overnight and pelleted by centrifugation at 
(16000 g, 5min).  The supernatant was removed and the cell pellets resuspended in 
PBS (7 nM NaHPO4, 7 mM NaH2PO4, 130 mM NaCl).  Cell suspensions were 
centrifuged again and the supernatants removed.  The cells were resuspended in PBS 
containing 4% (w/v) paraformaldehyde (Sigma) and fixed for 1 h.  The fixed cells 
were then rinsed in PBS and resuspended in 50% (v/v) ethanol and kept at -20°C for 
30 min prior to use.  A 100-μl volume of the fixed cells was then pelleted by 
centrifugation and the pellet washed in PBS and resuspended in 100 μl of 
hybridisation buffer (25 mM Tris-HCl, pH 9.0; 100 nM NaCl; 0.5% (w/v) SDS) 
containing 150-500 nM of fluorescently labelled PNA probe.  The cells were then 
incubated at 55°C for 30 min, centrifuged again, and resuspended in 500μl of wash 
solution (10 mM Tris pH 9.0, 1 mM EDTA).  After a further incubation of 10 min at 
55°C, the cells were recentrifuged, and this process was repeated twice for a total of 
three washes.  The cells were finally resuspended in 100 μl of wash solution and 2 μl 
of this was spread on to a clean microscope slide and air-dried.  Vectashield (Vector 
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laboratories Ltd, Peterborough, UK) mounting medium was applied and the 
preparation was overlaid by a coverslip, held in place with nail varnish. 
 
Preparation of bacteria for infection of in vitro (RHE) Reconstituted Human 
Epidermis.  
SkinEthic Laboratories (Nice, France) produced a 0.5 cm2 disc of reconstituted human 
epithelium (RHE) in vitro on a polycarbonate filter at the air-liquid interface in a 
chemically defined medium devoid of antibiotics for 17 days.  The RHE consisted of 
normal human keratinocytes (human foreskin derived) with a well differentiated 
epidermis consisting of basal, spinous and granular layers with a stratum corneum.  
At least four viable cell layers were present (fig 5.3). 
 
 
Figure 5.3.  Cell layers present in RHE as illustrated using Hoechst 33258 (2 μg/ml; 
Sigma) staining of the cell nuclei (cyan) 
 
Staphylococcus aureus (FRI 1151M) and P. aeruginosa (D40) were cultured on blood 
agar at 37°C overnight.  The resulting growth was used to inoculate 10 ml of brain 
heart infusion (BHI) medium and this was incubated at 37°C for 24 h.  Bacterial cells 
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were harvested by centrifugation and washed three times with PBS.  The pelleted 
bacterial cells were resuspended in RHE tissue maintenance medium (MCDB 153; 
SkinEthic Laboratories) containing 5 μg/ml of insulin and 1.5 mM CaCl2 with no 
antibiotics.  Two hundred μl of this bacterial suspension was added to the RHE 
surface.   Once infected, the RHE was incubated at 37°C for time periods of between 
24 and 72 h.   
 
Processing of infected RHE  
After incubation, the RHE was fixed in 10% (v/v) formalin for 24 h and stored in 10% 
formalin overnight.  The RHE was then embedded in paraffin wax using standard 
histological techniques.  Sections of varying thickness were then cut and placed on 
poly-L-lyseine coated microscope slides (Polysciences, Inc; Warrington, UK) and fixed 
overnight at 60°C.   
 
Following attachment of RHE to the poly-L-lyseine coated slides, the sections were 
de-waxed in xylene and then rehydrated by processing through graded alcohol to 
water.  It was to these rehydrated sections that the technique of PNA/FISH was 
applied.  To aid PNA probe hybridisation, sections were initially treated with 100 μl 
of lysozyme (10 mg/ml; Sigma) and these were incubated at 37°C for 30 min.  The 
sections were then briefly and carefully washed in pre-warmed wash solution (10 
mM Tris, pH 9.0, 1 mM EDTA) prior to probe hybridisation as previously described. 
For nuclear context, sections were counterstained with Hoechst 33258 dye (2 μg/ml; 
Sigma) for 20 min before washing in wash solution and mounting as previously 
described. 
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Processing of debrided wound samples  
Debrided wound tissue was collected from patients attending the wound healing 
clinics of the University Hospital of Wales between June and August 2009 and this 
was in line with the aforementioned ethical approval (Appendix 5) .  Full informed 
written consent was taken and information sheets provided.  A charcoal Amies swab 
was then taken from each wound surface (as detailed in Chapter 3) for 
microbiological analysis. Analgesia was with EMLA (Eutectic mixture of local 
anaesthetics).   (please see discussion section re antibacterial properties). Following 
30 minutes of EMLA application the leg was cleaned with sterile water and a sample 
of debrided tissue was obtained and fixed in 10% (v/v) formalin for 24 h. 
 
Hybridisation of PNA probes to bacteria in RHE biofilms and debrided wound tissue 
One hundred and fifty µl of pre warmed hybridisation buffer (25 mM Tris-HCl, pH 
9.0; 100 mM NaCl; 0.5% (w/v) SDS) containing 150-400 nM of fluorescently labelled 
PNA probe was added to each of the RHE/debrided tissue sections (20 µM).  The 
preparations were placed in a dark humidified chamber and incubated at 55°C for 90 
min.  The stringency of hybridisation conditions was adjusted by adding 30% (v/v) 
formamide to the hybridisation buffer for the S. aureus specific probe (Sta 16S03).  
After incubation each slide was washed with pre warmed solution and a magnetic 
stirrer for 30 min. 
 
Gram-staining of processed sections  
Sections of RHE and debrided wound tissue of varying thicknesses from 5 to 20 µm 
embedded in paraffin were first de-waxed with xylene, rinsed in 100% ethanol and 
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then in distilled water.  After the washing steps sections were stained with crystal 
violet (0.5% w/v) in 25% (v/v) ethanol for 3 min, rinsed briefly in distilled water and 
stained with Gram’s iodine for 3 min.  Sections were then decolourised in acetone 
for a few seconds and again briefly rinsed in water.  Sections were then stained with 
neutral red for 3 min, dehydrated in alcohol, rinsed briefly in saline and mounted 
with DPX mounting medium. 
 
Confocal Laser Scanning Microscopy (CLSM)  
PNA probe hybridised sections were viewed and analysed by CLSM using a Leica TCS 
SP2 AOBS spectral confocal microscope (Leica, Wetzlar, Germany).  The sections 
were scanned to full depth using appropriate settings for single, double or triple 
channel fluorescence recordings of FITC, CY5, CY3 or Hoechst 33258 dye.  All 
wavelengths were assigned a colour as outlined in Table 5.2. 
Flurochrome Laser 
excitation line  
(nm) 
Emissions 
Detected 
(nm) 
Colour 
assigned 
Hoescht 33258 405 410-485 Cyan 
FITC 488 498-540 Green 
CY3 543 550-610 Red 
CY5 633 635-700 Blue 
Table 5.2 CSLM scan parameters used for simultaneous excitation and detection of 
the fluorescent labels utilised in the PNA probe study 
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All multichannel recordings were scanned sequentially to eliminate any spectral 
overlap between probes (Table 5.2).  Selected images were presented either as 
single confocal optical sections or maximum intensity type reconstructions.  The 
emission detection spectrum was often narrowed further to demonstrate individual 
probe detection and reduce bleed through into adjoining probe spectrums. 
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Results 
 
Sensitivity and specificity of PNA probes for target planktonic bacteria 
Figures 5.4-5.7 show the results of single and multiplex PNA probe staining of 
planktonic S. aureus and P. aeruginosa.  In all cases the universal bacterial PNA probe 
was found to hybridise to all the bacteria tested (Fig. 5.4b, 5.5ba).  The respective 
species-specific probes were found to hybridise to their target species with no cross-
reactivity evident with non-target species (Fig 5.6).  
a)   b) 
Fig 5.4.  Staining of planktonic P. aeruginosa using the a) P.  aeruginosa probe and b) 
universal probe 
 a)  b) 
Fig 5.5.   Staining of planktonic S. aureus using the a) S. aureus probe and b) universal 
bacterial probe 
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 a)  b) 
c) 
Fig 5.6.  Multiplex staining of planktonic P. aeruginosa and S. aureus using the a) P. 
aeruginosa probe, b) S. aureus probe and c) universal bacterial probe 
 
Multiplex staining with all of the PNA probes was also shown to be feasible with 
differential detection of both P. aeruginosa and S. aureus occurring within the same 
specimen (Figures 5.6a-c).  Similar performance of PNA probe hybridisation was 
evident for both fixed and unfixed planktonic preparations.   
 
Detection of target bacterial species using PNA probe staining of biofilms prepared 
on RHE  
Bacteria in biofilms formed on RHE over 24 h, 48 h and 72 h were analysed by PNA 
probe hybridisation.  However, it was found that prolonged incubation of bacteria on 
the RHE (>24 h) caused the RHE and attached biofilms to separate from the 
supporting plastic insert making subsequent processing problematic.  Furthermore, 
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any specimens that were successfully embedded often appeared to be folded (Fig. 
5.7) and disintegrated into smaller sections making meaningful architectural 
information difficult to obtain.  As a consequence all RHE sections subsequently 
described and illustrated in these results were generated over a standard period of 
24 h.  
  
 
Fig, 5.7.  DIC (Differential interference contrast microscopy) imaging showing partial 
separation from plastic backing and folding of RHE 
 
In addition to the duration of biofilm formation, the thickness of RHE sections had to 
be optimised and several section thicknesses (5 µm, 10 µm and 20 µm) were 
examined.  It was evident that the 5 µm and 10 µm sections maintained better 
contact with the microscope slides during processing compared with the 20 µm 
sections.  The detachment of the 20 µm sections occurred even when longer fixation 
periods (48-72 h) at 60°C were used.  However, a major advantage of using 20 µm 
sections was that these sections were more readily visible, which made processing 
easier.  As a result 20 µm sections were selected for subsequent analysis by PNA 
probe staining and CLSM.  The most appropriate period for removal of paraffin by 
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xylene treatment was deemed to be 5 min, with subsequent 5 min washes in graded 
alcohols suitable for rehydration.   
 
Optimal results were obtained when probe solutions were pre-warmed to 60°C and 
in the case of multiplex staining when the probes were combined before addition to 
the specimen.  Incubation of the probes for 2 h gave optimal results, with 30 min 
monitoring and constant hydration of the specimen with the probe solutions was 
ensured.  To maximise probe hybridisation and retention of samples on slides, whilst 
maintaining sufficient washing to remove non-hybridised probes, various probe 
washing procedures were examined.  Of the methods used, pipetting of the wash 
solution (×3) directly on to the samples and incubation for 5 minutes was most 
appropriate.   
 
In the case of S. aureus, optimal PNA probe hybridisation required pre-treatment of 
tissue sections with lysozyme (immediately prior to PNA probe staining).  Excessive 
lysozyme treatment was implicated in detachment of the sections from the 
microscope slide as well as separation of the biofilms from the RHE, whereas 
inadequate lysozyme treatment resulted in limited penetration of probes into the 
Gram-positive S. aureus.  The most successful lysozyme treatment was therefore 1 h 
incubation using pre-warmed lysozyme at 60°C, in a moist dark container.   
 
Initially, Gram-staining of RHE biofilms was used to confirm the presence of bacterial 
biofilms after 24 h on the RHE.  It was found that all target bacteria produced 
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biofilms on the RHE after 24 h of incubation.  Gram-stained P. aeruginosa, S. aureus 
as well as a dual species biofilms on RHE are presented in fig. 5.8.  
 
a) b) 
c) 
Fig 5.8  Gram-stained images a) Pseudomonas aeruginosa, b) S. aureus as well as a c) 
dual species biofilm on RHE (x1000 original magnification) 
 
Figure 5.9a presents an uninfected control (24 h incubated) RHE tissue on its 
supporting plastic insert and imaged by DIC imaging.  No damage to this tissue was 
evident under these conditions.  Figure 5.9b shows the RHE with a mixed species 24 
hour biofilm by DIC imaging.  
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 a)  b) 
Fig 5.9 DIC imaging of a) uninfected control RHE and b) infected RHE 
The Hoescht stain was found to give nuclear context to the epithelial cells within the 
RHE layers and this provided greater detail and contrast to location of the biofilm 
(Fig 5.10).  
 
Fig 5.10 Hoescht staining of RHE showing nuclei of the epithelial cells 
It was interesting to note that on several occasions, the PNA probes successfully 
hybridised to bacteria that were in a loose or ‘immature’ biofilm, and yet failed to 
hybridise to those bacteria within the ‘mature’ biofilm lining the tissue (fig 5.11).  
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Fig 5.11.  P. aeruginosa biofilm on RHE stained with the P. aeruginosa probe and 
superimposed by a DIC image demonstrating position of biofilms 
 
Detection of P. aeruginosa in biofilms on RHE using PNA probe staining  
Utilising the optimised conditions described above, PNA probe hybridisation to P. 
aeruginosa in biofilms coupled with CLSM was able to detect the target bacteria (Fig. 
5.12).  Typically, an extensive biofilm was present with P. aeruginosa occurring in 
large numbers on the plastic insert support for the RHE.  There was no evidence of 
bacterial invasion or damage to the RHE.  On occasion, reduced fluorescence 
occurred for bacteria in the ‘deeper layers’ of the biofilm even though bacteria were 
present as previously demonstrated by gram-staining and DIC imaging.  It was also 
noted that both the universal bacterial and P. aeruginosa PNA probes detected P. 
aeruginosa with a very high rate of concordance (fig 5.13) as expected from 
planktonic studies.  Figure 5.13 demonstrates detection of P. aeruginosa biofilm on 
RHE using the P. aeruginosa probe, Universal bacterial probe, and Hoechst staining 
of the RHE epithelial cell nuclei.   
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Fig 5. 12.  PNA probe detection of P. aeruginosa biofilm with top left, P. aeruginosa 
probe, Universal bacterial probe (top right), and combined images (bottom left). 
Bottom right is blank. 
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Fig 5.13.  PNA probe detection of P. aeruginosa biofilm on RHE with P. aeruginosa 
probe top left, Universal bacterial probe top right, Hoescht dye bottom left,  and 
combined images bottom right. 
 
Detection of S. aureus in biofilms on RHE by PNA probe staining  
The species-specific PNA probe for S. aureus was able to detect S. aureus within 
biofilms when coupled with CLSM (Fig. 5.14 and 5.15).  Typically, an extensive biofilm 
was present on the RHE surface after 24 h.  Unlike P. aeruginosa, S. aureus was not 
detected on the plastic insert of the RHE in single species S. aureus biofilms.  The 
staining of the nuclei within the RHE enabled the demonstration of invasion of S. 
aureus from the biofilms into the tissue layers (fig. 5.15), a feature not seen with P. 
aeruginosa biofilms. 
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Fig 5.14  PNA probe detection of S. aureus biofilm on RHE. Hoescht staining top left, 
S. aureus PNA probe top right, DIC bottom left, and combined images bottom right.  
 
 
Fig 5.15 Invasion of RHE by S. aureus biofilm, stained with S. aureus PNA probe and 
Hoescht dye 
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Multiplex staining of mixed species biofilms on RHE 
RHE was inoculated with both P. aeruginosa and S. aureus in an attempt to 
reproduce a mixed species biofilm of the type encountered in chronic wounds.  
Importantly, multiplex staining of mixed species biofilms revealed the presence and 
location of each target bacterial species in fixed RHE specimens (fig 5.16, fig 5.17).  
Similar colonisation patterns and observed levels for each species were evident in 
these biofilm preparations.  The bacterial biofilms were homogenously distributed 
with no distinct microcolonies present.  Biofilm architecture consisted of deep and 
dense layers of bacteria with superficial and loosely aggregated cells.  Features 
distinctive of biofilm architecture such as water channels were evident (fig 5.18).  
Appendix I (CD) provides electronic representation of these structures as 3-
dimensional images, whilst z stack animations demonstrate the early biofilm 
architecture throughout the samples. 
  
Fig 5.16 Detection of S. aureus and P. aeruginosa in mixed species biofilms on RHE 
using Hoechst staining, top left  P. aeruginosa probe top right, universal bacterial 
probe bottom left, and S. aureus probe bottom right, Combined picture far right 
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shows mixed S. aureus and P. aeruginosa biofilm on RHE, with Hoescht staining and 
universal bacterial probe.  
 
a)  b) 
Fig 5.17 Mixed S. aureus and P. aeruginosa biofilm on RHE stained with Hoescht dye 
and, a) S. aureus probe and b) P. aeruginosa probe 
 
 
Fig 5.18 Mixed species biofilm stained with the universal probe and demonstrating 
water channels 
 
Interestingly when PNA probes were used in mixed S. aureus and P. aeruginosa 
biofilms, the P. aeruginosa specific probe appeared to hybridise not only to the 
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bacilli (P. aeruginosa) but also to cocci shaped cells (S. aureus).  Whilst the 
fluorescence of these cocci appeared weaker than that of the bacilli, it was 
noticeable over background (fig 5.19), but deemed not to be autofluorescence as it 
only occurred at the probe’s specific excitation wavelength.  Interestingly, this 
phenomenon was not present in S. aureus only biofilms treated with the P. 
aeruginosa probe or in mixed populations of planktonic bacteria.  
 
  
Fig 5.19 Mixed S. aureus and P. aeruginosa biofilm on RHE, with from clockwise, P. 
aeruginosa probe, universal bacterial probe, S. aureus probe and a recombination of 
the three. 
  
In these mixed species biofilms multiplex PNA probe staining demonstrated S. aureus 
adherent to the plastic underside of the RHE (fig. 5.17) and P. aeruginosa invading 
the tissue in concert with S. aureus (fig. 5.17). 
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Detection of S. aureus and P. aeruginosa in debrided wound tissue using PNA 
probe staining 
The PNA FISH protocol previously developed on planktonic bacterial preparations as 
well as infected RHE was used to detect the target bacterial species in debrided 
wound tissues.  Initial Gram staining of the debrided wound tissues did not show the 
presence of many bacteria and extensive biofilm presence was therefore not evident 
(fig 5.20). This was despite these wounds having previously been clinically 
categorised as infected, and the swabs yielding microbial growth upon culture 
(Chapter 3).  Single and multiplex PNA probe hybridisation to these samples did 
however reveal the presence of occasional isolated aggregations of bacteria (fig 5.19, 
5.20), although clear resolution of these aggregates was problematic.  
Autofluorescence of the tissue was encountered in a number of the tissue samples 
(fig 5.21), but this could be eliminated from specific probe hybridisation, as the 
former was present across a range of excitation wavelengths.   
 
  
Figure 5.20. Gram stained debrided wound tissue  
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5.21 FISH images showing overlay of S. aureus probe and universal bacterial probe 
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Fig 5.22 Autofluorescence of debrided wound tissue at differing wavelengths  
 
Of the five debrided wound tissue samples examined, single bacteria were evident in 
samples 1 and 3 using each of the PNA probes.  Meaningful colonies and mixed 
biofilms of P. aeruginosa and S. aureus were not detected using multiplex staining.  
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Discussion 
The occurrence of biofilms in chronic wounds is an important cause of patient 
morbidity and a significant financial burden to health care services worldwide.  The 
cost of managing chronic wounds is estimated at £2.3-3.1bn per annum in the UK 
alone and this constitutes 3-5% of the UK total health spend (Posnett and Franks, 
2008).  Chronic wounds increase in incidence with patient age and obesity, and as 
industrialised nations across the world have rapidly increasing aging populations and 
incidences of obesity and diabetes, this figure would be expected to increase 
dramatically in the near future (Yach et al., 2006) 
 
It is important to characterise not only the microbial composition of chronic wound 
biofilms, but also gain insight to their structure and the bacterial distribution within 
them.  By acquiring such information it may be possible to elucidate the processes 
involved in biofilm development in wounds and develop strategies to combat these.   
FISH using species-specific PNA probes can be utilised with CLSM for both the 
identification of target species and their location in the biofilm.  The approach 
enables deciphering of the biofilm architecture using microscopic resolutions that 
can demonstrate biofilm features such as water channels and areas of differing cell 
densities between deep and superficial biofilm regions.   
 
In the case of biofilm imaging, CLSM is preferred to standard light microscopy as it 
allows the three dimensional, non-invasive imaging of cells and the computational 
reconstruction of mature biofilms without distortion of structure (Thurneer et al., 
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2004).  This is important, as the functional properties of biofilms are intimately 
related to spatial architecture (Bridier et al., 2010).  An Increased awareness of the 
structure of biofilms serves to improve an understanding of biofilm function in terms 
of metabolism, tolerance to antibiotics and the immune system.  This in turn allows 
the complex behavioural and survival strategies of biofilms to be elucidated, which 
may lead new anti-biofilm treatment strategies to be developed based upon 
interfering with these mechanisms. 
 
The impact of biofilms on wound healing is far from fully understood.  However, 
there is a general agreement that biofilms within chronic wounds have serious 
detrimental effects on wound healing processes (Bjarnsholt et al., 2008,) and indeed 
there is a growing consensus that the chronicity of a wound may be related in a large 
part to its biofilm component  
 
Biofilms have been demonstrated within chronic wounds in several studies (Davis et 
al., 2008, Kirketerp-Moller et al., 2008) and a biofilm incidence of 60% in chronic 
wounds has been estimated using scanning electron microscopy (James et al., 2008). 
 
It is well recognised that the microflora of chronic wounds is polymicrobial (Fazli 
2009).  Pseudomonas aeruginosa and S. aureus are both frequently isolated from 
chronic wounds and are prolific biofilm formers.  To highlight this, in one study S. 
aureus and P. aeruginosa (Gjodsbol et al., 2006) were isolated from 93.5% and 52.2% 
of chronic venous leg ulcers respectively.  In 2008, Kirketerp-Moller et al., (2008) did 
however show that when compared with FISH analysis S. aureus was over-
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represented by culture from wound swabs, whilst P. aeruginosa was under-
represented.  These findings were possibly due to the relative positions of these 
species within biofilms.  Both of these bacterial species are widely known to cause 
biofilm based infections in their hosts (Fazli et al., 2009) and as a result were 
targeted in the current study. 
 
In this present chapter, FISH using PNA probes and CLSM were used to analyse the 
biofilm architecture and location of bacteria.  Biofilms were generated in vitro using 
an RHE model to simulate the formation of biofilms on a tissue surface.  This model 
had previously been used in the study of both Candida biofilms on reconstituted 
human oral epithelium (Silva et al., 2010) as well as chronic wound biofilms (Malic et 
al., 2009).  Subsequently, tissue debrided from the wounds of patients were 
analysed using developed methods. 
 
PNA probes have over recent years been increasingly incorporated into FISH 
applications (Malic et al., 2009).  PNA probes are DNA analogues with an uncharged 
polyamine backbone instead of conventional sugar phosphates and hybridise with 
complimentary DNA sequences through base pairing (Motor and Gobel 2000).  The 
uncharged backbone of the probes is claimed to allow superior hybridisation 
characteristics with higher specificity and more rapid hybridisation techniques.  It is 
also proposed that PNA probes can diffuse through hydrophilic cell walls allowing 
hybridisation to occur without stringent pre-treatment stages (Motor and Gobel, 
2000).  Hybridisation with PNA probes can be performed in a low salt buffer, 
therefore reduced stability of the rRNA secondary structure can be achieved, 
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allowing PNA probes to hybridise with otherwise inaccessible targets (Motor and 
Gobel, 2000).  It could therefore be argued that PNA probes have considerable 
advantages over oligonucleotide probes and were thus used in this study. 
 
The PNA-FISH methodology used had previously been described by Malic et. al. 
(2009) for imaging of fixed biofilms prepared on RHE, although in this present study, 
modification and optimisation of the protocol was required.  Probe specificity was 
verified by preliminary investigation using planktonic bacteria preparations.  This 
preliminary work demonstrated the specificity and sensitivity of the PNA probes 
when applied to S. aureus and P. aeruginosa in single and mixed species 
preparations (Figs 5.5 and 5.6). These investigations also provided a protocol for 
application to biofilms constructed in vitro on RHE surfaces as well as clinical 
specimens of debrided wound tissue. 
 
Analysis of biofilm structure and composition using PNA probes and CLSM 
As previously noted by Bridier et. al. (2010), the present study was able to obtain 
detailed structural information of the biofilms using confocal Z stacks.  The 
generation of Z-stacks by sequential imaging of sections through the biofilm allowed 
subsequent reconstruction into a three dimensional structure (Appendix CD). 
 
It was evident that P. aeruginosa biofilms generated over 24 h on RHE exhibited a 
mushroom shaped structure (Fig 5.8a), whilst biofilms produced by S. aureus had a 
more variable structure in accordance with other studies (Bridier et al., 2010, Pamp 
and Tolker-Nielsen, 2007, Davey et al., 2003, Harmsen et al., 2010).  It was also 
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possible to demonstrate the formation of hollow voids in the P. aeruginosa 
‘mushroom like’ biofilms and these were deemed to be water/waste channels (Fig. 
5.18) which are notable components of biofilms.  Water/waste channels and a 
structure of mushroom shaped microcolonies are a typical feature of P. aeruginosa 
biofilms.  The water/waste channels allow biofilm cells to obtain nutrients and 
remove toxic products of metabolism.  The presence of water channels have also 
been shown to facilitate cell-to-cell communication and biofilm organisation 
expression (Stoodley et al., 2002) 
 
The 24 h infected RHE specimens clearly exhibited a dense biofilm that was adherent 
to the RHE.  The denser regions were seemingly more resistant to penetration by the 
PNA probes compared with looser aggregates of biofilm-associated bacteria (Fig. 
5.13).  It is possible that this is secondary to a failure of the probes to penetrate the 
protective EPS of the biofilm (indicating the early and effective development of a 
protective EPS covering).  EPS is recognised as a barrier to the entry of various 
chemicals including antibiotics and may explain some of the negative results 
obtained in other samples with proven biofilm (seen by Gram-staining), but not 
visible using FISH. 
 
Comparison of Staphylococcus aureus and Pseudomonas aeruginosa biofilms  
Despite appearing homogenous on viewing prior to probe hybridisation, it was 
apparent that the single species biofilms had several distinctive characteristics.   As 
noted by Schaudin et. al., (2009) (who utilised both CLSM and SEM to study 
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endodontic biofilms), the present study was able to demonstrate individual rods and 
cocci in aggregates within the biofilm matrix (Fig. 5.19). 
Pseudomonas aeruginosa biofilms formed not only on the RHE, but also developed 
on the plastic tissue insert.  This was likely to be less a function of bacterial motility 
(as bacteria were inoculated into the broth surrounding both sides of the RHE) and 
more as a result of different adhesion characteristics.  Single species biofilms of S. 
aureus did not exhibit this trait with biofilm formation restricted to the RHE.  It 
would have been interesting to see if S. aureus would have formed biofilms over the 
plastic surface given more time, however, as previously stated, when incubated for 
greater than 24 h the RHE tended to detach from the insert making processing 
difficult.  This finding is clinically interesting as the adhesive abilities of biofilm 
forming bacteria is an essential component of their ability to cause infection and 
disease, and whilst slightly out of the scope of this thesis biofilms on implantable 
devices are an increasingly recognised clinical problem (Donlan, 2011). 
 
Both P. aeruginosa and S. aureus persisted in mixed species biofilms, with the former 
also appearing to promote attachment of S. aureus to the tissue insert.  This possibly 
indicated that the non-attachment previously encountered by S. aureus was likely to 
be related to poorer adhesion factors to this surface.  The similar attachment 
patterns of mixed species biofilms and P. aeruginosa may be indicative of increased 
virulence of a mixed species biofilm by allowing the S. aureus to form biofilms in 
areas it would not be able to attach to independently. 
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Staphylococcus aureus biofilms showed significant invasion of the RHE, which was 
depicted in figs 5.14 and 5.15.  This demonstration of virulence was not evident in 
any ‘Pseudomonas only’ biofilms, but was apparent with P. aeruginosa in a few 
mixed biofilms.  In the mixed biofilms, there is clear evidence of bacteria positive to 
the P. aeruginosa probe invading the tissue (Fig. 5.16), and it is tempting to speculate 
that these P. aeruginosa bacteria are exploiting the tissue invading S. aureus capacity 
to facilitate colonisation of a new environment.  This is clinically significant as it 
provides in vitro evidence of increased tissue invasion by P. aeruginosa in the 
presence of S. aureus.  Extrapolated to a wound, this could result in increased 
pathogenicity and subsequent difficulties in therapeutic management when both 
species are involved in infection.  Mixed species biofilms as opposed to single species 
biofilms are therefore likely to be more detrimental to the host in chronic wounds 
and in other medically significant biofilms.  Evidence of synergistic virulence factors 
although assumed, has not previously been described.  
 
Mixed species biofilms have been described as being more resistant to eradication 
with disinfectants than single species biofilms of the same bacteria (van der Veen 
and Abee, 2011, Harriott and Noverr, 2010) and some researchers have shown an 
inhibitory effect between species within biofilms (Bandara et al., 2010).  It is evident 
that species within biofilms interact in ways that are only now beginning to be 
understood, sometimes synergistically and sometimes competitively. It has been 
increasingly suggested that in human disease, the biofilm in its entirety rather than 
species should be considered the unit of pathogenicity (Siqueira and Rocas, 2009)  
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Limitations of PNA probe and Confocal Laser Scanning Microscopy methodology 
Due to the constraints of wavelength and quenching of fluorescence between 
adjacent excitation wavelengths for fluorescent labels, only a limited number of 
different probes can be used in any multiplex analysis of a single specimen.  The 
approach has several limitations, not least the fact that several of the stages involved 
in the fixation and embedding of the tissue are cidal to biofilm cells, thereby 
preventing subsequent assessments of viability and associated parameters.  
Furthermore, it could be argued that dehydration, and subsequent rehydration may 
adversely affect biofilm tissue and architecture.  This was not however evident in this 
study.   
 
One practical limitation of using PNA probes relates to the cost of the probes 
themselves, which are currently prohibitively expensive for routine diagnostic use.  
However, the optimised FISH approach described in this chapter generates efficient 
and accurate imaging of biofilm structures allowing the spatial location of targeted 
species to be determined.  Whilst the technique provides good imaging of biofilm 
structure, it does not give specific quantitative information (beyond assessments of 
volume) or dynamic information.  Further, given the multiple steps and corrosive 
chemicals involved it would not currently be a candidate for conversion to a direct 
wound diagnostic system due to patient safety concerns.  The method could 
however be utilised for rapid ‘off patient’ detection of bacteria in chronic wounds, 
and the rapid turnaround provided by such a test would allow for patient tailored 
treatment to be initiated far earlier than would be possible with conventional 
methods. 
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As reported by Malic et al., (2010), the current study was able to demonstrate 
specificity of the PNA probes against planktonic bacteria with detection of all 
bacteria evident when overlaid with DIC images.  Unlike Malic et al. (2009) the P. 
aeruginosa probe appeared to cross react in mixed species biofilm conditions with 
the cocci of S. aureus.  This may partly be due to imaging of ‘end on rods’ appearing 
as cocci in various sections.  In addition, the production of an adherent EPS by P. 
aeruginosa may have contributed to capture of the probe by EPS coated S. aureus 
cells.  Further study is needed to confirm this, although the absence of cross reaction 
in preparations devoid of P. aeruginosa might be suggestive that cross reaction was 
not through probe hybridisation to DNA.   
 
The study demonstrated the development of a multilayered community of bacteria 
on the RHE samples.  In addition, and in contrast to the study of Malic et al., (2009) 
invasion of this tissue by S. aureus was detected even without previous wounding of 
the tissue.  In agreement with Malic et al. (2009) the S. aureus probe appeared to 
have reduced fluorescence when compared with both the P. aeruginosa and the 
universal probe.  As with Hartmann et al., (2005) who utilised PNA FISH to detect S. 
aureus in blood the need for pre-treatment of staphylococci with enzymes 
(lysozyme) to allow entry of PNA probes was demonstrated.  The reasons for this 
apparent lower fluorescence of the S. aureus PNA probe could relate to a 
comparatively reduced probe uptake or the relative number of probe targets within 
the targeted cells.  In this study (as with Malic et al., 2009), the inclusion of 30% 
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formamide to the hybridisation buffer was necessary, along with lysozyme treatment 
to facilitate hybridisation of the S. aureus probe.   
 
Despite limitations, as with other studies using PNA probes and FISH studying the 
analysis of biofilms, the images of biofilms obtained through this method were of 
value (Malic et al., 2009, Kirketerp-Moller, 2008, Fazli, 2009, Bjarnsholt, 2008).  The 
ability to image biofilm structure with minimal disruption of the architecture is 
invaluable, and the use of fluorescent probes to accurately identify and locate 
individual species within that biofilm is particularly useful.   
 
Use of the RHE model 
Use of RHE as an in vitro model of wound infection is the most appropriate system 
commercially available.  However there are limitations of the RHE model in that it is 
largely devoid of a host immune response and the pro-inflammatory cytokines of 
chronic wounded tissue, which as previously mentioned may be vital to biofilm 
formation and regulation.  In the present study the RHE was not artificially wounded, 
but was intact, as it was felt wounding in this fashion would resemble an acute 
wound than a chronic wound.   
 
In vivo, multiple microbial species form a biofilm and for reasons of simplicity the 
microbial biofilm composition in this study was restricted to just S. aureus and P. 
aeruginosa.  As a caveat it should be recognised that the inclusion of other bacterial 
species could have affected biofilm structure and growth rate (Kroukamp et al., 
2010).  In this study the RHE samples were only incubated for 24 h and longer 
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incubation periods would potentially allow more extensive and mature biofilms to 
develop.  A longer incubation period would have enabled the studying of a more 
mature biofilm in a simulated chronic wound model, however this was not possible 
to process due to lifting of the RHE and biofilm layer from the plastic insert. 
 
Debrided wound tissue 
The CLSM/PNA method was able to demonstrate individual bacteria within debrided 
wound tissue and this is the first instance of successful application of the method to 
such specimens.   However, the demonstration of biofilms on the debrided wound 
tissue using gram-staining and CLSM/PNA was not evident. 
 
The results demonstrated both P. aeruginosa and S. aureus bacteria in debrided 
wound samples one and three.  This correlated with the classical microbiology from 
swabs of these wounds taken at the time of sampling.  It is however worth noting 
that sample two was also positive for both species on classical microbiological 
analysis. Recent work by Kirketerp-Moller et al., (2008) has demonstrated a poor 
concordance between FISH PNA and conventional microbiological culture with the 
latter approach possibly dependent on relative bacterial positions in biofilms.  In this 
study the absence of positive PNA detection in sample two may well be secondary to 
the nature of the debrided specimen obtained and processing.  
 
The question remains as to whether there are biofilms in chronic wounds and if so, 
why could they not be detected on the debrided wound tissue.  The current 
evidence suggests that biofilms abound on almost any surface and are prevalent in 
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chronic wounds (Davis et al 2008, Kirketerp-Moller et al., 2008, James et al., 2008).  
Indeed biofilms have been visualised through use of FISH on ‘punch biopsy’ 
specimens (Malic et al., 2009).  The debrided wound tissue obtained from infected 
chronic wounds was by its nature severely disrupted. In many cases surgical 
debridement is the treatment of choice in biofilm colonised wounds.  Therefore it is 
not overly surprising that any biofilm that may have been present was severely 
disrupted, and in all likelihood detached from the specimens through both the 
actions of physical debridement and then through processing in formalin, leaving 
only remnants of single bacteria behind as demonstrated by the highly specific 
CLSM/PNA system. 
 
One additional consideration to be made with regards to the study is the potential 
antibacterial eactivity ofEMLA (Eutectic mixture of local anaesthetics) contains two 
anaesthetic drugs: lidocaine 2.5% and prilocaine 2.5%. EMLA is known to have an 
antibacterial effect (Kerenyi et al., 2004), with its effect being described as powerful 
and rapid with test isolates of typical wound pathogenic bacteria (including S. aureus 
and P. aeruginosa) being significantly reduced within 1 hour and killed within 1–3 
hours particularly killing Staphylococcus species within 1 hour  (Berg et al., 2006).   
Despite this it would have been unethical to debride patients without appropriate 
analgesia, the alternative option of a field block with local anaesthetic injections was 
considered and discounted.  This was due to the fact that the alternative local 
anaesthetic agents are similarly antibacterial (Thompson et al., 1993)  when applied 
topically, and the multiple injections necessary for a field block were considered 
inappropriate due to the painful nature increased by using additive free lidocaine.  In 
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an attempt to minimise these antibacterial effects EMLA was applied for 30 minutes 
and each patient’s wounds were swabbed prior to application of local anaesthetic 
and debridement.  Swabs were placed in an ice filled labelled secure container and 
transported to the laboratory for microbiological analysis.  Sample analysis showed 
expected wound flora (see chapter 3 results) , however it must be considered that as 
well as debridement disrupting the biofilms the EMLA may have had some 
bactericidal effect in the 30 minutes of application post swabbing.  However the PNA 
probes should still have been able to detect these bacteria (as molecular metods do 
not detect only viable organisms) and the antibacterial effects of EMLA should not 
materially affect the results of the PNA FISH for debrided wound tissue.  
 
 
Summary 
It was encouraging that detection of P. aeruginosa and S. aureus in single and mixed 
species biofilms was achieved with PNA probe hybridisation. This allowed 
characteristics of each biofilm to be observed and described.  It was pleasing to be 
able to image biofilms within the first 24 h revealing definite structure with a densely 
adherent thick biofilm on the surface with likely EPS protection and more loosely 
aggregated bacteria superiorly to this.  In contrast to the research of Malic et al., 
(2009) this present study revealed extensive RHE biofilms after 24 h of incubation 
and that the S. aureus containing biofilms could invade epithelial layers in the 
absence of artificial wounding.  As Malic et al., (2010) reported biofilms with discrete 
clusters of individual bacterial species in microcolonies were evident in this present 
study, although more commonly the two species were present within microcolonies.  
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This latter feature was not as evident in the study of Malic et al., (2010) and may be 
due to the shorter incubation period for the mixed biofilms in the present research, 
which could lead to an inadequate time period for biofilms to mature and 
differentiate into separate species microcolonies. 
 
It was also interesting to visualise the individual rods in an early immature P. 
aeruginosa biofilms and cocci in a S. aureus biofilm, and the development of water 
channels in a mixed biofilm. 3D reconstructions demonstrate that the structure of 
these early biofilms is beginning to be organised with clusters of cells in 
microcolonies within the biofilm EPS. 
 
The combination of PNA labelled FISH probes and CLSM has enabled us to 
demonstrate the specificity of the probes in planktonic bacteria and biofilms.  In 
comparison to other techniques utilised in this thesis it demonstrated biofilm 
structure more clearly and reliably then the use of fluorescence microscopy, and 
identified species more quickly and accurately than the use of monoclonal antibodies 
and ELISA.  Uniquely it demonstrated both the structure of biofilms and location of 
individual species within them.  It was also valuable in showing the differing 
behaviour of different types of single species biofilm and of mixed biofilms. 
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Chapter 6: General Discussion 
 
 
Previous discussions have followed all experimental chapters focussing on the points 
raised within that section, the aim of this chapter is to bring together the salient 
points relevant to the topic and suggest further and new avenues of research. The 
complete characterisation of bacterial communities within chronic wounds is an 
ambitious and ongoing project.  In this thesis significant advancements to achieving 
this goal have been reached. 
 
Collection of varied wound samples and their microbiological typing to aid in the 
characterisation process is essential in any attempt to further knowledge.  Chronic 
wound fluid was collected in larger quantities than any other study allowing 
repetition and the use accurate controls in later identification experiments.  The 
microbiological and PCR results for this fluid (and indeed the other chronic wound 
samples) were consistent with the literature, with both P. aeruginosa and S. aureus 
very prevalant, confirming the validity of the decision to focus on these species.  The 
acute wound fluid collected was subjected to classical microbiological analysis on 
day one and two post-operatively for what appears to be the first time in the 
literature, and demonstrates the relatively sterile nature of this fluid. 
 
Utilising fluorescent microscopy and specifically developed monoclonal antibodies 
(MABs) to P. aeruginosa and S. aureus demonstrated that it was possible to identify 
planktonic bacteria using this method.  Utilising the MABs in a competitive ELISA was 
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successful in a number of ways.  It was demonstrated that MABs can accurately and 
repeatedly detect both the antigen and the relevant bacteria in planktonic bacterial 
and biofilm supernatants and more impressively within a chronic wound fluid 
environment, through the use of a competitive ELISA.  It was also possible to 
demonstrate for the first time the number of CFU/ml necessary to produce enough 
TNase to be detected by the MAB using a competitive ELISA. 
  
Biofilms of single and multiple species were successfully grown and demonstrated on 
RHE.  The use of FISH/PNA probes and the CLSM was successful at characterising 
bacterial species, identifying specific species in planktonic and biofilm states.  It was 
particularly useful in demonstrating the spatial arrangements within biofilms, with 
its non-invasive three dimensional imaging.  It allowed identification of individual 
bacteria within single species biofilms and with the use of multiplex staining, of 
multiple species biofilms demonstrating the position of the individual bacteria of 
each species within the biofilm.  It was particularly interesting to note the differing 
virulence factors of P. aeruginosa and S. aureus single species biofilms.   P. 
aeruginosa biofilms were far more adhesive, particularly to the plastic backing of 
RHE when compared with S. aureus only biofilms, and S. aureus biofilms actively 
invading the tissue, in a trait not seen in P. aeruginosa only biofilms.  It was also 
demonstrated that combined species biofilms enabled increased adhesion of S. 
aureus and invasion of P. aeruginosa indicating a synergy not previously described in 
multiple species biofilms, these data suggest that these biofilms may increase their 
virulence factors in vivo. 
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This research has demonstrated the importance of collection of chronic wound fluid 
samples and their microbiological typing for characterisation of bacteria within 
chronic wounds. 
   
The MAB work reiterated the potential of MABs for the rapid and accurate 
identification of bacteria within chronic wounds as previously demonstrated by (Gu 
et al., 2005). The study has shown the possibility of detecting antigens and bacteria 
within a chronic wound environment for the first time, demonstrating both the 
sensitivity and specificity required for a clinical test.  The experiment to determine 
the number of CFUs/ml required for detection of S. aureus has not previously been 
performed, and has demonstrated a useful method of calibrating the sensitivity of 
MABs. 
 
The use of FISH/PNA probes and CLSM built on the already promising work of Malic 
et al., (2009) confirming the utility of the method in detecting individual bacteria 
within in the biofilm state, in both single and multiple species biofilms  and, also in 
delineating biofilm architecture.  It also demonstrated for the first time a synergy of 
virulence factors of S. aureus biofilms in terms of invasion and adhesion. 
 
The relevance of this work to the clinical problem of people suffering from chronic 
wounds is the advancement of the base of knowledge in methods for identification 
of bacteria and the characterisation of them within chronic wounds. MABs have 
proved accurate at rapid detection of bacteria within the complex chronic wound 
environment, as a result, future rapid bacterial detection and identification systems 
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could be developed leading to more rapid treatment and monitoring of treatment 
effectiveness in these patients. 
  
The FISH/PNA CLSM work demonstrated the effectiveness of this approach as a tool 
for examining biofilm architecture and positions of individual bacteria within 
biofilms. This has already yielded interesting information of a possible synergistic 
relationship between two pathogens.  A wide range of clinically important biofilms 
can be studied and modelled using this method, with the possibility of developing 
and testing therapeutic interventions as a result. 
 
Given the opportunity to repeat this research with the benefit of hindsight, there are 
certain methodological changes that could be considered.  Although pleased with 
the large quantities of wound fluid collected and the advantages previously 
mentioned, concentrated wound fluid would (despite the problems of collection and 
repeatability of experiments) have been very useful to fully test the MABs and would 
have avoided the need for, and attendant difficulties of concentrating the chronic 
wound fluid.  It would have been useful to be in possession of full epitope mapping 
for the monoclonal antibodies used.  Complete information regarding binding sites 
and detection concentrations would have been very helpful.  It may have been 
possible to choose a different and more specific target for both of the antibodies.  
The attachment of non-quenching fluorescent markers would have made the 
interpretation of the MAB fluorescent microscopy work far easier. 
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Whilst the FISH/PNA CLSM work demonstrated biofilms grown in vitro on RHE it was 
unsuccessful in demonstrating this in debrided wound tissue. This is likely to be 
secondary to the disordered nature of the specimens post debridement and punch 
biopsy from chronic wounds infected with biofilm samples as utilised by Malic et al 
(2009), may have hopefully demonstrated the efficacy of this method on wound 
biofilms. 
 
As previously mentioned the majority of bacteria found in chronic wounds are 
“unculturable” for these bacteria the molecular methods described in this thesis of 
MABS and ELISA work and PMA FISH CLSM work may prove particularly useful in 
detection and elucidating the roles of these bacteria within chronic wounds. 
 
To expand on the work in this thesis there are several recommended research 
avenues.  It would be possible to expand with the judicious production of MABs to 
any other bacteria found within wounds, MAB ELISA has the benefit of being a 
molecular method and is therefore not reliant on the viability of bacteria.  Ideally 
these MABs would be produced to a prominent unique structure on the cell wall of 
the organism in question allowing ease of detection.  The development of MABs to a 
unique protein produced by the bacteria in question is also an option to be 
considered and worked well in these experiments but is limited by the knowledge of 
the circumstances and quantities in which the protein is expressed. The competitive 
ELISA model developed in this thesis could then be applied to rapidly detect the 
presence of many different bacteria within wound fluid.  The potential of this ELISA 
to be developed into a wound diagnostic is exciting.  Work on optimising the 
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Competitive ELISA to function effectively on wound imprints is an important avenue 
of research for achieving a rapid clinic based diagnostic ELISA.  The rapid nature of 
this test and the non-invasive nature of the sampling method required would make 
this a very exciting diagnostic.  
 
If non-quenching fluorescent markers could be added to the MABS and the problems 
of autofluorescence overcome it may be possible to expand on the CDFF and RHE 
generated biofilm work and produce detailed images of the structure and 
architecture within biofilms of a comparable nature to FISH. 
 
The obvious first area to expand on the PNA CLSM FISH work described in this thesis 
is to obtain specimens of biofilms in wounds that are not disrupted as debrided 
wound tissue was.  This may be possible through punch biopsy or even through 
obtaining complete chronic wounds with biofilms from amputated limbs, and 
applying the processes described in chapter 5 to demonstrate the structure of 
biofilms within these chronic wounds, rather than attempting to construct a model.   
 
It is also evident that the RHE biofilm model work could be easily expanded to 
include different species found in chronic wounds, which could be then analysed 
using PNA CLSM FISH. maximising our knowledgee of the structure of single and 
multispecies biofilms.  Different combinations of species could be assessed to 
determine whether tissue invasion/destruction or other virulence factors are 
maximised with particular combinations of bacteria, as demonstrated with the P. 
aeruginosa and S. aureus combinations, or whether with certain species there is 
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direct competition rather than synergy.  It would also be worthwhile to grow 
biofilms for different time periods prior to observation.  This approach could allow 
the observation of particular bacteria or combinations of bacteria demonstrating 
differing degrees of tissue destruction/invasion.  It would also allow the observation 
of the effect time had on the relative numbers of bacteria of different species 
present over time to be elucidated.   It would be interesting to see if the trend is 
towards uniformity or heterogeneity.  
 
It would also be useful to observe the changes to the biofilm in response to external 
“shocks” such as antibiotic treatment, addition of Ionic silver, iodine, 
polyhexamethylenen biguanides, or potassium permanganate, and possible recovery 
from these shocks. It is reasonable to hypothesise that biofilms of differing species 
are more susceptible to different treatments, or treatment combinations allowing 
the possibility of developing more tailored treatments to biofilms of known species. 
 
Moving away from direct follow up work from this thesis  there are several future 
avenues of research suggested by this work.  A rapid detection system could be 
developed for bacteria within chronic wounds involving the use of discarded 
dressings and ELISAs with MABs to rapidly detect the bacteria present whilst the 
patient is in clinic.  This could allow rapid, effective targeted treatments, and indeed 
test response to treatment 
 
It would also be clinically relevant and highly useful to the health service if a MAB 
could be developed to the altered penicillin binding regions of methicillin resistant S. 
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aureus, a rapid diagnostic test utilising MABs would not only detect the bacteria but 
also its antibiotic resistance, leading to faster treatment and isolation of 
contaminated patients.   Currently every patient admitted to a UK hospital is 
swabbed for MRSA and isolated if this is found, but the process can take over 24hrs 
at which point other patients could have been colonised or infected.  This principle 
of targeting the cause of antibiotic resistance rather than the bacterial species could 
be extended to other methods of antibiotic resistance again allowing early targeted 
treatment. 
 
Future investigations of biofilms could involve the combination of CLSM and non-
quenching fluorescent markers which may allow the observation of a biofilm in real 
time without dehydrating; such an approach would greatly enhance our knowledge 
of the behaviour of biofilms. 
 
This thesis has implications for clinical practice in the management of chronic 
wounds.  In the short term the need for accurate appropriate and as rapid as 
possible antibiotic prescription, and together with monitoring in the event of 
infection within chronic wounds should be emphasised.  As a result of the likely 
synergies in the virulence factors of S. aureus and P. aeruginosa multispecies biofilms 
may benefit from more aggressive treatments and surgical debridement should be 
considered in this eventuality. 
 
In the short term it should be possible to produce commercially available reliable 
reproducible and rapid bedside tests to identify bacteria utilising this technology, 
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In the medium term advances in the characterisation of living biofilms utilising 
MABs/FISH technology should be possible, leading to increased knowledge of the 
biofilm phenotype, the development of novel strategies to treat these biofilms, and 
a means of monitoring treatment efficacy.  
 
In the long term it is to be hoped that these therapies, developed secondary to 
better knowledge of bacterial interaction within biofilms and life cycles and 
pathogenicity of bacteria present, will provide an effective method of treating 
biofilms within chronic wounds and the whole spectrum of biofilm infection and 
disease.  This may be achieved through eradication of certain species, an entire 
biofilm or the application of a known beneficial biofilm on wounding 
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Consent acute wound fluid collection 
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1 PURPOSE 
The purpose of this Standard Operating Procedure (SOP) is to ensure that staff 
involved in research covered by the Human Tissue Act 2004 understand the 
procedure and mechanisms for the disposal of human tissue. 
 
The purpose of the Human Tissue Act 2004 is to provide a consistent legislative 
framework for issues relating to whole body donation and the taking, storage and 
use of human organs and tissue. It makes consent the fundamental principle 
underpinning the lawful storage and use of human bodies, body parts, organs and 
tissue and the removal of material from the bodies of deceased persons. It 
introduces regulation of other activities like post mortem examinations, and the 
storage of human material for education, training and research. It is intended to 
achieve a balance between the rights and expectations of individuals and families, 
and broader considerations, such as the importance of research, education, training, 
pathology and public health surveillance to the population as a whole. 
 
2 SCOPE 
This SOP applies to all Cardiff University staff responsible for the disposal of human 
tissue for research or teaching purposes.   
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3 RESPONSIBLE PERSONNEL 
The Principal Investigator/Research Supervisor is ultimately responsible for ensuring 
that this SOP is correctly applied in the conduct of research and each researcher also 
has individual responsibility for applying this SOP when required to do so. 
 
The individual member of staff will be responsible for ensuring that this SOP is 
correctly applied when disposing of human tissue. 
 
The Corporate Compliance Unit (in conjunction with the Research and Commercial 
Development Division) are responsible for ensuring that the SOP remains fit for 
purpose. 
 
4 DEFINITIONS 
Anatomical examination – macroscopic examination of the body of a deceased 
person, or separated parts of such a body, by dissection for anatomical purposes 
(teaching or studying, or researching into the gross structure of the human body). 
 
Human Tissue – Any and all constituent parts of the human body formed by cells. 
 
Principal Investigator (PI) – is the appropriately qualified individual at each project 
site who has responsibility for the conduct of the project at that site. 
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5 PROCEDURE 
 
5.1 General Principles 
Human tissue must be disposed of with respect.  As an absolute minimum tissue 
identified for disposal should be disposed of separately from other clinical waste.   
 
Human tissue samples must be tracked and recorded at all times. 
 
Appropriate methods of destruction, storage and arrangements with people 
involved must be planned and arranged in advance, and considered when preparing 
risk assessments. 
  
No human tissue may be transported from one establishment to another unless both 
establishments have full ethical approval from a recognised ethical approval service 
(REC) or are subject to an appropriate Human Tissue Authority (HTA) Licence. 
  
Any recipient of transported tissue must be the subject of and compliant with an 
appropriate ethical approval or HTA licence. 
 
5.2 Organs/tissue removed from the living 
The Human Tissue Act 2004 makes it lawful to treat as ‘waste’ any relevant material 
which has come from a relevant person who was 
- in the course of receiving medical treatment 
- undergoing diagnostic testing or 
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- participating in research 
 
Material no longer used, or stored for use, for any scheduled purpose can be dealt 
with as human tissue waste1. 
Material taken from the living should normally be disposed of by incineration in 
accordance with current guidelines2. Fetal tissue must be dealt with as per HTA 
advice3. 
 
5.3 Patients wishes 
Some patients/donors may wish to retain tissue samples or make their own 
arrangements for disposal.  Such requests should be considered on a case-by-case 
basis assessing the risk to the patient and others.  Patients should be given sufficient 
information to allow them to make an informed decision.  
 
5.4 Organs/tissues removed after death 
Tissue and organs should be handled in accordance with any reasonable wishes 
expressed by relatives or the deceased person, as long as the method of disposal is 
legal.  The time, place and method of disposal must be recorded. 
 
5.5 Surplus material from tissue samples 
Such material should be disposed of as human tissue waste.  This includes: 
                                                 
1 Cardiff University Guidance on the disposal of Hazardous Waste 
http://www.cf.ac.uk/osheu/environment/waste/envwaste.html  
2 Safe disposal of clinical waste, second edition, HSE books, 1999. 
3 Code of Practice – the removal, storage and disposal of human organs and tissue, Human 
Tissue Authority, 2006. 
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- tissue fragments trimmed from the tissue sample before it is processed 
- tissue in the sections trimmed from a wax embedded block before the usable 
sections are cut and 
- unrecoverable material that is washed out of tissue during its processing into 
a waxed block.   
 
5.6 Existing holdings of unidentifiable, and identifiable but unclaimed, tissue  
Detailed guidance on the disposal of such collections is available in Appendix A of 
HTA Code 54 
 
5.7 Protective equipment 
Personal protective equipment (lab-coat, gloves) should be worn at all times when 
disposing of human tissue. 
 
5.8 Incineration (witness burns) 
Witness burns are carried out by the approved OSHEU vendor. 
 
Material for disposal is identified on the database and marked appropriately.  
University staff place the material for disposal is sealable containers, which are then 
labelled correctly. 
                                                 
4 Code of Practice – the removal, storage and disposal of human organs and tissue, Human 
Tissue Authority, 2006. 
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The material is then collected by the company carrying out the witness burn, 
supervised by the appropriate member of University staff (generally the Person 
Designated). 
 
5.9 Cremation/Burial 
Cremations and burials are carried out by the approved OSHEU vendor and the 
deceased is moved in a careful and respectful manner in conjunction with local 
procedures and as per any specifically stated wishes of the relatives of the deceased.   
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Appendix 6 
 
Tables of microbiological cultural analysis of chronic wound samples 
 
Sample Blood plate 
bacteria/ml 
MSA plate bacteria/ml Pseudomonas  
plate/ml 
CHR1 2x105 9.7x105 Unknown 
CHR2 2.2x107 1.0x106 6.3x106 
CHR3 5.6x104 1.6x104 6.5x104 
CHR4 1.7x108 2.4x107 3.4x109 
CHR5 3.0x107 3.3x104 4.5x106 
CHR6 
8.0x106 
No growth 
White colonies from blood 
reincubated on MSA 
4.2x106 
CHR7 7.1x104 3.6x103 1.02x103 
CHR8 4x105 1.68x104 4.8x105 
CHR9 1.6X106 7.2X104 1.6X106 
CH10 1.11x107 2.3x106 7.8x106 
Table of bacterial counts for chronic wound samples 
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Sample Blood  plate 
appearance 
MSA plate appearance Pseudomonas 
plate 
appearance 
CHR1 White colonies, yellow 
with haemolysis, P. 
aeruginosa  like 
Yellow, agar turned 
yellow 
White 
colonies 
CHR2 White colonies, yellow 
with haemolysis, P. 
aeruginosa  like 
White and off white- 
turns agar yellow 
White 
colonies 
CHR3 
Grey/white 
Yellow and White 
colonies 
White 
colonies agar 
green 
CHR4 
Grey white with alpha 
haemolysis 
White/yellow colonies- 
agar turned yellow 
Whitecolonise 
-agar 
unchanged 
CHR5 White pseudlike 
colonies 
White colonies- agar 
turned yellow 
white/yellow 
colonies 
CHR6 Heavy growth of 
Pseuds, some small 
white colonies 
no growth reincubated 
on msa – white colonies 
from blood agar 
flourescent 
yellow/green 
colonies 
CHR7 
Proteus, small white 
and yellow colonies. 
White and yellow 
colonies-agar-yellow 
White 
colonies- agar 
fluorescent 
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CHR8 
White and clear 
colonies 
White colonies- agar 
yellow 
Flourescent  
green 
colonies 
CHR9 
 White and clear Clear and yellow 
Flourescent 
green 
CH10 
White and clear Yellow 
Flourescent 
green 
 
Table of appeareances of CFUs of chronic wound fluid samples 
 
 
 
 
 
 
Sample Plate Tests 
Gram Stain Catalase Oxidase Coagulase Conclusion 
CHR1 MSA White 
(W)=+dipploc
occi 
Yellow(Y)=+c
occi 
W positive 
Y positive 
W negative 
Y negative 
W 
positive 
Y negative 
W= 
coryneforms 
Y=S. aureus 
 Pseud -rods Positive Positive Negative P. 
302 
 
omon
as 
aureginosa 
CHR2 MSA White(W)=+c
occi 
Off White 
(OW)=+cocci 
W positive 
OW 
positive 
W negative 
OW negative 
W 
negative 
OW 
negative 
W=CNS 
OW=CNS 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR3 MSA White(W)=+c
occi 
Yellow(Y)=+c
occi 
W positive 
Y positive 
W negative 
Y negative 
W 
negative 
Y positive 
W=CNS 
Y=S. aureus 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR4 MSA White(W)=+c
occi 
Yellow(Y)=+c
occi 
W positive 
Y positive 
W negative 
Y negative 
W 
negative 
Y negative 
W=CNS 
Y=S. aureus 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
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CHR5 MSA +cocci Positive Negative Postive S. aureus 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR6 MSA +cocci Positive Negative Positive CNS 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR7 MSA White(W)=+c
occi 
Pale(P)=+coc
ci 
W positive 
P negative 
W negative 
P negative 
W 
negative 
P negative 
2 strains of 
CNS 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR8 MSA +cocci Positive Negative Negative CNS 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR9 MSA Clear 
(C)=+rods 
Yellow(Y)=+c
occi 
C positive 
Y positive 
C negative 
Y negative 
C negative 
Y positive 
C= 
coryneforms 
Y=S. aureus 
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 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
CHR10 MSA +cocci Positive Negative Negative CNS 
 Pseud
omon
as 
-rods Positive Positive Negative P. 
aureginosa 
Table of chronic wound fluid sample derived colonies demonstrating classical 
microbiological tests and conclusions of likely bacteria present. 
 
 
305 
 
Appendix 7 
 
Table of Microbial isolate storage samples 
Storage no. Chronic 1 Yellow SA 
2 Chronic 1 White Coryneform 
3 Chronic 1 Pseud Pseud 
4 Chronic 2 White CNS 
5 Chronic 2 Off White CNS 
6 Chronic 3 Yellow SA 
7 Chronic 5 Pseud Pseud 
8 Chronic 6 clear CNS 
9 Chronic 6 Pseud Pseud 
10 Chronic 7 Pseud Pseud 
11 Chronic 7 Yellow CNS 
12 Chronic 8 Pseud Pseud 
13 Chronic 8 clear CNS 
14 Chronic 9 Yellow SA 
15 Chronic 9 clear Coryneform 
16 Chronic 9 Pseud Pseud 
17 Acute 1 clear CNS 
18 Acute 1 Pale CNS 
19 Acute 2 White SA 
20 Acute 2 Yellow SA 
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21 Acute 3 White CNS 
22 Acute 3 Pale CNS 
23 Acute 5 White SA 
24 Acute 5 Yellow CNS 
25 Acute 6 Pale CNS 
26 Acute 7 White CNS 
27 Acute 7 White CNS 
28 WD4 white pseud 
29 WD4 yellow CNS 
30 WD6 White Pseud 
31 WD6 White CNS 
32 WD7 White CNS 
33 WD8 White Pseud 
34 WD8 Yellow CNS 
35 WD5 
proteus 
swarm proteus 
36 WD7 
proteus 
swarm proteus 
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Appendix 8 
Data for ELISAs Chapter 4 
 
Data for Figure 4.10 
ng/ml OD1 OD2 Ave SD Blank 
corrected 
10000 3.566 3.598 3.582 0.023 3.336 
5000 3.867 3.712 3.790 0.110 3.544 
2500 3.633 3.633 3.633 0.000 3.387 
1250 3.598 3.482 3.540 0.082 3.294 
625 3.758 3.508 3.633 0.177 3.387 
312.5 3.482 3.370 3.426 0.079 3.180 
156 3.598 3.434 3.516 0.117 3.270 
78 3.411 3.297 3.354 0.081 3.108 
39 3.181 3.121 3.151 0.042 2.905 
20 2.913 2.820 2.867 0.066 2.621 
9.8 2.605 2.557 2.581 0.034 2.335 
4.9 2.198 1.889 2.043 0.218 1.797 
2.44 1.666 1.515 1.590 0.107 1.344 
1.22 1.215 1.069 1.142 0.104 0.896 
0.61 0.950 0.791 0.870 0.112 0.624 
0.31 0.703 0.559 0.631 0.102 0.385 
0.2 0.557 0.429 0.493 0.091 0.247 
0.076 0.416 0.382 0.399 0.024 0.153 
0.038 0.371 0.348 0.359 0.017 0.113 
0.019 0.346 0.334 0.340 0.009 0.094 
0.0095 0.318 0.295 0.307 0.016 0.061 
0.0047 0.297 0.285 0.291 0.009 0.045 
 
ng/ml OD1 OD2 Ave SD Blank 
corrected 
10000 3.314 3.314 3.314 0.00 3.075 
5000 3.350 3.457 3.403 0.075 3.164 
2500 3.314 3.314 3.314 0.00 3.075 
1250 3.281 3.250 3.265 0.022 3.026 
625 3.099 3.168 3.133 0.049 2.894 
312.5 2.913 2.988 2.950 0.053 2.711 
156 2.396 2.502 2.449 0.075 2.210 
78 1.743 1.880 1.811 0.097 1.572 
39 1.220 1.350 1.285 0.092 1.046 
19.5 0.868 0.892 0.880 0.017 0.641 
9.8 0.586 0.613 0.599 0.018 0.360 
4.88 0.407 0.400 0.403 0.004 0.164 
2.44 0.325 0.328 0.327 0.002 0.088 
1.22 0.307 0.273 0.290 0.024 0.051 
0.61 0.277 0.280 0.278 0.002 0.039 
0.3 0.263 0.257 0.260 0.004 0.021 
0.15 0.253 0.238 0.246 0.011 0.007 
0.08 0.232 0.242 0.237 0.007 0.000 
0.04 0.251 0.242 0.247 0.007 0.000 
0.02 0.243 0.239 0.241 0.003 0.000 
0.01 0.240 0.243 0.241 0.002 0.000 
0.005 0.248 0.229 0.239 0.014 0.000 
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Data for Fig 4.11 
Blank     
0.085     
0.091     
0.085     
0.094     
0.086     
0.087     
0.096     
0.087 0.088875    
 
 
     
FRI115M     
1st Run 2nd Run Ave SD Blank 
corrected 
0.843 0.803 0.823 0.028 0.733 
1.983 2.037 2.010 0.038 1.920 
2.264 2.266 2.265 0.001 2.175 
2.353 2.357 2.355 0.003 2.265 
2.36 2.367 2.364 0.005 2.274 
2.379 2.397 2.388 0.013 2.298 
2.41 2.410 2.410 0.000 2.320 
2.401 2.404 2.403 0.002 2.313 
2.387 2.382 2.385 0.004 2.295 
2.39 2.374 2.382 0.011 2.292 
2.389 2.368 2.379 0.015 2.289 
     
 
SaB2     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.578 1.532 1.555 0.033 1.465 
2.275 2.284 2.280 0.006 2.190 
2.305 2.330 2.318 0.018 2.228 
2.383 2.389 2.386 0.004 2.296 
2.401 2.399 2.400 0.001 2.310 
2.386 2.404 2.395 0.018 2.305 
2.385 2.393 2.389 0.006 2.299 
2.384 2.407 2.396 0.016 2.306 
2.422 2.390 2.406 0.023 2.316 
2.364 2.390 2.377 0.018 2.287 
2.387 2.370 2.379 0.012 2.289 
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TNase     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.327 0.312 0.320 0.011 0.230 
0.632 0.626 0.629 0.004 0.539 
0.975 1.046 1.011 0.050 0.921 
1.549 1.622 1.586 0.052 1.496 
1.939 2.074 2.007 0.095 1.917 
2.207 2.265 2.236 0.041 2.146 
2.302 2.306 2.304 0.003 2.214 
2.358 2.338 2.348 0.014 2.258 
2.345 2.347 2.346 0.001 2.256 
2.361 2.355 2.358 0.004 2.268 
2.335 2.336 2.336 0.001 2.246 
     
No competition        
1st Run 2nd Run Ave SD Blank 
corrected 
2.319 2.297 2.308 0.016 2.218 
2.317 2.330 2.324 0.009 2.234 
2.336 2.322 2.329 0.010 2.239 
2.346 2.356 2.351 0.007 2.261 
2.34 2.326 2.333 0.010 2.243 
2.34 2.341 2.340 0.001 2.251 
2.34 2.333 2.337 0.005 2.247 
2.329 2.346 2.338 0.012 2.248 
2.374 2.337 2.356 0.026 2.266 
2.333 2.277 2.305 0.040 2.215 
2.294 2.290 2.292 0.003 2.202 
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Data for figure 4.12 
Blank     
0.227     
0.224     
0.230     
0.209     
0.238     
0.244     
0.250     
0.225 0.23105    
     
FRI115M spt     
1st Run 2nd Run Ave SD Blank 
corrected 
0.476 0.509 0.493 0.024 0.263 
1.277 1.384 1.330 0.076 1.100 
1.411 1.521 1.466 0.078 1.236 
1.516 1.529 1.523 0.009 1.293 
1.510 1.573 1.541 0.045 1.311 
1.631 1.621 1.626 0.007 1.396 
1.649 1.700 1.674 0.036 1.444 
1.654 1.681 1.667 0.019 1.437 
1.681 1.681 1.681 0.000 1.451 
1.666 1.714 1.690 0.037 1.460 
1.413 1.445 1.429 0.023 1.412 
     
FRI 115M spt and cells     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.342 0.350 0.346 0.006 0.116 
1.019 1.124 1.071 0.074 0.841 
1.360 1.388 1.374 0.020 1.144 
1.521 1.503 1.512 0.013 1.282 
1.604 1.532 1.568 0.051 1.338 
1.611 1.622 1.616 0.008 1.386 
1.686 1.665 1.675 0.015 1.445 
1.680 1.691 1.685 0.008 1.455 
1.685 1.666 1.676 0.014 1.446 
1.675 1.686 1.680 0.008 1.450 
1.368 1.380 1.374 0.009 1.420 
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Pseudomonas spt     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.396 1.598 1.497 0.142 1.401 
1.602 1.305 1.454 0.210 1.420 
1.576 1.614 1.595 0.027 1.460 
1.622 1.627 1.624 0.003 1.394 
1.656 1.725 1.690 0.049 1.460 
1.701 1.793 1.747 0.065 1.517 
1.733 1.808 1.771 0.053 1.541 
1.743 1.732 1.737 0.007 1.507 
1.745 1.743 1.743 0.002 1.514 
1.713 1.718 1.715 0.004 1.485 
1.452 1.401 1.426 0.036 1.382 
     
 
 
No competitor (TNase B only)     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.666 1.328 1.497 0.239 1.562 
1.683 1.663 1.673 0.014 1.658 
1.637 1.699 1.668 0.044 1.562 
1.727 1.881 1.804 0.109 1.658 
1.713 1.872 1.792 0.113 1.562 
1.799 1.977 1.888 0.125 1.658 
1.724 2.026 1.875 0.214 1.645 
1.754 2.010 1.882 0.181 1.652 
1.793 1.841 1.817 0.035 1.587 
1.777 1.930 1.853 0.108 1.623 
1.474 1.652 1.563 0.126 1.616 
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FRI115M data 1-5 hours 
Blank     
0.299     
0.286     
0.313     
0.330     
0.328     
0.023     
0.034     
0.288 0.23775    
     
0 hours     
1st Run 2nd Run Ave SD Blank 
corrected 
2.185 2.164 2.175 0.015 1.938 
2.230 3.061 2.645 0.587 2.408 
2.262 2.650 2.456 0.274 2.219 
2.486 2.562 2.524 0.053 2.287 
0.970 2.159 1.565 0.841 1.328 
     
     
1 hour     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.909 2.863 2.386 0.675 2.149 
2.574 2.811 2.693 0.167 2.456 
2.574 2.422 2.498 0.108 2.261 
2.325 2.510 2.418 0.131 2.181 
2.457 2.505 2.481 0.034 2.244 
     
     
     
2 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.689 3.123 2.906 0.307 2.669 
2.741 3.600 3.170 0.608 2.934 
2.857 3.413 3.135 0.393 2.898 
2.895 3.134 3.015 0.170 2.778 
2.370 2.685 2.527 0.223 2.290 
     
 
 
 
 
 
 
313 
 
3 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.158 2.863 3.010 0.209 2.773 
2.966 2.863 2.914 0.073 2.677 
2.440 2.665 2.552 0.159 2.315 
2.584 2.459 2.521 0.088 2.284 
2.281 2.301 2.291 0.014 2.054 
 
         
4 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.701 1.832 2.266 0.615 2.029 
3.538 2.982 3.260 0.393 3.023 
3.101 2.646 2.874 0.322 2.637 
2.943 3.042 2.993 0.070 2.756 
2.746 2.839 2.792 0.066 2.555 
     
     
5 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.033 3.015 3.024 0.0125 2.787 
2.577 2.565 2.571 0.0088 2.334 
2.502 2.454 2.478 0.0339 2.241 
2.454 2.505 2.479 0.0357 2.242 
2.322 2.120 2.221 0.1426 1.984 
     
     
     
No competition     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.484 3.869 3.676 0.273 3.439 
3.123 3.568 3.346 0.315 3.109 
3.267 3.299 3.283 0.023 3.046 
3.081 3.316 3.198 0.167 2.961 
2.990 3.252 3.121 0.185 2.884 
 
 
 
 
 
 
Repeat of FRI115M Data 0-5 hours 
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Blank     
0.332     
0.316     
0.372     
0.381     
0.290     
0.333     
0.358     
0.472 0.3566    
     
0 hours     
1st Run 2nd Run Ave SD Blank 
corrected 
2.890 2.691 2.791 0.141 2.434 
3.104 3.093 3.098 0.007 2.742 
3.254 3.054 3.154 0.141 2.797 
3.486 3.073 3.279 0.292 2.923 
3.570 3.254 3.412 0.224 3.055 
     
     
1 hour     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.637 3.438 3.537 0.141 3.181 
3.602 3.570 3.586 0.023 3.230 
3.461 3.570 3.516 0.077 3.159 
2.583 3.254 2.918 0.475 2.562 
1.280 3.093 2.187 1.282 1.830 
     
     
     
2 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.663 2.835 2.749 0.122 2.392 
2.968 3.225 3.097 0.182 2.740 
2.656 3.239 2.947 0.413 2.591 
2.984 3.355 3.169 0.262 2.813 
3.225 3.254 3.239 0.021 2.883 
     
 
 
 
 
 
3 hours     
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1st Run 2nd Run Ave SD Blank 
corrected 
3.301 3.570 3.4357 0.190 3.079 
3.239 3.336 3.28755 0.066 2.930 
3.318 3.374 3.34605 0.039 2.989 
3.083 3.269 3.17595 0.132 2.819 
3.148 3.336 3.24205 0.133 2.885 
     
     
     
4 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.984 2.802 2.893 0.128 2.537 
2.910 3.083 2.996 0.122 2.640 
3.374 3.225 3.299 0.105 2.943 
3.637 3.540 3.589 0.069 3.232 
3.570 3.318 3.444 0.178 3.088 
     
     
5 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.512 3.301 3.407 0.149 3.050 
3.239 3.000 3.120 0.169 2.763 
3.301 3.083 3.192 0.155 2.835 
3.301 3.285 3.293 0.012 2.937 
3.486 3.301 3.393 0.130 3.037 
     
     
     
No competition     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.415 3.486 3.450 0.049 3.094 
2.859 2.945 2.902 0.061 2.545 
2.976 3.063 3.019 0.062 2.663 
3.318 3.486 3.402 0.118 3.045 
3.486 3.637 3.561 0.107 3.205 
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FRI115M data 6-11 hours 
 
Blank     
0.307     
0.325     
0.356     
0.326     
0.338     
0.336     
0.348     
0.328 0.333075    
     
6 hours     
1st Run 2nd Run Ave SD Blank 
corrected 
2.486 2.419 2.452 0.047 2.119 
2.835 3.336 3.086 0.354 2.753 
3.026 3.570 3.298 0.385 2.965 
3.637 3.675 3.656 0.027 3.323 
3.136 3.486 3.311 0.247 2.978 
     
     
7 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.435 2.633 2.534 0.140 2.201 
2.633 2.853 2.743 0.155 2.410 
2.006 2.160 2.083 0.109 1.750 
2.044 1.727 1.885 0.224 1.552 
2.210 1.957 2.083 0.178 1.750 
     
 
 
        
8 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.301  3.269 3.285 0.023 2.952 
2.787 3.239 3.013 0.320 2.680 
3.336 3.336 3.336 0 3.003 
3.762 3.637 3.699 0.088 3.366 
3.285 3.461 3.373 0.125 3.040 
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9 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.748 2.762 2.755 0.010 2.422 
3.000 2.637 2.818 0.257 2.485 
2.251 2.227 2.239 0.016 1.906 
1.749 1.849 1.799 0.070 1.466 
1.850 1.933 1.892 0.058 1.559 
     
     
     
10 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.008 3.125 3.067 0.082 2.734 
3.114 3.017 3.065 0.069 2.732 
3.285 3.336 3.310 0.036 2.977 
3.570 3.871 3.720 0.213 3.387 
3.225 3.354 3.289 0.092 2.956 
     
     
11 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
2.299 2.411 2.355 0.079 2.022 
2.198 Nil 2.198 Nil 1.865 
2.005 2.099 2.052 0.066 1.719 
1.784 1.740 1.762 0.031 1.429 
1.707 1.606 1.657 0.072 1.324 
     
No competition     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.637 3.461 3.549 0.125 3.216 
2.896 3.160 3.028 0.186 2.695 
3.318 2.687 3.002 0.446 2.669 
3.813 3.762 3.787 0.036 3.454 
3.160 3.254 3.207 0.066 2.874 
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Repeat of FRI115M Data 6-11 hours 
 
Blank     
0.304     
0.288     
0.337     
0.366     
0.306     
0.293     
0.322     
0.285 0.31275    
     
6 hours     
1st Run 2nd Run Ave SD Blank 
corrected 
0.028 2.915 1.4712 2.041275856 1.1592 
0.022 3.600 1.81105 2.529957352 1.49905 
2.544 3.392 2.9677 0.59962655 2.6557 
2.908 3.811 3.35925 0.638588134 3.04725 
3.600 3.635 3.61735 0.024536605 3.30535 
     
 
     
7 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.760 3.673 3.7161 0.061659711 3.4041 
3.869 3.600 3.7344 0.190070303 3.4224 
3.760 3.673 3.7161 0.061659711 3.4041 
3.714 3.600 3.65695 0.080539462 3.34495 
3.413 3.568 3.49035 0.10953084 3.17835 
     
     
     
8 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.237 3.352 3.2945 0.081600123 2.9825 
3.352 3.352 3.3522 0 3.0402 
3.237 3.635 3.43575 0.281357788 3.12375 
3.635 3.635 3.6347 0 3.3227 
3.635 3.568 3.60125 0.047305444 3.28925 
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9 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.568 3.568 3.5678 0 3.2558 
3.600 3.568 3.5839 0.022768838 3.2719 
3.568 3.484 3.52565 0.059609102 3.21365 
3.484 3.372 3.4275 0.079195959 3.1155 
3.538 3.252 3.39465 0.202444671 3.08265 
     
         
10 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.195 3.283 3.239 0.061659711 2.927 
3.538 3.568 3.5528 0.021213203 3.2408 
3.714 3.673 3.6932 0.029274221 3.3812 
3.811 3.635 3.72275 0.124521504 3.41075 
3.635 3.538 3.58625 0.068518647 3.27425 
     
     
11 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.352 3.372 3.36185 0.013647161 3.04985 
3.392 3.372 3.3816 0.014283557 3.0696 
3.538 3.568 3.5528 0.021213203 3.2408 
3.510 3.568 3.5388 0.041012193 3.2268 
3.538 3.435 3.4865 0.072549156 3.1745 
     
     
     
No competition     
     
1st Run 2nd Run Ave SD Blank 
corrected 
4.112 3.435 3.77355 0.478499159 3.46155 
3.673 3.936 3.80415 0.186181215 3.49215 
3.936 3.811 3.8733 0.088388348 3.5613 
3.811 3.352 3.5815 0.32427917 3.2695 
3.760 3.600 3.67985 0.112924953 0.55985 
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FRI115M data 12-24 hours 
 
Blank     
0.328     
0.347     
0.349     
0.375     
0.409     
0.367     
0.335     
0.357 0.3582375    
     
12 hours     
1st Run 2nd Run Ave SD Blank 
corrected 
1.515 0.848 1.18175 0.471710934 0.82375 
1.695 1.946 1.82035 0.177554513 1.46235 
2.393 2.832 2.6126 0.31070272 2.2546 
3.195 3.208 3.20125 0.00940452 2.84325 
2.200 2.451 2.32525 0.17727167 1.96725 
     
     
16 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.568 0.640 0.6043 0.050770267 0.2463 
0.781 0.995 0.8877 0.151462273 0.5297 
0.739 0.806 0.7727 0.047658997 0.4147 
0.864 0.887 0.87565 0.016617009 0.51765 
1.187 1.097 1.14175 0.063286057 0.78375 
     
     
     
24 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.027 0.023 0.025 0.002969848 -0.333 
0.560 0.649 0.6043 0.063356768 0.2463 
1.250 1.119 1.18475 0.09284312 0.82675 
1.908 1.709 1.8084 0.140289985 1.4504 
1.759 1.532 1.6457 0.160654661 1.2877 
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No competition     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.637 3.461 3.54875 0.124521504 3.19075 
2.896 3.160 3.02805 0.186181215 2.67005 
3.318 2.687 3.0023 0.446467222 2.6443 
3.813 3.762 3.7873 0.036203867 3.4293 
3.160 3.254 3.20665 0.066397327 2.84865 
  
 
Repeat of FRI115M data 12-24 hours 
Blank     
0.312     
0.321     
0.436     
0.334     
0.370     
0.348     
0.301     
0.310 0.3415375    
     
12 hours     
1st Run 2nd Run Ave SD Blank 
corrected 
1.708 1.815 1.76175 0.075448294 1.42075 
2.689 2.806 2.7475 0.082590072 2.4065 
3.413 3.413 3.4134 0 3.0724 
3.635 3.635 3.6352 0 3.2942 
3.635 3.760 3.6977 0.088388348 3.3567 
     
16 hours         
1st Run 2nd Run Ave SD Blank 
corrected 
0.796 0.807 0.80115 0.007707464 0.46015 
1.374 1.542 1.45805 0.11886465 1.11705 
1.759 1.332 1.54535 0.30242957 1.20435 
2.085 1.184 1.6345 0.63710321 1.2935 
0.921 0.887 0.904 0.024465895 0.563 
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24 hours     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.562 0.556 0.5586 0.004242641 0.2176 
1.103 1.103 1.10315 0.000353553 0.76215 
1.634 1.707 1.67045 0.051265242 1.32945 
2.535 2.562 2.54875 0.018879751 2.20775 
2.895 2.929 2.912 0.024183052 2.571 
     
     
        
No competition     
     
1st Run 2nd Run Ave SD Blank 
corrected 
3.869 4.016 3.9424 0.103379011 3.6014 
3.760 4.016 3.88785 0.180524361 3.54685 
3.760 3.936 3.84825 0.124521504 3.50725 
3.538 3.869 3.7038 0.234052345 3.3628 
3.317 3.811 3.5639 0.349876435 3.2229 
     
Data for Fig 4.18 
Blank      
0.225      
0.226      
0.233      
0.218      
0.246      
0.252      
0.254      
0.231 0.2356375     
      
Wound fluid vs TNase      
1st Run 2nd Run Ave SD Blank 
corrected 
1.781 1.775 1.77805 0.004596194 1.54305 
1.850 1.790 1.8199 0.042992092 1.5849 
1.846 1.873 1.8592 0.019233304 1.6242 
1.911 1.807 1.85915 0.073892659 1.62415 
1.916 1.886 1.90085 0.021708178 1.66585 
2.024 1.827 1.9255 0.139017193 1.6905 
2.024 2.006 2.0147 0.012869343 1.7797 
1.997 1.935 1.96585 0.044335595 1.73085 
2.041 2.005 2.0228 0.025597265 1.7878 
1.967 2.013 1.99035 0.032456201 1.75535 
2.026 2.049 2.03785 0.016192745 1.80285 
  
      
 
323 
 
Wound fluid spike (1:1) vs TNase      
      
1st Run 2nd Run Ave SD Blank 
corrected 
1.908 1.187 1.12455 0.08860048 0.88955 
2.249 1.479 1.4788 #DIV/0! 1.2438 
2.382 1.612 1.6737 0.087681241 1.4387 
2.553 1.699 1.7692 0.099843478 1.5342 
2.556 1.682 1.7486 0.093903781 1.5136 
2.443 1.670 1.74605 0.107692363 1.51105 
2.591 1.726 1.78075 0.077711035 1.54575 
2.497 1.771 1.8004 0.041153615 1.5654 
2.471 1.811 1.83985 0.040517219 1.60485 
2.594 1.812 1.8535 0.059114127 1.6185 
2.611 1.906 1.8872 0.026445794 1.6522 
      
 
 
 
 
 
 
Wound fluid spiked (1:2) vs TNase      
      
1st Run 2nd Run Ave SD Blank 
corrected 
1.031 0.914 0.97245 0.082943625 0.73745 
1.431 1.362 1.3964 0.048790368 1.1614 
1.400 1.559 1.47925 0.112217846 1.24425 
1.595 1.645 1.62005 0.035567471 1.38505 
1.693 1.789 1.74065 0.067670119 1.50565 
1.697 1.714 1.7057 0.011737973 1.4707 
1.747 1.877 1.812 0.092206724 1.577 
1.733 1.746 1.73965 0.00940452 1.50465 
1.767 1.776 1.77185 0.00629325 1.53685 
1.781 1.819 1.8001 0.026587215 1.5651 
1.754 1.912 1.833 0.111864293 1.598 
 
 
 
 
 
 
 
 
 
 
 
      
      
324 
 
S.aureus spt vs TNase     
      
1st Run 2nd Run Ave SD Blank 
corrected 
0.812 0.803 0.8076 0.007 0.573 
1.376 1.311 1.3436 0.046 1.109 
1.561 1.639 1.5998 0.055 1.365 
1.736 1.723 1.7297 0.009 1.495 
1.770 1.839 1.80445 0.048 1.569 
1.862 1.781 1.8216 0.058 1.587 
1.918 1.915 1.9162 0.002 1.681 
1.806 1.780 1.7928 0.018 1.558 
1.886 1.847 1.8665 0.028 1.632 
1.930 1.915 1.9225 0.011 1.688 
1.964 2.031 1.99725 0.048 1.762 
 
      
 
 
      
      
No competition      
1st Run 2nd Run Ave SD Blank 
corrected 
2.189 2.125 2.157 0.045 1.922 
2.213 2.174 2.194 0.027 1.959 
2.018 2.047 2.032 0.025 1.797 
2.058 1.957 2.008 0.072 1.773 
1.894 1.924 1.910 0.021 1.674 
2.065 1.964 2.015 0.072 1.780 
2.121 2.085 2.103 0.026 1.868 
2.193 2.068 2.131 0.089 1.896 
2.189 1.957 2.073 0.164 1.838 
2.213 1.924 2.069 0.205 1.834 
2.018 1.964 1.991 0.038 1.756 
  
      
      
      
 
 
 
 
 
 
 
 
 
 
 
325 
 
Repeat of Data for fig 4.18    
      
      
   
 Blank     
 0.240     
 0.235     
 0.247     
 0.251     
 0.256     
 0.240     
 0.216     
 0.226 0.2388375    
      
  
 
Wound fluid vs TNase     
  
1st Run 2nd Run Ave SD Blank 
corrected 
1.222 1.245 1.234 0.016 0.996 
1.220 1.258 1.239 0.027 1.001 
1.277 1.282 1.279 0.003 1.041 
1.299 1.252 1.275 0.033 1.037 
1.221 1.218 1.220 0.003 0.982 
1.240 1.268 1.254 0.020 1.016 
1.269 1.270 1.270 0.001 1.032 
1.241 1.257 1.249 0.012 1.011 
1.243 1.269 1.256 0.018 1.018 
1.236 1.281 1.259 0.032 1.021 
1.257 1.267 1.262 0.007 1.024 
      
 Wound fluid spike (1:1) vs TNase     
      
  
1st Run 2nd Run Ave SD Blank 
corrected 
0.929 0.971 0.060 0.733 0.733 
1.149 1.138 1.143 0.008 0.905 
1.235 1.215 1.225 0.014 0.987 
1.241 1.240 1.240 0.001 1.002 
1.281 1.218 1.249 0.044 1.011 
1.275 1.216 1.246 0.041 1.008 
1.255 1.257 1.256 0.001 1.018 
1.271 1.279 1.275 0.006 1.037 
1.211 1.209 1.210 0.002 0.971 
1.167 1.204 1.186 0.026 0.948 
1.181 1.209 1.195 0.020 0.957 
      
 
326 
 
Wound fluid spiked (1:2) vs TNase     
      
1st Run 2nd Run Ave SD Blank 
corrected 
0.832 0.861 0.846 0.020 0.608 
0.952 0.947 0.949 0.004 0.711 
1.082 1.041 1.061 0.029 0.823 
1.083 1.085 1.084 0.001 0.846 
1.054 1.173 1.113 0.084 0.875 
1.197 1.282 1.240 0.060 1.002 
1.209 1.285 1.247 0.054 1.009 
1.217 1.252 1.234 0.025 0.996 
1.220 1.235 1.228 0.011 0.990 
1.215 1.220 1.217 0.004 0.979 
1.201 1.192 1.196 0.007 0.958 
      
      
 S.aureus spt vs TNase    
      
  
1st Run 2nd Run Ave SD Blank 
corrected 
0.563 0.558 0.560 0.003 0.323 
0.836 0.866 0.850 0.021 0.613 
0.990 0.997 0.993 0.005 0.755 
1.046 1.105 1.075 0.042 0.837 
1.127 1.121 1.124 0.004 0.886 
1.160 1.205 1.182 0.032 0.944 
1.217 1.269 1.243 0.037 1.005 
1.233 1.273 1.253 0.028 1.015 
1.224 1.290 1.257 0.046 1.019 
1.220 1.296 1.258 0.054 1.020 
1.233 1.325 1.279 0.065 1.041 
      
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
327 
 
No competition     
  
1st Run 2nd Run Ave SD Blank 
corrected 
1.236 1.257 1.246 0.0150 1.008 
1.281 1.267 1.274 0.0102 1.036 
1.167 1.181 1.174 0.009 0.936 
1.204 1.209 1.206 0.003 0.968 
1.215 1.201 1.208 0.009 0.970 
1.220 1.192 1.206 0.020 0.968 
1.220 1.233 1.226 0.009 0.988 
1.296 1.325 1.311 0.020 1.073 
1.236 1.257 1.246 0.0150 1.008 
1.281 1.267 1.274 0.0102 1.036 
1.167 1.181 1.174 0.009 0.936 
      
      
      
Data for Fig 4.20 
 
Blank     
0.2544     
0.2478     
0.2722     
0.2743     
0.2929     
0.2761     
0.2442     
0.2533 0.2644    
     
 
 
 
Acute 3b     
1st Run 2nd Run Ave SD Blank 
corrected 
1.067 1.089 1.078 0.016 0.814 
1.240 1.218 1.229 0.015 0.965 
1.375 1.401 1.388 0.019 1.124 
1.463 1.480 1.471 0.012 1.207 
1.623 1.582 1.602 0.029 1.338 
1.676 1.652 1.664 0.017 1.400 
1.736 1.745 1.741 0.007 1.477 
1.807 1.760 1.783 0.033 1.519 
1.736 1.854 1.795 0.084 1.531 
1.769 1.736 1.753 0.023 1.489 
1.844 1.792 1.818 0.037 1.554 
     
     
 
328 
 
Acute 4a     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.185 1.237 1.211 0.037 0.947 
1.397 1.458 1.428 0.043 1.164 
1.530 1.557 1.543 0.007 1.279 
1.551 1.583 1.567 0.023 1.303 
1.649 1.604 1.626 0.032 1.362 
1.715 1.724 1.719 0.006 1.455 
1.758 1.730 1.744 0.020 1.480 
1.773 1.666 1.720 0.076 1.456 
1.689 1.697 1.693 0.005 1.429 
1.702 1.685 1.694 0.012 1.430 
1.739 1.727 1.733 0.009 1.469 
     
 
Acute 2b     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.231 1.179 1.205 0.037 0.941 
1.217 1.116 1.167 0.072 0.903 
1.352 1.270 1.311 0.058 1.047 
1.440 1.424 1.432 0.011 1.168 
1.599 1.519 1.559 0.057 1.295 
1.758 1.719 1.738 0.027 1.474 
1.763 1.787 1.775 0.017 1.511 
1.727 1.773 1.750 0.033 1.486 
1.743 1.726 1.735 0.012 1.471 
1.735 1.757 1.746 0.016 1.482 
1.785 1.760 1.776 0.014 1.512 
     
     
TNase line     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.302 0.296 0.299 0.004 0.035 
0.367 0.377 0.372 0.007 0.108 
0.239 0.436 0.337 0.139 0.073 
0.515 0.499 0.507 0.011 0.243 
0.920 0.952 0.936 0.023 0.672 
1.138 1.225 1.182 0.061 0.918 
1.225 1.320 1.272 0.067 1.008 
1.368 1.451 1.409 0.058 1.145 
1.442 1.492 1.467 0.035 1.203 
1.689 1.700 1.695 0.008 1.430 
1.721 1.701 1.711 0.014 1.447 
 
Data for Fig 4.21 and 4.22  
329 
 
 
Blank     
0.221     
0.249     
0.237     
0.257     
0.248     
0.272     
0.246     
0.243 0.2465125    
     
Chronic 1     
1st Run 2nd Run Ave SD Blank 
corrected 
1.502 1.385 1.444 0.0826 1.204 
1.611 1.493 1.552 0.0841 1.312 
1.579 1.465 1.522 0.0805 1.282 
1.504 1.500 1.502 0.0025 1.262 
1.520 1.513 1.516 0.0050 1.276 
1.502 1.415 1.459 0.0615 1.219 
1.502 1.390 1.446 0.0790 1.206 
1.439 1.421 1.430 0.0126 1.190 
1.516 1.530 1.523 0.0098 1.283 
1.508 1.483 1.496 0.0180 1.256 
1.542 1.434 1.488 0.0767 1.248 
     
 
 
 
 
     
Chronic 2     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.370 1.315 1.342 0.040 1.102 
1.417 1.354 1.386 0.045 1.146 
1.377 1.284 1.331 0.007 1.091 
1.486 1.360 1.423 0.089 1.183 
1.602 1.349 1.475 0.179 1.235 
1.442 1.396 1.419 0.033 1.179 
1.387 1.365 1.376 0.016 1.136 
1.288 1.292 1.290 0.002 1.050 
1.374 1.365 1.370 0.006 1.130 
1.424 1.374 1.399 0.036 1.159 
1.319 1.339 1.329 0.014 1.089 
     
     
     
 
330 
 
Chronic 3     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.142 1.176 1.159 0.024 0.919 
1.249 1.272 1.261 0.016 1.021 
1.301 1.373 1.337 0.052 1.097 
1.348 1.402 1.375 0.038 1.135 
1.406 1.454 1.430 0.034 1.190 
1.395 1.467 1.431 0.051 1.191 
1.319 1.454 1.387 0.095 1.147 
1.357 1.372 1.364 0.011 1.124 
1.377 1.437 1.407 0.043 1.167 
1.386 1.392 1.389 0.004 1.149 
1.326 1.357 1.341 0.021 1.101 
     
 
 
 
 
 
     
TNase line     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.372 0.296 0.334 0.054 0.094 
0.471 0.380 0.425 0.064 0.185 
0.697 0.725 0.711 0.020 0.471 
0.952 0.954 0.953 0.002 0.713 
1.108 1.236 1.172 0.090 0.932 
1.261 1.323 1.292 0.044 1.052 
1.177 1.365 1.271 0.133 1.031 
1.331 1.348 1.339 0.012 1.099 
1.394 1.434 1.414 0.028 1.174 
1.403 1.401 1.402 0.001 1.162 
1.394 1.407 1.401 0.009 1.160 
           
  
 
 
 
 
 
 
 
 
 
 
 
331 
 
Blank     
0.235     
0.255     
0.237     
0.249     
0.238     
0.265     
0.232     
0.231 0.2426875    
     
Chronic 4     
1st Run 2nd Run Ave SD Blank 
corrected 
1.546 1.623 1.58425 0.054517933 1.34425 
1.619 1.637 1.6282 0.012586501 1.3882 
1.759 1.677 1.71805 0.058336309 1.47805 
1.697 1.737 1.71675 0.028213561 1.47675 
1.649 1.671 1.65955 0.015485639 1.41955 
1.606 1.667 1.63635 0.042638539 1.39635 
1.658 1.582 1.62025 0.053952247 1.38025 
1.599 1.662 1.6305 0.044406306 1.3905 
1.554 1.631 1.5925 0.053881537 1.3525 
1.528 1.642 1.5848 0.080185909 1.3448 
1.625 1.564 1.59415 0.042921382 1.35415 
     
     
Chronic 5     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.663 1.575 1.6192 0.061942554 1.3792 
1.710 1.694 1.70215 0.011667262 1.46215 
1.522 1.617 1.5692 0.006858936 1.3292 
1.686 1.606 1.64615 0.056497832 1.40615 
1.708 1.566 1.637 0.100833427 1.397 
1.620 1.565 1.5927 0.03860803 1.3527 
1.565 1.545 1.5551 0.0145664 1.3151 
1.540 1.604 1.5721 0.045254834 1.3321 
1.632 1.612 1.62235 0.014212846 1.38235 
1.598 1.595 1.5966 0.001697056 1.3566 
1.552 1.548 1.5499 0.002969848 1.3099 
     
 
 
 
 
 
  
    
     
332 
 
Tris buffered saline     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.418 1.606 1.51205 0.132582521 1.27205 
1.606 1.657 1.63155 0.036415999 1.39155 
1.652 1.517 1.5846 0.095742258 1.3446 
1.691 1.507 1.59865 0.130036937 1.35865 
1.554 1.547 1.5505 0.005091169 1.3105 
1.619 1.566 1.5928 0.037476659 1.3528 
1.556 1.524 1.54015 0.022698128 1.30015 
1.602 1.595 1.59845 0.00516188 1.35845 
1.558 1.631 1.5945 0.052043059 1.3545 
1.608 1.565 1.5863 0.030547013 1.3463 
1.543 1.511 1.5268 0.022203153 1.2868 
 
     
  
 
    
TNase line     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.385 0.366 0.37555 0.013788582 0.13555 
0.552 0.539 0.5454 0.009050967 0.3054 
0.802 0.817 0.8093 0.010606602 0.5693 
1.053 1.048 1.0508 0.003676955 0.8108 
1.218 1.306 1.2621 0.062083975 1.0221 
1.376 1.331 1.3533 0.031536962 1.1133 
1.430 1.498 1.4643 0.048224682 1.2243 
1.511 1.517 1.51415 0.003889087 1.27415 
1.547 1.566 1.5563 0.013717872 1.3163 
1.552 1.564 1.5579 0.007919596 1.3179 
1.612 1.652 1.63215 0.028496403 1.39215 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
333 
 
Blank     
0.210     
0.214     
0.221     
0.203     
0.232     
0.237     
0.236     
0.213 0.220525    
     
Chronic 6     
1st Run 2nd Run Ave SD Blank 
corrected 
1.342 1.361 1.35185 0.01350574 1.13185 
1.366 1.249 1.30745 0.082095097 1.08745 
1.110 1.192 1.1507 0.057699913 0.9307 
1.397 1.240 1.31845 0.111369318 1.09845 
1.513 1.517 1.5148 0.002969848 1.2948 
1.515 1.501 1.50775 0.010111627 1.28775 
1.528 1.564 1.54595 0.025667976 1.32595 
1.450 1.520 1.48505 0.049285343 1.26505 
1.553 1.522 1.5373 0.021496046 1.3173 
1.598 1.568 1.58275 0.021142493 1.36275 
1.601 1.584 1.59245 0.011667262 1.37245 
 
     
     
Chronic 7     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.444 1.435 1.4397 0.00622254 1.2197 
1.249 1.240 1.24455 0.006858936 1.02455 
1.249 1.240 1.24455 0.006858936 1.02455 
1.291 1.295 1.29275 0.002899138 1.07275 
1.370 1.390 1.38025 0.013930004 1.16025 
1.412 1.326 1.36895 0.060740473 1.14895 
1.450 1.352 1.40085 0.06880149 1.18085 
1.425 1.428 1.42635 0.001767767 1.20635 
1.448 1.410 1.42935 0.026799347 1.20935 
1.543 1.566 1.55445 0.016192745 1.33445 
1.463 1.528 1.4955 0.046103362 1.2755 
     
 
 
 
 
 
     
     
334 
 
Chronic 8     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.340 1.216 1.27765 0.08761053 1.05765 
1.050 1.036 1.0432 0.010182338 0.8232 
1.009 0.987 0.9979 0.016122035 0.7779 
1.163 0.982 1.07245 0.127774195 0.85245 
1.308 1.141 1.22445 0.118298964 1.00445 
1.340 1.226 1.2828 0.080610173 1.0628 
1.430 1.237 1.33345 0.135976634 1.11345 
1.303 1.209 1.2559 0.066892302 1.0359 
1.469 1.344 1.40665 0.08860048 1.18665 
1.585 1.457 1.52105 0.0907218 1.30105 
1.572 1.505 1.53875 0.047164022 1.31875 
     
 
 
     
TNase line     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.244 0.243 0.2438 0.000848528 0.0238 
0.282 0.264 0.27325 0.012657211 0.05325 
0.309 0.262 0.28555 0.033163308 0.06555 
0.343 0.294 0.3183 0.034789654 0.0983 
0.481 0.351 0.4156 0.092065303 0.1956 
0.726 0.512 0.6191 0.151038008 0.3991 
1.115 0.313 0.7137 0.567382481 0.4937 
1.142 1.010 1.0761 0.092913831 0.8561 
1.251 1.057 1.154 0.136895873 0.934 
1.463 1.262 1.3626 0.142269884 1.1426 
1.480 1.401 1.4406 0.055437172 1.2206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
335 
 
Blank     
0.233     
0.253     
0.236     
0.248     
0.238     
0.264     
0.228     
0.230 0.241075    
     
Chronic 9       
1st Run 2nd Run Ave SD Blank 
corrected 
1.278 1.368 1.32325 0.0635689 1.08225 
1.322 1.411 1.36615 0.062861793 1.12515 
1.029 1.255 1.1421 0.159947554 0.9011 
1.125 1.235 1.18 0.077781746 0.939 
1.290 1.204 1.247 0.061376869 1.006 
1.404 1.486 1.4446 0.057841335 1.2036 
1.264 1.153 1.20845 0.078842406 0.96745 
1.124 1.279 1.2011 0.109742972 0.9601 
1.296 1.292 1.29415 0.003181981 1.05315 
1.600 1.426 1.5132 0.12303658 1.2722 
1.502 1.356 1.4292 0.102954747 1.1882 
     
     
Chronic 10     
     
1st Run 2nd Run Ave SD Blank 
corrected 
1.446 1.388 1.41695 0.040800061 1.17595 
1.485 1.445 1.46505 0.028213561 1.22405 
1.232 0.372 1.24455 0.006858936 1.00355 
1.345 0.994 1.16945 0.248265191 0.92845 
1.421 1.482 1.45115 0.043204224 1.21015 
1.532 1.466 1.49885 0.046174073 1.25785 
1.383 1.395 1.38925 0.008273149 1.14825 
1.467 1.278 1.3726 0.133784603 1.1316 
1.467 1.456 1.46135 0.008273149 1.22035 
1.490 1.504 1.49705 0.01039447 1.25605 
1.558 1.604 1.58125 0.032597623 1.34025 
     
 
 
 
     
     
     
  
    
336 
 
TNase line     
     
1st Run 2nd Run Ave SD Blank 
corrected 
0.302 0.296 0.29855 0.00417193 0.05755 
0.367 0.377 0.372 0.007495332 0.131 
0.239 0.436 0.3372 0.139441457 0.0962 
0.515 0.499 0.50695 0.010818734 0.26595 
0.920 0.952 0.9359 0.022344574 0.6949 
1.138 1.225 1.18165 0.061164737 0.94065 
1.225 1.320 1.2723 0.067316566 1.0313 
1.368 1.451 1.4094 0.058265599 1.1684 
1.442 1.492 1.4668 0.035213918 1.2258 
1.471 1.522 1.49625 0.035850314 1.25525 
1.533 1.645 1.5889 0.079195959 1.3479 
 
 
 
 
Concentrating data books 
Fig 4.23 blank adjusted data prior to averaging 
1 x 
conc 
1.042 1.056 0.979 0.991 0.975 0.957 0.969 1.015 0.945 1.009 1.040 
 0.999 0.936 0.928 0.933 0.995 0.965 0.950 0.939 0.925 0.962 0.980 
75x 
conc 
0.664 0.795 0.842 0.873 0.917 0.895 0.924 0.946 0.894 0.873 0.894 
 0.658 0.839 0.850 0.907 0.945 0.923 0.961 0.967 0.937 0.957 0.991 
spiked 0.016 -
0.006 
0.085 0.204 0.364 0.553 0.726 0.828 0.888 0.953 0.970 
 0.016 0.035 0.097 0.197 0.360 0.590 0.735 0.827 0.853 0.923 0.975 
TNase 
control 
0.021 0.046 0.110 0.213 0.377 0.533 0.695 0.799 0.821 0.906 0.984 
control 1.061 1.020 0.929 0.963 0.997 0.944 0.961 1.012 1.009 1.078 1.046 
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Fig 4.24 blank adjusted data prior to averaging 
1 x 
conc 
0.867 0.833 0.941 0.970 0.948 0.940 0.884 0.883 0.877 0.933 0.926 
 0.844 0.849 0.926 0.895 0.935 0.838 0.919 0.904 0.894 0.902 0.922 
75x 
conc 
0.065 0.194 0.386 0.604 0.703 0.727 0.796 0.787 0.817 0.880 0.798 
 0.094 0.220 0.384 0.656 0.767 0.820 0.840 0.871 0.851 0.911 0.930 
spiked 0.012 0.070 0.164 0.293 0.485 0.626 0.771 0.831 0.861 0.868 0.889 
 0.026 0.053 0.139 0.259 0.411 0.547 0.713 0.751 0.836 0.872 0.880 
TNase 
control 
0.014 0.057 0.127 0.254 0.365 0.506 0.693 0.775 0.835 0.905 0.920 
control 1.002 1.102 1.080 1.047 1.018 0.927 0.988 0.984 0.954 0.987 1.027 
 
 
 
 
 
Fig 4.25 blank adjusted data prior to averaging 
 
1 x 
conc 
0.998 1.053 1.067 1.104 1.093 1.119 1.165 1.174 1.151 1.177 1.239 
 1.093 1.064 1.129 1.167 1.168 1.173 1.182 1.190 1.172 1.217 1.138 
75x 
conc 
0.133 0.203 0.263 0.490 0.651 0.812 1.008 1.063 1.065 1.028 1.070 
 0.162 0.217 0.305 0.477 0.691 0.881 1.004 1.069 1.061 1.028 1.067 
spiked -
0.005 
0.032 0.115 0.203 0.428 0.609 0.829 0.941 0.961 1.001 1.039 
 0.023 0.039 0.156 0.228 0.401 0.613 0.753 0.855 0.946 0.909 0.990 
TNase 
control 
0.045 0.060 0.153 0.307 0.457 0.605 0.772 0.911 0.961 0.898 1.071 
control 1.428 1.292 1.297 1.312 1.255 1.208 1.250 1.200 1.181 1.270 1.219 
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Fig 4.26 blank adjusted data prior to averaging 
 
1 x 
conc 
1.084 1.195 1.172 1.232 1.145 1.145 1.175 1.149 1.148 1.122 1.299 
 1.135 1.255 1.268 1.297 1.298 1.264 1.265 1.251 1.315 1.199 1.304 
75x 
conc 
0.341 0.434 0.543 0.687 0.774 0.918 0.969 1.095 1.145 1.035 1.107 
 0.407 0.475 0.584 0.713 0.820 0.991 1.084 1.206 1.223 1.218 1.315 
spiked 0.009 -
0.009 
0.077 0.181 0.400 0.667 0.818 0.982 1.077 1.129 1.216 
 0.006 0.014 0.101 0.206 0.409 0.711 0.918 0.990 1.076 1.117 1.244 
TNase 
control 
0.014 0.063 0.139 0.255 0.467 0.688 0.829 0.957 1.073 1.122 1.223 
control 1.353 1.354 1.286 1.330 1.324 1.327 1.302 1.247 1.349 1.398 1.341 
 
Fig 4.27 blank adjusted data prior to averaging 
1 x 
conc 
1.286 1.341 1.297 1.190 1.261 1.236 1.266 1.299 1.318 1.140 1.563 
 1.269 1.218 1.192 1.255 1.287 1.302 1.312 1.359 1.266 1.342 1.284 
75x 
conc 
0.104 0.258 0.384 0.787 1.048 1.157 1.286 1.295 1.277 1.234 1.206 
 0.126 0.305 0.501 0.855 1.090 1.285 1.310 1.427 1.383 1.310 1.265 
spiked -
0.015 
0.040 0.153 0.317 0.528 0.777 1.068 1.276 1.318 1.398 1.184 
 0.008 0.047 0.173 0.325 0.590 0.824 1.108 1.297 1.432 1.430 1.275 
TNase 
control 
0.012 0.054 0.155 0.323 0.506 0.807 1.033 1.296 1.296 1.418 1.287 
control 1.478 1.430 1.602 1.521 1.456 1.473 1.533 1.413 1.434 1.526 1.343 
 
 
 
 
 
Fig 4.28 blank adjusted data prior to averaging 
 
1 x 
conc 
0.463 0.520 0.544 0.372 0.569 0.436 0.596 0.532 0.593 0.612 0.628 
 0.502 0.564 0.608 0.467 0.613 0.558 0.623 0.631 0.642 0.617 0.571 
75x 
conc 
0.076 0.167 0.160 0.299 0.379 0.420 0.471 0.527 0.590 0.569 0.546 
 0.113 0.178 0.217 0.306 0.359 0.412 0.462 0.536 0.572 0.579 0.575 
spiked 0.012 0.102 0.211 0.283 0.431 0.495 0.532 0.573 0.590 0.614 0.597 
 0.023 0.093 0.231 0.321 0.403 0.492 0.505 0.540 0.592 0.599 0.567 
TNase 
control 
0.024 0.089 0.175 0.270 0.362 0.450 0.486 0.549 0.586 0.645 0.630 
control 0.667 0.782 0.731 0.715 0.675 0.676 0.710 0.709 0.679 0.619 0.662 
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Fig 4.29 blank adjusted data prior to averaging 
 
1 x 
conc 
0.696 0.752 0.814 0.805 0.771 0.811 0.823 0.805 0.797 0.784 0.798 
 0.651 0.694 0.764 0.755 0.808 0.807 0.802 0.799 0.797 0.756 0.739 
75x 
conc 
0.630 0.623 0.654 0.675 0.667 0.722 0.768 0.801 0.784 0.742 0.738 
 0.519 0.624 0.611 0.620 0.628 0.693 0.737 0.781 0.748 0.714 0.747 
spiked 0.034 0.096 0.267 0.408 0.565 0.647 0.700 0.718 0.745 0.702 0.683 
 0.044 0.104 0.252 0.359 0.504 0.607 0.674 0.688 0.697 0.691 0.705 
TNase 
control 
0.039 0.110 0.236 0.381 0.521 0.636 0.681 0.716 0.727 0.696 0.719 
control 0.783 0.783 0.728 0.781 0.788 0.761 0.769 0.763 0.764 0.759 0.687 
 
 
 
Fig 4.30 blank adjusted data prior to averaging 
 
1 x 
conc 
0.590 0.712 0.511 0.783 0.784 0.811 0.753 0.756 0.755 0.770 0.853 
 0.585 0.702 0.743 0.803 0.785 0.783 0.773 0.785 0.809 0.776 0.788 
75x 
conc 
0.245 0.298 0.356 0.432 0.461 0.522 0.622 0.689 0.715 0.721 0.682 
 0.380 0.333 0.385 0.434 0.481 0.564 0.648 0.708 0.739 0.736 0.833 
spiked 0.012 0.052 0.181 0.293 0.445 0.620 0.677 0.723 0.723 0.711 0.744 
 0.027 0.055 0.210 0.270 0.417 0.590 0.625 0.677 0.669 0.732 0.798 
TNase 
control 
0.045 0.114 0.227 0.403 0.535 0.629 0.685 0.751 0.765 0.754 0.803 
control 0.859 0.853 0.795 0.797 0.801 0.764 0.804 0.812 0.800 0.769 0.803 
 
 
Fig 4.31 blank adjusted data prior to averaging 
 
1 x 
conc 
0.720 0.809 0.807 0.838 0.786 0.850 0.853 0.873 0.862 0.825 0.821 
 0.730 0.777 0.813 0.835 0.810 0.843 0.801 0.818 0.822 0.821 0.723 
75x 
conc 
0.049 0.172 0.234 0.443 0.570 0.641 0.660 0.696 0.771 0.761 0.755 
 0.093 0.158 0.286 0.424 0.541 0.601 0.662 0.732 0.746 0.725 0.760 
spiked 0.020 0.109 0.212 0.355 0.537 0.649 0.721 0.764 0.741 0.751 0.784 
 0.042 0.111 0.235 0.354 0.550 0.671 0.710 0.738 0.721 0.714 0.137 
TNase 
control 
0.052 0.135 0.240 0.383 0.511 0.654 0.658 0.718 0.726 0.740 0.727 
control 0.925 0.951 0.884 0.899 0.877 0.883 0.896 0.822 0.820 0.830 0.786 
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Fig 4.32 blank adjusted data prior to averaging 
1 x 
conc 
0.923 1.025 1.085 1.034 1.108 1.034 0.996 1.053 1.109 1.051 1.057 
 0.898 0.990 1.065 1.143 1.016 1.112 1.054 1.152 1.116 0.999 0.921 
75x 
conc 
0.508 0.653 0.534 0.699 0.780 0.792 0.824 0.918 0.908 0.879 0.922 
 0.671 0.647 0.697 0.741 0.791 0.800 0.861 0.985 0.987 1.049 1.061 
spiked 0.029 0.186 0.186 0.450 0.660 0.771 0.891 0.978 0.967 1.034 1.040 
 0.051 0.187 0.205 0.444 0.636 0.751 0.827 0.903 0.973 0.988 0.963 
TNase 
control 
0.052 0.185 0.193 0.457 0.647 0.809 0.884 1.032 0.993 1.046 1.022 
control 1.062 1.031 1.111 1.114 1.060 1.092 1.104 1.134 1.136 1.082 1.051 
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Appendix 9 
CD of Animations Utilising PNA/FISH CLSM 
 
 
 
 
 
 
 
